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Executive summary 
 
Introduction 
DRUID (Driving under the Influence of Drugs, Alcohol and Medicines) aimed to combat the problem of 
driving under the influence of psychoactive substances by providing a solid scientific base for 
European policy makers. It brought together experienced organisations in Europe to assemble a co-
ordinated set of data resources and measures. DRUID is an integrated European research project 
which consisted of different sub-projects (Work Packages) that were aimed at different topics such as 
the prevalence and risk of psychoactive substances, enforcement, classification of medicines, 
rehabilitation of offenders and withdrawal of driving licenses (www.druid-project.eu). 
 
The main objective of WP2 of DRUID was to assess the situation in Europe regarding the prevalence 
and risk of the use of illicit drugs, alcohol and psychoactive medicinal drugs by drivers. 
 
The main aim of this study was to obtain more insight in the use of psychoactive substances among 
drivers in European traffic. Thirteen countries participated in this study by conducting roadside surveys 
according to a general design. In total almost 50,000 randomly selected drivers participated between 
January 2007 and July 2009. 
 
 
 
1. Belgium (BE)  6. Hungary (HU) 11. Poland (PL) 
2. Czech Republic (CZ)  7. Italy (IT) 12. Portugal (PT) 
3. Denmark (DK)  8. Lithuania (LT) 13. Sweden (SE) 
4. Spain (ES)  9. Netherlands (NL)  
5. Finland (FI) 10. Norway (NO)  
 
All participating countries are members of the European Union (EU) except for Norway, which is 
associated with the European Union as a member of the European Economic Area (EEA). 
 
Participants, i.e. drivers of passenger cars and vans, were randomly selected using a stratified multi-
stage sampling design. In the first stage, one or more regions per country were selected. These 
regions were meant to be representative for the country with regard to substance use and traffic 
distribution. Within the selected regions smaller research areas were selected, and within these areas, 
survey locations were selected, where subjects were stopped at random, and were requested to 
participate in the study. With regard to days of the week and times of the day, the study population 
sample was stratified into eight time periods over the week, for each of the survey areas. The time 
periods did not overlap each other and covered all the days of the week and all times of the day. 
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Method 
All hours of the day and all days of the week were covered by four time periods: weekdays (04.00-
21.59), weeknights (22.00-03.59), weekend days (04.00-21.59), and weekend nights (22.00-03.59).  
 
All countries have used a StatSure Saliva Sampler device for saliva collection, except for the 
Netherlands, where saliva was collected by means of ordinary spit cups.  
Blood samples were collected in Belgium, Italy, the Netherlands and Lithuania. All four countries used 
glass tubes for the collection containing sodium fluoride and potassium oxalate.  
Extraction of the substances was based on liquid-liquid (LLE) or solid phase (SPE), chromatographic 
separation was performed by gas chromatography (GC) or Liquid chromatography (LC), detection was 
done by mass spectrometry.  
In total 23 substances have been included in the core substance list at the beginning of the project. 
The list of core substances was based on discussions between all partners.  
For each substance an analytical cut-off has been selected based on the lowest limit of quantitation 
(LOQ) that could be measured by all toxicological laboratories that were involved in the analysis of the 
substances. LOQ's reflect the lowest concentrations for substances at which quantitative results can 
be reported with a high degree of confidence. For the final results presented in this report, equivalent 
cut-offs, and not the LOQ's, are used for analysis of the core substances to correct for differences in 
concentrations of substances in blood and in saliva.  
The distribution of the study population sample by time periods was not proportionate to the 
distribution of the general driving population over these periods. This was unavoidable since in many 
of the thirteen countries the researchers had to take into account the preferences of the police who 
were needed to stop the drivers from moving traffic. Weight factors were applied to correct for this 
disproportion based on the ratio by time period between the distribution of traffic and the distribution of 
the participants. 
 
Main results 
 
• Alcohol is still by far the number one psychoactive substance on European roads, 
followed by illicit drugs and medicinal drugs. 
 
• On a European level alcohol is estimated to be used by 3.48% of the drivers, illicit drugs 
by 1.90% of the drivers, medicinal drugs by 1.36% of the drivers, drug-drug combinations 
by 0.39% of the drivers and alcohol-drug combinations by 0.37% of the drivers. 
 
• For illicit drugs THC is the most frequently detected drug in traffic, followed by cocaine. 
Amphetamines and illicit opiates were less frequently detected. 
 
• Illicit drugs were in general mainly detected among young male drivers, during all times of 
the day but mainly in the weekend  
 
• Medicinal drugs were in general mainly detected among older female drivers during 
daytime hours.  
 
• Benzodiazepines were the most prevalent medicinal drug in traffic, Z-drugs were less 
prevalent. However, considerable differences between countries were present. 
 
• The use of substances among drivers in the general driving population in Europe 
(prevalence) varies very much per country, but general patterns can be distinguished on 
the level of European regions: 
 
o The medicinal drugs Z-drugs and medicinal opiates and opioids were in general 
relatively frequently detected in Northern European countries.  
 
o Illicit drugs, alcohol and benzodiazepines are relatively frequently detected in 
Southern European countries.  
 
o In Eastern Europe the prevalence of alcohol and drugs was relatively low compared to 
the other European regions.  
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o In Western Europe, drug use is more or less on the European average. 
 
 
Figures 1 – 6 on the following pages provide geographical presentations as a summary of the main 
findings. 
 
 
A more detailed overview of the findings is presented in the table on page 9. This table shows the 
prevalences per substance group and per country as well as the estimated European means. The 
European mean can be used to distinguish per substance whether a country prevalence is around, 
below or above this European mean. The table presents the spread of the prevalence around the 
estimated European mean. A yellow colour of a particular prevalence value indicates that the 
European mean lies within the 95% confidence interval of the prevalence. A green coloured value 
indicates that the confidence interval suggests that it is below the European mean, and a red coloured 
value indicates that the confidence interval suggests that it is above the European mean. 
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Figure 1 and 2. Geographical presentation of psychoactive substance use and illicit drug use by car drivers in the EU 
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Figure 3 and 4. Geographical presentation of medicinal drug  and single alcohol use by car drivers in the EU 
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Figure 5 and 6. Geographical presentation of alcohol and drugs and drug-drug combinations by car drivers in the EU 
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Overview of the estimated European prevalences of psychoactive substances; prevalences in percentage; 95% confidence intervals in italics 
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Recommendations  
  
The results of this study can generally be used in selecting overall activities and target groups in the 
policy field of psychoactive substance use in traffic across Europe. The results indicate, however, that 
the prevalence of psychoactive substances by gender, age and time period varies largely per country. 
Therefore, recommendations for national activities regarding, e.g., policy issues, enforcement, 
education or campaigns, should primarily be based on the results of the country reports, rather than on 
the general report.  
 
Alcohol is still the most prevalent substance in traffic, as well as it is among injured and killed drivers 
(Isalberti et al., 2011). Therefore, with regard to enforcement on psychoactive substances it is 
recommended that this would remain to be mainly focused on alcohol use among drivers.  Since 
enforcement of drug driving legislation is costly in terms of time and money, selective drug testing is 
recommended above random drug testing. However, drug enforcement should not go at cost of 
alcohol enforcement (Veisten et al., 2010). 
  
The thirteen roadside surveys that were conducted within the DRUID-project provided a very valuable 
insight in the prevalence of psychoactive substances among car drivers in Europe. In the near future 
new legislations on drug driving will be applied in several European countries (e.g. the Netherlands) 
and the results from the DRUID project may affect future policies towards drink and drug driving. 
Therefore, it would be very valuable to monitor if these changes will indeed have a positive effect on 
the use of psychoactive substances in traffic. National roadside surveys on the prevalence of 
substance use in traffic on a regular, say, annual or bi-annual base would be a helpful tool to monitor 
the trend of drink and drug driving. It is recommended that these monitoring surveys would be carried 
out in more countries than the thirteen European countries that participated in the DRUID roadside 
surveys, in order to get a more representative European overview. 
Since the main purpose of this roadside survey would be to monitor the trend of drug driving, the 
number of samples per country might be smaller than in the present study. A power study should be 
conducted to estimate the required number of samples from randomly selected car drivers.  
 
In order to compare the results from new roadside surveys in Europe with the data collected in DRUID 
it is recommended to follow the study design guidelines from the DRUID roadside surveys (See annex 
1) as much as possible.  
 
It is recommended to collect saliva samples when the roadside surveys are solely used for monitoring 
the prevalence of drug use in traffic, since higher non-response rates are to be expected when 
collecting blood samples.  
 
If the roadside survey is part of a case-control study, it is recommended to use the same sample 
collection method at the roadside as is used in the hospital, in order to be able to make good 
comparisons between cases and controls. 
 
Furthermore, in order to reduce non-response researchers should invite the participants of the survey 
before the police tests the driver for alcohol.  
 
It is mandatory to have permission of the various national Medical Ethics Commission to conduct a 
roadside survey like this. The process of getting this permission can take a lot of time in some 
countries, this should be taken into account when planning future prevalence studies on psychoactive 
substances. 
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1. Introduction 
1.1 General background  
DRUID (Driving under the Influence of Drugs, Alcohol and Medicines) aimed to combat the problem of 
driving under the influence of psychoactive substances by providing a solid scientific base for 
European policy makers. It brought together experienced organisations in Europe to assemble a co-
ordinated set of data resources and measures. DRUID is an integrated European research project 
which consisted of different sub-projects (Work Packages) that were aimed at different topics such as 
the prevalence and risk of psychoactive substances, enforcement, classification of medicines, 
rehabilitation of offenders and withdrawal of driving licenses (www.druid-project.eu). 
 
The main objective of WP2 of DRUID was to assess the situation in Europe regarding the prevalence 
and risk of the use of illicit drugs, alcohol and psychoactive medicinal drugs by drivers. 
 
The prevalence of drug driving was estimated by means of roadside surveys and the prevalence of 
drugs in injury accidents was estimated by means of hospital surveys of seriously injured and/or killed 
drivers. Accident risk estimates for drug driving were assessed by relating the prevalence of drugs 
among the general driving population to the prevalence among seriously injured and/or killed drivers, 
by relating medication records to accident data and by relating substance use among accident-
involved drivers to accident culpability. 
1.2 Study design 
A cross-sectional roadside survey was conducted to determine the prevalence of psychoactive 
substances among the general driving population in thirteen European countries. In order to be able to 
compare the thirteen different studies, guidelines for a uniform design were developed for all 
participating countries (see Annex 1). 
 
1.3 Part 1 and 2 of the report 
PART 1 of this report presents the general results of the roadside surveys. The representativeness of 
the driving population is discussed in chapter 2, which also includes an assessment of the non 
response issues in the various countries. Chapter 3 describes method, substances as well as 
weighting and analyses used. Chapter 4 provides an overview of the most important general results 
based on the weighted prevalence estimates for a range of substance groups. Chapter 5 presents an 
analysis of factors that influence the prevalence. In chapter 6 the obtained results are discussed and 
conclusions and recommendations are formulated. 
 
The general results in this report are based on the thirteen country reports that were written by all 
partners and are combined in PART 2 of the report. This second part includes a report from each of 
the participating countries with more specific details on method, results and representativeness of the 
study. 
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1.4 Sampling design and data collection 
Participants, i.e. drivers of passenger cars and vans, were randomly selected using a stratified multi-
stage sampling design. In the first stage, one or more regions per country were selected. These 
regions were meant to be representative for the country with regard to substance use and traffic 
distribution. The representativeness of the regions is discussed in chapter 2 and the results of the 
substance use are presented in chapter 4. Within the selected regions smaller research areas were 
selected, and within these areas, survey locations were selected, where subjects were stopped at 
random, and were requested to participate in the study. With regard to days of the week and times of 
the day, the study population sample was stratified into eight time periods over the week, for each of 
the survey areas. The time periods did not overlap each other and covered all the days of the week 
and all times of the day. 
The distribution of the study population sample by time periods was not proportionate to the 
distribution of the general driving population over these periods. This was unavoidable since in many 
of the thirteen countries the researchers had to take into account the preferences of the police who 
were needed to stop the drivers from moving traffic. Weight factors were applied to correct for this 
disproportion based on the ratio by time period between the distribution of traffic and the distribution of 
the participants. 
Information like gender and age was collected for each subject, as well as a saliva and/or a blood 
sample. For more information on the items of the data collection see Annex 1. 
1.5 Participating countries in the roadside survey 
Roadside surveys were carried out in thirteen European countries. These countries are presented in 
table 1.1 and figure 1.1. 
Table 1.1. Participating countries 
 1. Belgium (BE)  6. Hungary (HU) 11. Poland (PL) 
 2. Czech Republic (CZ)  7. Italy (IT) 12. Portugal (PT) 
 3. Denmark (DK)  8. Lithuania (LT) 13. Sweden (SE) 
 4. Spain (ES)  9. Netherlands (NL)  
 5. Finland (FI) 10. Norway (NO)  
 
 
Figure 1.1. Participating countries 
All participating countries are members of the European Union (EU) except for Norway, which is 
associated with the European Union as a member of the European Economic Area (EEA). 
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2. Method 
2.1 Operation of the survey 
The operation of the roadside survey was based on a uniform design. Allthough differences between 
countries were present, some general steps in the survey protocol can be described.  
Drivers were stopped by the police at the request of the acting research coordinator. The subjects 
were breath tested for alcohol by a police officer, using a screening breath test analyzer.  
As soon as a member of the research team was ready for interviewing and/or blood or saliva sampling 
a driver, the next car approaching the research site was stopped. The stopped drivers were asked to 
cooperate with the research team on a voluntary basis. In some countries informed consent was 
mandatory. In these countries the drivers who agreed to cooperate signed a written consensus form 
before they were interviewed. Besides the interview, in some countries a physical examination was 
performed with particular attention paid to clinical signs of drug use or abuse.  
The interviews and the medical examinations were conducted in most countries in a specially 
equipped mobile research unit with enough space to accommodate the research team and two  
subjects. The results for each driver, including breath test data, were entered on a uniquely numbered 
anonymous research form. More detailed information on the research protocol is presented in the 
country reports that can be found in part 2 of this report. 
2.2 Time periods 
All hours of the day and all days of the week were covered by the eight time periods that were 
selected in the DRUID project. All hours of the day were distributed over four six-hour time periods 
(04.00-09.59, 10.00-15.59, 16.00-21.59, and 22.00-03.59). The days of the week were distributed over 
weekdays and weekend days.  
Figure 2.1 presents the eight different DRUID time periods. 
 
  Monday Tuesday Wednesday Thursday Friday Saturday Sunday Monday 
04.00-09.59 Period 1 Period 5 
  
10.00-15.59 Period 2 Period 6 
  
16.00-21.59 Period 3 Period 7   
22.00-23.59   Period 4   Period 8 
  
00.00-03.59       
 Figure 2.1. DRUID time periods 
 
The eight time periods have been clustered into four time periods in the analysis in order to increase 
the statistical power of the study. The four new time periods in the analysis are the following: 
weekdays (04.00-21.59), weeknights (22.00-03.59), weekend days (04.00-21.59), and weekend nights 
(22.00-03.59). The Lithuanian roadside survey did not collect data in time period 5. After clustering of 
the data however, all four new time periods were covered by the results of the roadside survey. 
Clustering was not needed for all countries, but in order to have comparable data, results are 
presented for the distribution over four time periods for all countries. 
2.3 Substances 
All countries have used a StatSure Saliva Sampler device for saliva collection, except for the 
Netherlands, where saliva was collected by means of ordinary spit cups. The Statsure Saliva Sampler 
is a saliva collection device, which the partners agreed upon to use at the beginning of the project. By 
the time this decision was made, the roadside survey in the Netherlands already had been started. 
After consultation with the partners, the Dutch researchers decided not to restart their collection of 
samples, but to continue the roadside survey with the ordinary spit cups. Blood samples were 
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collected in Belgium, Italy, the Netherlands and Lithuania. All four countries used glass tubes for the 
collection containing sodium fluoride and potassium oxalate.  
Extraction of the substances was based on liquid-liquid (LLE) or solid phase (SPE), chromatographic 
separation was performed by gas chromatography (GC) or Liquid chromatography (LC), detection was 
done by mass spectrometry.  
Annex 2 provides a detailed overview of the toxicological methods that were used by the partners as 
well as information on the proficiency tests. 
 
In total 23 substances have been included in the core substance list at the beginning of the project. 
The list of core substances was based on discussions between all partners. These core substances 
should at least be included in the sample analysis. Furthermore, the analysis for additional substances 
was permitted as well. Some countries have included the results from their additional substances in 
their country reports (see part 2 of this report). In this general part of the report only the results of the 
analysis of the core substances will be discussed.  
For each substance an analytical cut-off has been selected based on the lowest limit of quantitation 
(LOQ) that could be measured by all toxicological laboratories that were involved in the analysis of the 
substances. LOQ's reflect the lowest concentrations for substances at which quantitative results can 
be reported with a high degree of 95% confidence. For the final results presented in this report, 
equivalent cut-offs, and not the LOQ's, are used for analysis of the core substances to correct for 
differences in concentrations of substances in blood and in saliva. The reason for this is that for many 
substances the concentrations in oral fluid are much higher than in blood, while for some compounds 
the concentrations are lower (Gjerde et al., 2010; Wille et al., 2009). This means that if LOQ's for oral 
fluid samples were used to collect information on recent drug use, the prevalence for most substances 
would probably have been higher than that it would have been the case if blood was used as a 
sampling matrix. For the core substances diazepam, flunitrazepam and zolpidem, as well as for 7-
amino-flunitrazepam, which is a metabolite of flunitrazepam, the equivalent cut-offs for oral fluid were 
below the LOQ. So, in order to get comparable results between the thirteen, the equivalent cut-offs 
were used. Table 2.2 provides an overview of the initial and the equivalent cut-offs for all core 
substances. 
 
Table 2.2. Recommended equivalent cut-offs for DRUID core substances 
Substance Cut-off in 
whole blood 
(ng/mL) 
Cut-off in 
oral fluid 
(ng/mL) 
Recommended 
equivalent cut-off in 
oral fluid (ng/mL) 
Recommended 
equivalent cut-off in 
whole blood (ng/mL) 
6-AM 10 5 161 10 
Alprazolam 10 1 3.5 10 
Amphetamine 20 25 360 20 
Benzoylecgonine 50 10 95 50 
Clonazepam 10 1 1.7 10 
Cocaine 10 10 170 10 
Codeine 10 20 94 10 
Diazepam 20 5 5.02 140 
Flunitrazepam 2 1 1.02 5.31 
Lorazepam 10 1 1.1 10 
MDA 20 25 2201 20 
MDEA 20 25 2703 20 
MDMA 20 25 2701 20 
Methadone 10 20 22 10 
Methamphetamine 20 25 410 20 
Morphine 10 20 95 10 
Nordiazepam 20 1 1.1 20 
Oxazepam 50 5 13 50 
THC 1 1 27 1.0 
Zolpidem 20 10 102 37 
Zopiclone 10 10 251 10 
Tramadol 50 50 480 50 
7-amino-clonazepam 10 1 3.11 10 
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7-amino-flunitrazepam 2 1 1.02 8.51 
1 data based on less than 10 individual cases 
2 recommended cut-off in oral fluid lower than the original DRUID cut-off in oral fluid, therefore the cut-
off in blood has been raised 
3 no positive cases, cut-off MDEA used for MDMA 
 
Substances of the same type are combined into substance groups in the analysis. Table 2.3 presents 
the substance groups and the core substances that were included in each of the groups. The 
substance groups (including those who tested negative on all substances) are mutually exclusive, so 
each record in a database is either negative or linked to one of the substance groups.  
For calculating prevalence, substances of the same type were combined into following substance 
groups: alcohol, amphetamines, cocaine, THC, illicit opiates, benzodiazepines, Z-drugs, and medicinal 
opioids. The presence of THCCOOH alone (a metabolite of THC which is only detectable in blood 
samples), is regarded as negative. 
 
Substance groups are aggregated into the following substance classes: alcohol, illicit drugs, medicinal 
drugs and the following combinations: drug-alcohol and drug-drug. This last class is specified as a 
combination of different substance groups. For example: zolpidem + cocaine will be considered a 
drug-drug combination but zolpidem + zopiclone will be considered a single use of Z-drugs. 
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Table 2.3. DRUID substance groups for the prevalence among drivers in general traffic 
Type Group Analytical findings 
Alcohol alcohol ethanol 
Illicit amphetamines amphetamine 
drugs   methamphetamine or methamphetamine + amphetamine 
    MDMA or MDMA + MDA 
    MDEA or MDEA + MDA 
    MDA 
  cocaine benzoylecgonine or cocaine + benzoylecgonine or cocaine  
  THC THC or THC+THCCOOH 
  illicit opiates 
6-acetylmorphine or 6-AM + codeine or 6-AM + morphine or 6-AM + 
codeine + morphine or (morphine + codeine and morphine>= codeine) 
Medicinal benzodiazepines  
diazepam or diazepam + nordiazepam or diazepam + oxazepam or 
diazepam + nordiazepam + oxazepam 
drugs   nordiazepam or nordiazepam + oxazepam 
    oxazepam 
    lorazepam 
    alprazolam 
    flunitrazepam or flunitrazepam + 7-aminoflunitrazepam 
    clonazepam or clonazepam + 7-aminoclonazepam 
  Z-drugs zolpidem 
    zopiclone 
  medicinal  morphine 
  opioids codeine or (codeine + morphine and codeine> morphine) 
    methadone 
    tramadol 
Various alcohol-drugs all combinations (except ethanol+THCCOOH) 
combinations multiple drugs all combinations (except drug+THCCOOH) 
   
2.4 Evaluation method 
Prevalence of alcohol and drugs was calculated on the basis of the available body fluids in the 
different roadside surveys. In case of two samples – both blood and saliva, the value of blood was 
leading. This leads to the following conclusions for the observations: 
 
Table 2.4. Decision rules for results from different body fluid combinations 
 Blood sample Saliva sample Observation 
Scenario 1 Positive Not Available Positive 
Scenario 2 Positive Negative Positive 
Scenario 3 Positive Positive Positive 
Scenario 4 Negative Not Available Negative 
Scenario 5 Negative Negative Negative 
Scenario 6 Negative Positive Negative 
Scenario 7 Not Available Negative Negative 
Scenario 8 Not Available Positive Positive 
Scenario 9 Not Available Not Available Not Available 
 
Three out of thirteen countries have collected both blood and saliva samples: Belgium, Italy and the 
Netherlands. In Lithuania only blood was collected and in all other participating countries only saliva 
samples were collected.  
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2.5 Weighting 
The roadside sample should be representative for all drivers who participated in road traffic. Since 
random sampling was applied, drivers are expected to be representative for gender and age during 
the sampling sessions. However for practical reasons, in many of the national roadside surveys, the 
selection of the samples could not be distributed equally with traffic volumes over the different time 
periods.  
In order to correct for the difference between the distribution of the roadside samples and the 
distribution of traffic over the eight different time periods, weight factors were calculated by dividing the 
general distribution of traffic by time period by the distribution of sampled drivers in the same time 
period. For most countries traffic data by time period was derived from national traffic surveys.   
Table 2.5 provides an overview of the distribution of traffic by country rounded off on two decimals. For 
some countries no data was available on the distribution of traffic by time period. For these countries 
average distributions were applied based on information of a selection of OECD member states which 
representatives provided data after a request for information by the DRUID WP2 partners. If countries 
with missing traffic data had reasons to believe that the distribution of traffic was deviating in some 
direction from the average distribution, they were allowed to make small adjustments in the average 
distribution to fit it more into the expected distribution in their country. In the end, adjustments have 
only been made for Sweden. Annex 4 provides more detailed information on the method of estimating 
the average distribution.  
 
Table 2.5. Distribution of proportion general traffic by time period; rounded off on 2 decimals  
Time 
period 
Weekday 
morning 
Weekday 
afternoon 
Weekday 
evening 
Weekday 
night 
Weekend 
morning 
Weekend 
afternoon 
Weekend 
evening 
Weekend 
night 
BE 0.19 0.25 0.25 0.06 0.06 0.08 0.08 0.03 
CZ 0.20 0.29 0.16 0.02 0.08 0.11 0.13 0.01 
DK 0.22 0.31 0.17 0.02 0.03 0.11 0.11 0.03 
ES 0.17 0.27 0.22 0.04 0.03 0.08 0.14 0.05 
FI 0.19 0.29 0.20 0.03 0.06 0.09 0.13 0.02 
HU* 0.21 0.26 0.25 0.02 0.04 0.12 0.08 0.02 
IT* 0.21 0.26 0.25 0.02 0.04 0.12 0.08 0.02 
LT* 0.21 0.26 0.24 0.03 0.04 0.11 0.09 0.02 
NO 0.15 0.27 0.23 0.06 0.01 0.08 0.15 0.05 
NL 0.22 0.24 0.27 0.04 0.03 0.11 0.08 0.02 
PL* 0.21 0.26 0.25 0.02 0.04 0.12 0.08 0.02 
PT* 0.21 0.26 0.25 0.02 0.04 0.12 0.08 0.02 
SE* 0.21 0.26 0.25 0.02 0.04 0.12 0.08 0.02 
* Based on average distribution of a selection of OECD member states 
In the Portuguese data a second weight factor was included, which was based on the skewness 
between the distribution of traffic over each of the three survey regions and the distribution of the 
samples over these regions. For all other countries, no such weight factor was applied because the 
sample distribution was in accordance with the distribution of traffic in these regions or information on 
the distribution of traffic over the regions was not available. 
The Lithuanian data did not include samples from time period 5. Therefore, the weight factors for the 
seven remaining time periods were adjusted for the absence of time period 5, in order to be able to 
calculate valid weighting factors.  
 
2.6 Preparation of the data 
In each database a number of columns were included with if-then statements to determine to which 
substance group a record belonged. The if-then statements were based on the distribution of 
substances (see table 2.3) and the equivalent cut-offs for substance concentrations (see table 2.2).  
Records were removed from the databases of the thirteen countries in case toxicological analyses 
were missing for one or more total substance groups or if samples were not analysed at all. Finally, 
underage drivers (aged 17 years and younger) were removed as well from the databases. Table 2.6 
presents the total number of included samples per country. The 'cleaned' databases from the 13 
countries contained between 1264 and 9236 records. In total almost 50.000 records were included. 
The number of excluded drivers is presented in Annex 3. The main reason for exclusion was that no 
body fluid sample analysis was available. Furthermore, around 250 records were deleted since one or 
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more substance groups were missing. Finally, some records were removed from the database since 
they belonged to underage drivers.  
The exact number of removed records is hard to give since some partners already removed records 
with no sample analysis or from underage drivers before sending the database to SWOV and DTU for 
analysis. Therefore, in table 2.6 only the number of included records are presented. 
 
Table 2.6. Participating countries and the number of samples included per country 
Participating countries Number of included samples 
 1. Belgium (BE) 2949 
 2. Czech Republic (CZ) 2037 
 3. Denmark (DK) 3002 
 4. Spain (ES) 3174 
 5. Finland (FI) 3841 
 6. Hungary (HU) 2738 
 7. Italy (IT) 1310 
 8. Lithuania (LT) 1264 
 9. Netherlands (NL) 4822 
10. Norway (NO) 9236 
11. Poland (PL) 4005 
12. Portugal (PT) 3965 
13. Sweden (SE) 6199 
      Total 48542 
 
The weight factors in the final analysis are based on the 'clean' version of the national databases. 
2.7 Analysis  
2.7.1 Prevalence 
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS version 9.2. Tables have been created by using the "proc freq statement", including a 
statement on the weight factors to be used. The weighted prevalence of the substance under scrutiny 
is calculated by dividing the weighted number of positives for this substance by the weighted total of 
samples. Because lower and upper 95% confidence limits calculated using traditional approximations 
may result in limits outside the (0,1) interval, a more elaborate approximation is used. To that end, the 
Wilson 95% confidence interval formula is used as it is supplied by SAS as one of the available 
options. The prevalence results are reported in chapter 4. 
2.7.2 Underlying factors 
Logistic regression models were constructed to describe differences in independent variables 
explaining prevalence. Logistic regression is a method that reveals (significant) relations between 
given explanatory variables (quantitative or qualitative) such as time period, age, gender and a binary 
response variable. Here, the response variable consisted of a collection of samples that were either 
positive or negative for alcohol/psychoactive substances. The models were to include all countries 
where samples had been taken so that prevalence patterns across countries could be revealed. 
Prevalence of the various substance groups was related to time period, age of the driver, driver 
gender, country and interactions of these variables. The results of the logistic regression analysis are 
reported in chapter 5. Annex 5 provides more detailed information on the modelling procedure. 
2.8 Ethical approval  
Ethical approval was needed in all countries except for Italy where the participation in the study was 
mandatory. Written informed consent was needed in six countries: Belgium, Spain, Finland, Hungary, 
Norway and Poland. In the six other countries (Czech Republic, Denmark, Lithuania, The Netherlands, 
Portugal and Sweden) the national Medical Ethics Committees decided that written informed consent 
was not needed. 
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3. Representativeness of the study population in the EU 
Member States 
3.1 Introduction 
In January 2007, when the first roadside surveys started, the European Union consisted of 27 Member 
States with a total of 495 million inhabitants (Lanzieri, 2008). This represents 60% of all European 
inhabitants. 
According to the United Nations geoscheme (United Nations Statistics Division, 2007), which is 
created for statistical purposes, the region Europe can be divided in four geographical sub-regions. 
This division does not imply any assumption regarding political or other affiliations of countries or 
territories. 
Table 3.1 presents an overview of the participating countries arranged by European sub-region. All 
participating countries are marked by the grey colour. Based on the population numbers it can be 
calculated that the population of Southern EU countries are represented for 89%, and the population 
from Eastern EU countries is represented for almost two-thirds (63%). The population of the Northern 
EU countries together with Norway are represented for only 29% due to the absence of a roadside 
survey in the United Kingdom which accounts for 63% of the total Northern EU population. Finally, the 
population of the Western Member States are only represented for 11%, since large Member States 
such as Germany and France, together accounting for 80% of the total Western EU population, did not 
participate in the DRUID roadside surveys. 
 
A small coverage of the countries that are part of a European region does not necessarily mean that 
the survey results are not representative for the whole region. However, in general the 
representativeness will increase if the geographical coverage is larger. On the other hand, a good 
coverage of countries may result in poor representativeness too if the survey samples are not 
representative for the general driving populations.  
Therefore, a conclusion on the European representativeness of the roadside survey results can only 
be given after an assessment of the representativeness at a national level. This assessment will focus 
on two aspects. The first aspect is the survey sample's representativeness of the national driving 
population, and the second considers the non-response bias. Both aspects will be discussed in the 
next two sections. 
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Table 3.1. DRUID coverage of EU countries, by subregion (source: Eurostat, 2008) 
Coverage by subregion Number of inhabitants (million) 
Northern Europe (29%) United Kingdom (UK)  60.9 
 Sweden (SE)  9.1 
 Denmark (DK)  5.4 
 Finland (FI)  5.3 
 Norway* (NO) 4.7 
 Ireland (IE)  4.3 
 Lithuania (LT)  3.4 
 Latvia (LV)  2.3 
 Estonia (EE)  1.3 
   
Eastern Europe (63%) Poland (PL)  38.2 
 Romania (RO)  21.6 
 Czech Republic (CZ)  10.3 
 Hungary (HU)  10.1 
 Bulgaria (BG)  7.7 
 Slovakia (SK)  5.4 
   
Southern Europe (89%) Italy (IT)  59.1 
 Spain (ES)  44.5 
 Greece (EL)  11.2 
 Portugal (PT)  10.6 
 Slovenia (SI)  2.0 
 Cyprus (CY)  0.8 
 Malta (MT)  0.4 
   
Western Europe (15%) Germany (DE)  82.3 
 France (FR)  63.4 
 The Netherlands (NL)  16.4 
 Belgium (BE)  10.6 
 Austria (AT)  8.3 
 Luxembourg (LU)  0.5 
   
Total EU (46%) European Union  499.8 
* Norway is not a member of the EU 
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3.2 Representativeness of the national driving population 
A previous prevalence study regarding drugs in road traffic (Mathijssen and Houwing, 2005) showed 
that the presence of illicit drugs in the Netherlands was mainly concentrated in night-time hours, 
whereas the presence of medicinal drugs was more concentrated in daytime hours. To make sure that 
in the present study all periods of the week were sufficiently covered, the study population in the 
participating countries was stratified into eight different time periods, which were expected to be more 
or less homogeneous with regard to the prevalence of drugs and alcohol. 
An advantage of a practical kind was that stratification allowed a flexible approach in each of the 
periods. In principle, a proportionate stratification in all roadside surveys would seem to be ideal. This 
means that the sample distribution by day and time would be proportionate to the distribution of the 
general driving population.  
However, in many countries normal police enforcement activities on driving under the influence of 
drugs and alcohol are mostly concentrated in night-time hours, when the prevalence of alcohol and 
illicit drugs is the highest. The use of strata allowed researchers to have a disproportionate 
stratification that was in line with the preferences of the cooperating police forces. After collecting the 
data, adjustment factors could be applied to correct the disproportionate sample distribution into a 
proportionate one. 
Each stratum needed to have a sufficient number of observations in order to allow statistically 
significant outcomes. The required sample size was depending on the expected prevalence, the 
sampling error and the 95% confidence intervals. An insufficient sample size would result in outcomes 
with large 95% confidence intervals.  
 
Table 3.2 presents an overview of the representativeness of the various roadside surveys based on a 
comparison between the distribution of the survey sample and the distribution of the driving population 
according to the eight DRUID time periods. Information on the distribution of the national driving 
population was collected by each partners. Most partners used data from national traffic surveys and 
for countries which did not have any information on traffic distribution by time period available, an 
estimation was used based on the mean of a group of OECD (Organisation of Economic Cooperation 
and Development) member states that were able to provide this information. As explained above, 
differences between the sample distribution and the distribution of the general driving population are 
solved by applying adjustment factors. For instance, if the share of the study population in a given 
period was 10% and the share of the general driving population in that same time period was 20%, an 
adjustment factor of 20/10=2.0 is needed to correct for the skewness caused by the sampling design. 
However, if the adjustment factor becomes very high, the quality of the survey results may be 
endangered, since a serious under-representation of a time period in combination with a small sample 
size may cause a representativeness issue. Therefore, in this assessment the upper limit for an 
adjustment factor was set at 3, although there are no specific guidelines for the maximum size of an 
adjustment factor. The results of this assessment should therefore be sheen as purely indicative, and 
not to be used for any statistical purposes.  
 
Table 3.2. Representativeness of roadside surveys by day and time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Country Adjustment factor > 3 (for any 6 hour time period) 
Belgium No 
Czech Republic No 
Denmark No 
Spain No 
Finland No 
Hungary Yes 
Italy Yes 
Lithuania Yes 
Netherlands No 
Norway No 
Poland Yes 
Portugal No 
Sweden Yes 
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Five countries had a large under-representation in one or more time periods: Hungary, Italy, Lithuania, 
Poland and Sweden. For these five countries the potential bias and the need for clustering of day-and-
time periods was assessed. The assessment included two indicating factors: 
1. The number of time periods with a sample size < 100 subjects. 
2. The share of underrepresented time periods. 
A high adjustment factor can be an indicator for clustering of time periods for one or more substances. 
Furthermore, it indicates the likelihood of bias. The results of the additional assessment for the five 
countries are presented in table 3.3. The share of underrepresented time periods is calculated by 
summing up the share of traffic in those time periods where the sample size was less than 100 and the 
adjustment factor was more than three. If the share of underrepresented time periods was smaller 
than 25% the likelihood of bias was estimated as low. Otherwise it was estimated as high. 
 
Table 3.3. Assessment of representativeness for countries with adjustment factor > 3 
 
 
 
 
 
 
 
 
 
The Hungarian roadside survey contained one DRUID time period (time period 6: weekend days 
10:00-15:59) with a significant underrepresentation. This time period accounted for 11% of the person 
kilometres driven. The sample size of time period 5 (N=91), which included weekend mornings 04:00 - 
09:59, is not reported in table 3.3, since the share of the roadside sample and the general driving 
population were almost equal (and both very small). Therefore, a possible bias for this day-and-time 
period would have only a small effect on the final results. 
 
The Italian roadside survey contained three time periods with a small sample size, in combination with 
a significant underrepresentation. Most roadside survey sessions took place during weekend and 
weekday nights. As a result, the daytime sample size accounted for only 35% of the total sample size, 
while the traffic share for that period added up to 94% of the total traffic volume. 
 
In Lithuania sampling took place mostly during daytime periods between 10:00 and 21:59, covering 
73% of the general driving population. Only 99 samples were collected during early morning and night-
time sessions, comprising barely 6% of all cases. Even when clustering would be applied, the 
likelihood of bias was high since time periods, which were assumed to have higher prevalence 
percentages, such as weekday and weekend nights and weekend mornings, were represented by 
small numbers of samples (35, 16, and 0, respectively).  
 
The Polish roadside survey comprised only one time period with a serious underrepresentation in 
combination with a low number of samples. This time period covered the weekday mornings 04:00 - 
09:59, which included a large share of the general driving population. The number of samples in this 
time period was only slightly lower than 100, so the potential bias was estimated as limited.  
 
In Sweden the adjustment factor for weekday mornings 04:00 - 09:59 was higher than 3. However, 
almost 400 samples were collected in this time period meaning that the 95% confidence interval of the 
calculated prevalence was probably relatively small. 
 
The geographical coverage of a country was another important factor with regard to 
representativeness. If traffic distribution and/or psychoactive substance use varies substantial between 
regions, selecting only one survey region may not give a good representation of the national situation. 
The number of survey regions per country is presented in table 3.4.  
 
 
Country 
Number of time periods 
with sample size < 100 
and an adjustment 
factor > 3 
Share of 
underrepresented time 
periods 
Likelihood of bias 
Hungary 1 11% Low 
Italy 3 56% High 
Lithuania 2 30% High 
Poland 1 21% Low 
Sweden 0 0% Low 
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Table 3.4. National geographical coverage of the roadside surveys 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three countries selected only one survey region (or cluster of regions). These three countries were 
Hungary, Italy, and Sweden. The selected region in each of these countries might have been 
representative of the whole country, but this has to be made plausible.  
 
According to the Hungarian country report (see Part 2) their survey region was representative of the 
South Eastern part of Hungary. However, information on differences or similarities between the South 
Eastern part and the rest of Hungary was lacking. Therefore, the representativeness of the results of 
the Hungarian roadside survey is not known. 
 
In the Italian country report it is stated that the police may have applied a pre-selection of people that 
were sent to the researchers for the DRUID protocol, based either on the use of presumptive tests for 
alcohol or physical signs of impairment, according to their standard protocols. However, the results 
obtained are in agreement with epidemiological studies on the use of alcohol and drugs, evidencing 
that the sampled population can be considered a representative sample of Italy. 
 
The Swedish country report indicates that the study was conducted in a relatively small part of 
Sweden, which comprises several medium-sized cities. Since this is the first study of its kind in 
Sweden, it is difficult to know if the results are representative for other parts of the country. However, 
the authors found two studies of drug prevalence in general; one is a survey of drug use among young 
adults (mostly men) signing in for the Swedish army (CAN, 2009; table 19) and one is about cannabis 
use among the general population (age 16-84; FHI, 2011). Both studies showed that drug use varied 
between counties but there were no evidence that the DRUID study region differed substantially from 
other counties, at least not if the counties including the big cities Stockholm, Göteborg and Malmö 
were excluded.  
3.3 Non-response bias 
Non-response and non-response bias are common problems in epidemiological studies (Berghaus et 
al., 2007). Non-response bias occurs when people who do not respond to the survey, differ with regard 
to drug use from those who do respond. The presence of non-response bias is difficult to indicate, but 
differences in the distribution by age and gender, and differences in alcohol prevalence if available 
provide some information on the likelihood of non-response bias. The higher the non-response rate, 
the higher the possibility for a non-response bias. 
The non-response rate of the thirteen prevalence studies varied between 0% and 52%. In general the 
size and nature of the non-response depends on two factors: study design and external factors, the 
latter rather affects variation in the size of non-response than the total size of the non-response. 
3.3.1 Non response due to study design factors 
Study design factors could affect the size and nature of the non-response in various ways. The first 
issue is the choice of body fluids to be collected and analysed for recent drug use: in the case of the 
DRUID roadside survey either blood or saliva (see Annex 2). Since blood sampling is more invasive 
than saliva sampling, drivers would probably have been less eager to give blood than saliva. 
Country Number of regions (or clusters of regions) 
Belgium 3 
Czech Republic 6 
Denmark 3 
Spain 4 
Finland 2 
Hungary 1 
Italy 1 
Lithuania 5 
Netherlands 6 
Norway 3 
Poland 6 
Portugal 3 
Sweden 1 
  28 
Furthermore, several subjects who refused to give blood informed the researcher that they were afraid 
of needles or blood. 
A second design factor which might affect the non-response was the sequence of police enforcement 
and research activities. For example, it is likely that the willingness of drivers in cooperating with the 
research decreased strongly if they had been arrested by the police before being requested to 
cooperate with the research (if the police allowed suspects to cooperate at all). 
A third factor relates to the voluntary character of the survey. Only in Italy participation was mandatory 
and people who refused cooperation were fined. It is obvious that mandatory cooperation resulted in 
very low non-response rates. And in Spain, the voluntary participation was requested while drivers 
were waiting for the result of the mandatory saliva test performed by the police. This also resulted in 
very low non-response rates. 
Finally, the need for a written informed consent from each driver, as was required in some countries, 
might have negatively influenced the response rate. Written informed consent, confirmed by an 
autograph might raise questions on the level of anonymity. Furthermore, during the time spent reading 
the document, participants had time to reconsider their participation. 
Table 3.5 presents an overview of the four study design factors that may have influenced the size and 
nature of non-response.  
 
Table 3.5. Study design and non-response 
Country Body fluid Precedence Mandatory Informed consent Non-response 
Belgium Saliva/blood Police first No Yes 52% 
Czech Republic Saliva Police first No No 23% 
Denmark Saliva Police first No No 5% 
Spain Saliva Police first No Yes 2% 
Finland Saliva Police first No Yes 48% 
Hungary Saliva Police first No Yes 10% 
Italy Saliva/blood Police first Yes NA 0% 
Lithuania Blood Researcher first No No 24% 
Netherlands Saliva/blood Researcher first No No 5% 
Norway Saliva Police first No Yes 6% 
Poland Saliva Researcher first No Yes 1% 
Portugal Saliva Researcher first No No 3% 
Sweden Saliva Police first No No 38% 
 
Nine countries collected only saliva and three countries both saliva and blood. In Lithuania, only blood 
was collected. In the Netherlands a blood sample was asked and in case of refusal a saliva sample. 
25% of the drivers refused to give blood. However, most of these refusers were willing to give a saliva 
sample. In total 5% of the drivers refused both blood and saliva sampling. In Lithuania, no saliva 
samples were asked. The refusal of blood sampling in Lithuania was of a comparable size as that for 
the Netherlands, namely 24%. In Poland and Portugal, where the study design was in terms of 
precedence quite similar to the Dutch and Lithuanian surveys, saliva-only was requested, resulting in 
1% and 3% non-response, respectively.  
In all countries where the police performed a mandatory drug test or where drug testing by 
researchers preceded the mandatory breath test for alcohol, non-response was very low (0-5%). In 
countries where the police performed the mandatory breath test for alcohol before the voluntary drug 
test was performed by a researcher, the non-response range was quite broad: 5-52%. Only in two of 
these countries (Denmark and Norway) a non-response below 10% was achieved. Therefore, the 
precedence seems to be a noteworthy factor for the rate of non response. 
In Spain, saliva sampling took place while drivers were waiting for police test results and, in Italy, 
saliva sampling was mandatory. As a result, these two countries had a very low non-response of 2% 
and 0%, respectively. In countries where drug testing was not mandatory, non-response varied from 1-
52%. Summarising: mandatory drug testing resulted in very low refusal rates, but voluntary drug 
testing not always resulted in high refusal rates. 
Similarly, written informed consent was not always associated with increased non-response. 
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3.3.2 Non-response due to external factors 
Within each of the thirteen prevalence studies, several external factors can be indicated. These factors 
may have had an effect on the size of the non-response, but they could hardly have been influenced 
by the design of the study.  
One of those factors were weather conditions. Some countries reported that people were less willing 
to cooperate under adverse conditions like storm and rain. The Hungarian study reported a 17.6-
42.9% non-response during winter months, while in spring and summer non-response varied from 6.1-
14.7%. 
A second external factor was negative publicity. In Hungary, the collection of saliva was associated 
with the collection of DNA, on national television. Although the programme was not specifically aimed 
at saliva collection within the DRUID project, it was decided to interrupt the roadside survey for a 
couple of months, in order to prevent high non-response rates. 
A third factor was the experience of the survey team in convincing drivers to participate in the study. A 
trend line of the Dutch survey showed a continuously increasing response rate from the start to the 
end of the project.  
A fourth factor was the day of the week and the time of the day. Early in the morning people were 
hasty to get to work in time. They were probably less willing to lose time than people who travel later in 
the morning or in the early afternoon. During early morning sessions, some people travel back home 
after a night shift. When confronted with a request for voluntary study participation, they were not 
always very eager to participate. This was reflected in the non-response rates at the various time 
periods. 
All the factors mentioned above may have affected the overall non-response rates. However, it is not 
likely that one of these external factors in itself would really be able to cause a high non-response.  
3.3.3 Selectivity of the non-response group 
Another important aspect is the selectivity of the non-response group. Results of the roadside surveys 
would underestimate the prevalence of psychoactive substances, if drivers under the influence would 
be more likely to refuse participation. This might for instance be the case if they believed that 
participation could result in a judicial sanction.  
Underestimation of the prevalence of psychoactive substances among the general driving population 
is especially problematic if the roadside survey sample is used as a control sample in a case-control 
study. Underestimation of the prevalence among controls will then result in overestimation of the risk 
associated with psychoactive substance use.  
We assume that the effect of non-response bias is small in this roadside survey study when the size of 
non-response is not exceeding the size of prevalence. This assumption should be regarded as a 
practical rule-of-thumb. The non-response bias will only be discussed for countries with higher non-
response than prevalence figures. Table 3.6 presents those countries included and shows both their 
prevalence and their non-response percentage. 
 
Table 3.6. High non-response countries 
Country Prevalence  Non-response  
Belgium 10.65% 52% 
Czech Republic 2.8% 23% 
Finland 2.9% 48% 
Hungary 2.3% 12% 
Lithuania 5.5% 24% 
Sweden 1.3%* 38% 
*No information available on alcohol in Sweden 
 
The Belgian roadside survey suffered from a high non-response rate, which could lead to a large bias 
if the non-response group was selective. For the non-responders, data was available on age, gender, 
transport mode and alcohol use. Comparison between the response and non-response groups on 
these four characteristics gave no indication of non-response bias (see Part 2). 
 
The Czech roadside survey had a non-response of 23%. 84% of these non-respondents were male 
and 16% were female. This distribution is similar to the distribution of the driving population. There is 
no information available on other aspects. Nevertheless, the authors of the national roadside survey 
report stated that there may be some bias in the results. In their opinion, non-cooperating drivers were 
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most likely afraid that the police would be informed about the alcohol or drug presence in their saliva, 
because they knew they violated the road traffic act (see Part 2). 
 
The non-response rate of the Finnish study was almost as high as the Belgian one. Due to judicial 
limitations, no comparison was possible between the response and non-response groups. The 
majority of the refusals were on the initial request to participate by the police, before the drivers 
learned about the nature of the study. It was an obligation of the ethical advisory board that the drivers 
were informed of the time required to participate in the study. Hence the researchers state that it is 
reasonable to assume that one of the main reasons for refusal was the lack of time. Comparison of the 
DRUID study population with a recently conducted study on the Finnish traffic distribution show that 
the demographic profile of the respondents was representative of the Finnish general driving 
population and had not been influenced by the variance in response between sessions (see Part 2).  
Due to agreements with the Finnish police, no roadside sampling took place between 01:00-07:00. No 
large bias in the total prevalence is expected due to this missing time period since it represents only a 
small share of the total driving population during weekend and weekday nights. The proportion of 
drivers during the weekday mornings, from 04:00-07:00, was larger than between 07:00 - 10:00 but 
the prevalence of psychoactive substances between 04:00 - 10:00 would probably not be very 
different from the prevalence from 07:00-10:00. 
 
The Hungarian study had a non-response of 12%, which was above the prevalence of alcohol and 
drugs in Hungary. The Hungarian country report (see Part 2) shows there tends to be a small 
overrepresentation of women in the non-response group, as well as an overrepresentation of persons 
aged 35-40 years as compared to those who had participated. This would probably not result in a 
large bias. However, it was reported that some drivers could avoid being stopped and checked by the 
police. If this fact is taken into consideration, it cannot be ruled out that the prevalence figures may 
have been underestimated. 
The Lithuanian roadside survey had a non-response of 24%. Somewhat surprisingly, there was a large 
overrepresentation of women in the non-response group: two-thirds of the non- responders were 
females, mostly in the age group below 35 years. The main reason of refusal appeared to be lack of 
time, and no signs of impairment were observed in this group. Therefore, the non-response bias is not 
expected to be high (see Part 2). 
Non-response in the Swedish roadside survey was 38%. No information was gathered about the non-
responders. However, in a similar study conducted a couple of years ago, where participation was 
mandatory, the gender and age distributions were similar. The researchers concluded that it was 
impossible to estimate how much the results deviate from the real prevalence (see Part 2). 
Furthermore, no data on alcohol above the legal limit of 0.2 g/L BAC was collected because of the 
Swedish legislation.  
3.4 Conclusion  
Based on the previous assessment it can be concluded that there are some limitations with regard to 
representativeness and non-response for one or more of the thirteen roadside survey studies. The 
overall representativeness for Northern and Western Europe is quite low. Therefore, generalisation of 
outcomes to a European level will be difficult and can only be calculated with the aid of some 
assumptions on the representativeness. 
The expected representativeness on a national level varies per country. In order to correct for large 
under-representations in one of the eight time periods, clustering of the data is needed. Clustering will 
certainly not solve all representativity issues, but at least it will improve the validity of the data to some 
extent.
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4. Results 
 
This chapter presents the results of the 13 roadside surveys that were conducted in the DRUID-
project. In the first paragraph general results will be presented. The second paragraph presents the 
average prevalence for Europe and the four European sub-regions. And finally an overview will be 
given for each of the substance groups.  
The results in all tables are based on the weighted results for the participating countries. Weighted 
numbers and their 95% confidence intervals (see 2.7.1) are included in the tables and figures in 
section 4.3. The weighted numbers for male and female drivers may not always sum up to the total 
weighted number of samples due to missing values for gender and round up of sample numbers. For 
more information on the weighting procedure see section 2.4.   
 
4.1 General results 
The general results provide an overview of the general use of drugs in traffic by substance type (illicit 
drugs, medicinal drugs, alcohol and alcohol and drugs) and by substance group: amphetamines, 
cocaine, cannabis, illicit opiates, benzodiazepines, Z-drugs, medicinal opiates and opioids, alcohol 
and alcohol and drugs. 
4.1.1 Prevalence by substance type 
Table 4.1 provides an overview of the prevalence by substance group and by country. The following 
groups of drugs are regarded as illicit: amphetamines, cocaine, THC, and illicit opiates.  
The group of medicinal drugs is formed by benzodiazepines, Z-drugs and medicinal opiates and 
opioids.  
Drug-drug combinations are formed by the combination of drugs from two or more separate drug 
substance groups, either illicit or medicinal. The combined use of two substances from the same 
substance group, e.g. two different types of benzodiazepines is regarded as single substance use. 
More information on the effect of different drugs on driving behaviour will be presented in paragraph 
4.3. 
 
The results in table 4.1 show that the prevalence of Illicit drugs is the highest in Spain (8.20%), 
meaning that 8.2% of all drivers was positive for one or more illicit drug, Italy (3.92%), the Netherlands 
(2.51%), and Portugal (1.80%). For all other countries the prevalence varied between 0.22% (Sweden) 
and 0.94% (Belgium). 
 
Medicinal drugs are most prevalent in Belgium (2.99%) and Portugal (2.84%). The prevalence of 
medicinal drugs in the other countries varied between 0.17% in Poland and 1.71% in Finland. The 
majority of the countries (7 out of 13) had a prevalence rate between 1.4 and 1.8%. 
 
Single alcohol use (≥ 0.1 g/L) was most frequently detected in Italy (8.59%), Belgium (6.42%), 
Portugal (4.93%), Spain (3.92%) and Lithuania (3.86%). For all other countries the prevalence varied 
between 0.15% (Hungary) and 2.53% (Denmark). No data on alcohol was available for Sweden. 
Therefore Sweden was not coloured in figure 4.4. 
 
The combination alcohol and drugs was most prevalent in Spain (1.14%) and Italy (1.01%). In all other 
countries the prevalence varied between 0.00% in Poland and 0.42% in Portugal. No information on 
the combined use of alcohol and drugs was available for Sweden. The expected prevalence for 
Sweden is low, because of the relatively low prevalence of illicit and medicinal drugs in Sweden. 
Therefore Sweden was not coloured in figure 4.5. 
 
Figures 4.1-4.6 present a geographical representation of the prevalence of the various substance 
groups for the different countries. 
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Table 4.1. Overview of general prevalence by substance type and by country; prevalence are in %; in 
italics the 95% confidence intervals are shown. 
  negative illicit drugs medicinal drugs alcohol 
drug+drug 
combinations alcohol+drugs 
BE 89.35 0.64 2.99 6.42 0.3 0.31 
  88.18 - 90.41 0.41 – 1.00 2.43 - 3.66 5.59 - 7.36 0.16 - 0.58 0.16 - 0.58 
CZ 97.20 0.82 0.83 0.99 0.11 0.05 
  96.39 - 97.83 0.51 – 1.31 0.52 - 1.33 0.65 - 1.53 0.03 - 0.38 0.01 - 0.28 
DK 95.52 0.22 1.58 2.53 0.06 0.10 
  94.72 - 96.2 0.10 – 0.46 1.19 - 2.09 2.02 - 3.15 0.02 - 0.24 0.03 - 0.3 
ES 85.15 7.63 1.59 3.92 0.57 1.14 
  83.87 - 86.34 6.76 – 8.61 1.21 - 2.09 3.3 - 4.66 0.36 - 0.89 0.83 - 1.58 
FI 98.66 0.12 1.71 0.64 0.29 0.08 
  96.58 - 97.63 0.06 – 0.30 1.35 - 2.17 0.43 - 0.94 0.16 - 0.52 0.03 - 0.23 
HU 97.68 0.23 1.68 0.15 0.27 0.00 
  97.04 - 98.18 0.11 – 0.49 1.26 - 2.23 0.06 - 0.38 0.13 - 0.54 0 - 0.14 
IT 84.99 2.7 1.50 8.59 1.22 1.01 
  82.95 - 86.82 1.95 – 3.73 0.97 - 2.31 7.19 - 10.23 0.75 – 1.97 0.59 - 1.71 
LT 94.49 0.22 1.41 3.86 - 0.03 
  93.09 - 95.61 0.07 – 0.66 0.9 - 2.23 2.93 - 5.06 - 0 - 0.36 
NL 95.52 2.16 0.60 2.15 0.35 0.24 
  93.81 - 95.1 1.79 – 2.61 0.42 - 0.87 1.78 - 2.6 0.22 - 0.56 0.13 - 0.42 
NO 97.03 0.6 1.69 0.32 0.28 0.07 
  96.67 - 97.36 0.46 – 0.78 1.45 - 1.98 0.23 - 0.46 0.19 - 0.42 0.03 - 0.15 
PO 97.63 0.71 0.17 1.47 0.02 0.00 
  97.11 - 98.05 0.49 – 1.02 0.08 - 0.35 1.14 - 1.9 0.00 - 0.14 0 - 0.1 
PT 90.01 1.57 2.84 4.93 0.23 0.42 
  89.04 - 90.91 1.23 – 2.01 2.37 - 3.41 4.29 - 5.64 0.12 - 0.44 0.26 - 0.67 
SE 98.66 0.1 1.12 - 0.12 - 
  98.34 - 98.92 0.04 – 0.21 0.89 - 1.42 - 0.06 - 0.25 - 
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Figure 4.1. Geographical presentation of psychoactive substance use by car drivers in the EU 
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Figure 4.2. Geographical presentation of illicit drug use by car drivers in the EU 
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Figure 4.3. Geographical presentation of medicinal drug use by car drivers in the EU 
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Figure 4.4. Geographical presentation of single alcohol use by car drivers in the EU 
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Figure 4.5. Geographical presentation of combinational use of alcohol and drugs by car drivers in the EU 
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Figure 4.6. Geographical presentation drug-drug combinations by car drivers in the EU 
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In conclusion, the prevalence of illicit drugs was higher than the prevalence of medicinal drugs in the 
Southern European countries Spain and Italy and in the Netherlands, Czech Republic and Poland. 
Medicinal drugs were relatively more frequently detected than illicit drugs in the Northern European 
countries, Belgium, Portugal, Lithuania and Hungary. 
The prevalence of drugs (including both illicit and medicinal drugs) exceeded the prevalence of alcohol 
in Czech Republic, Spain, Finland, Hungary, the Netherlands, and Norway. In all other countries the 
prevalence of alcohol was higher than that of other psychoactive substances. 
4.1.2 Prevalence by substance group and country 
Table 4.2 presents the prevalence of the substances by country for substance groups. This more 
detailed overview of prevalence of psychoactive substances shows that for illicit drugs THC is the 
most commonly detected drug in traffic, followed by cocaine. Amphetamines and illicit opiates were 
less frequently detected. 
In general benzodiazepines were the most prevalent medicinal drugs in traffic. However, in Denmark 
and Sweden medicinal opiates and opioids were more frequently detected. Z-drugs were less 
prevalent and even not detected at all in Southern Europe and the Eastern European countries Czech 
Republic, Lithuania, and Poland. Only in Norway, the prevalence of Z-drugs was relatively high (0.69% 
of all drivers). 
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Table 4.2. Overview of general prevalence by substance groups and by country in percentages; 95% confidence intervals are shown in italics 
  
 
negative 
 
 
amphe- 
tamines 
 
cocaine 
 
THC 
 
illicit 
opiates 
 
benzodia- 
zepines 
 
Z-drugs 
 
medicinal 
opiates 
 
alcohol 
 
alcohol 
+ drugs 
 
drugs-
drugs 
BE 89.35 - 0.2 0.35 0.09 2.01 0.22 0.75 6.42 0.31 0.3 
  88.18 - 90.41 - 0.09 - 0.43 0.19 - 0.64 0.03 - 0.28 1.57 - 2.59 0.1 - 0.47 0.5 - 1.13 5.59 - 7.36 0.16 - 0.58 0.16 - 0.58 
CZ 97.2 0.36 - 0.46 - 0.62 - 0.21 0.99 0.05 0.11 
  96.39 - 97.83 0.17 - 0.72 - 0.25 - 0.86 - 0.36 - 1.07 - 0.08 - 0.52 0.65 - 1.53 0.01 - 0.28 0.03 - 0.38 
DK 95.52 0.02 - 0.2 - 0.47 0.32 0.79 2.53 0.1 0.06 
  94.72 - 96.2 0 - 0.16 - 0.09 - 0.43 - 0.28 - 0.79 0.17 - 0.59 0.53 - 1.18 2.02 - 3.15 0.03 - 0.3 0.02 - 0.24 
ES 85.15 0.11 1.49 5.99 0.05 1.4 - 0.19 3.92 1.14 0.57 
  83.87 - 86.34 0.04 - 0.3 1.12 - 1.97 5.22 - 6.87 0.01 - 0.2 1.05 - 1.87 - 0.09 - 0.41 3.3 - 4.66 0.83 - 1.58 0.36 - 0.89 
FI 97.15 0.05 0.03 0.04 - 0.79 0.36 0.56 0.64 0.08 0.29 
  96.58 - 97.63 0.02 - 0.19 0.01 - 0.16 0.01 - 0.17 - 0.56 - 1.13 0.21 - 0.6 0.37 - 0.85 0.43 - 0.94 0.03 - 0.23 0.16 - 0.52 
HU 97.68 - 0.04 0.19 - 1.5 0.07 0.11 0.15 - 0.27 
  97.04 - 98.18 - 0.01 - 0.21 0.08 - 0.44 - 1.11 - 2.03 0.02 - 0.26 0.04 - 0.32 0.06 - 0.38 - 0.13 - 0.54 
IT 84.99 - 1.25 1.15 0.3 0.97 - 0.53 8.59 1.01 1.22 
  82.95 - 86.82 - 0.78 - 2.01 0.7 - 1.89 0.12 - 0.78 0.57 - 1.67 - 0.25 - 1.09 7.19 - 10.23 0.59 - 1.71 0.75 - 1.97 
LT 94.49 0.22 - - - 1.41 - - 3.86 0.03 - 
  93.09 - 95.61 0.07 - 0.66 - - - 0.9 - 2.23 - - 2.93 - 5.06 0 - 0.36 - 
NL 94.49 0.19 0.3 1.67 0.01 0.4 0.04 0.16 2.15 0.24 0.35 
  93.81 - 95.1 0.1 - 0.36 0.18 - 0.5 1.34 - 2.07 0 - 0.09 0.25 - 0.62 0.01 - 0.15 0.08 - 0.32 1.78 - 2.6 0.13 - 0.42 0.22 - 0.56 
NO 97.03 0.06 0.06 0.48 - 0.84 0.69 0.16 0.32 0.07 0.28 
  96.67 - 97.36 0.02 - 0.13 0.03 - 0.14 0.36 - 0.64 - 0.67 - 1.05 0.54 - 0.88 0.1 - 0.27 0.23 - 0.46 0.03 - 0.15 0.19 - 0.42 
PL 97.63 0.05 - 0.57 0.09 0.14 - 0.03 1.47 - 0.02 
  97.11 - 98.05 0.01 - 0.18 - 0.38 - 0.85 0.04 - 0.25 0.06 - 0.31 - 0.01 - 0.15 1.14 - 1.9 - 0 - 0.14 
PT 90.01 - 0.03 1.38 0.15 2.73 - 0.11 4.93 0.42 0.23 
  89.04 - 90.91 - 0.01 - 0.16 1.07 - 1.8 0.07 - 0.33 2.27 - 3.29 - 0.04 - 0.27 4.29 - 5.64 0.26 - 0.67 0.12 - 0.44 
SE 98.66 0.07 - 0.03 - 0.19 0.31 0.63 - - 0.12 
 98.34 - 98.92 0.03 - 0.17 - 0.01 - 0.12 - 0.11 - 0.33 0.2 - 0.48 0.46 - 0.86 - - 0.06 - 0.25 
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4.2 Estimate of a European mean 
 
The general results of the prevalence of psychoactive substances among drivers show differences in 
substance use between countries in the different European regions. These differences should be 
taken into account when trying to estimate the mean prevalence of substances for the European 
Union. 
To estimate this mean prevalence the number of inhabitants of each country had to be used, since, 
unfortunately, traffic volume figures were not available in each of the 13 countries (SafetyNet, 2007). 
Therefore population was used as a surrogate exposure measure for the traffic volume in each 
country. Weight factors for each country have been calculated by dividing in each European region the 
number of inhabitants in a participating country by the total number of inhabitants in all participating 
countries in its European region.  
Then a weighted mean was calculated for each region based upon the weight of each country.  
Finally a weighted mean for the European Union was calculated by using the share of the number of 
inhabitants per European region by the total population of the EU as a weight factor. 
All these calculations have been made under the assumption that the results of the roadside surveys 
are representative for the thirteen participating countries (see chapter 2). 
 
Originally Lithuania was regarded as a Northern European country according to the geographical 
classification by the United Nations. However, looking at the pattern of the substance use and the 
political background it can be argued that Lithuania is not a Northern European country but an Eastern 
European country. Therefore, Lithuania is regarded in this report as an Eastern European country.  
 
The European mean can be used to distinguish per substance whether a country is around, below or 
above the European mean. Table 4.3 presents the spread of the prevalence around the European 
mean. A yellow colour of the prevalence means that the European mean is within the 95% confidence 
interval of the prevalence. A green coloured prevalence indicates that the confidence interval is below 
the European mean, and for a red coloured prevalence the confidence interval is entirely above the 
European mean. 
 
The results indicate that the use of psychoactive substances in traffic is in general low in Northern 
Europe. However, medicinal opiates and opioids and Z-drugs were more frequently detected among 
drivers in Northern European countries than in the rest of Europe. In Finland and Norway, 
benzodiazepines and drugs-drugs combinations were not used less than the European average, 
whereas in Denmark and Sweden they were. 
 
Among drivers in the participating Eastern European countries the prevalence of psychoactive 
substances was even less than in Northern Europe. However, benzodiazepines were relatively more 
frequently detected in Lithuania and Hungary than on average in Europe. In Czech Republic 
amphetamines were detected the most from all participating countries. 
 
The prevalence of psychoactive substances in traffic was the highest in Southern European countries. 
All illegal drugs except amphetamines were relatively highly prevalent, as well as benzodiazepines 
and alcohol. Z-drugs were not detected at all.  
 
Western Europe is only represented by Belgium and the Netherlands and their relative prevalence is 
almost the exact opposite. In Belgium relatively high prevalence is observed for benzodiazepines, 
medicinal drugs and alcohol, whereas the use of THC and amphetamines is relatively low. In the 
Netherlands the use of THC and amphetamines is relatively high and the prevalence of 
benzodiazepines, medicinal drugs and alcohol is relatively low. For all other substance groups both 
countries have an average prevalence. 
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Table 4.3. Estimated European prevalence of psychoactive substances; prevalence in percentage; 95% confidence intervals in italics 
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4.3 Results per substance 
The results per substance will be discussed in the following sections. Interesting findings on the results 
by gender, by age and by time period will be presented. The results will be shown for single use of 
each substance group. The combination of a substance with a substance from another substance 
group will be regarded as combinational use. The share of combinational use in relation to single use 
is presented as well for each substance. 
The 95% confidence intervals can vary between countries and within countries for the different 
disaggregations. Therefore, differences between the participating countries should be interpreted with 
care, especially the differences for disaggregations by gender, age and time period. 
4.3.1 Alcohol 
In all European countries alcohol is a legal drug for persons who are old enough to drive a car. 
Worldwide there has already been a lot of research conducted on the prevalence and risk of driving 
under the influence of alcohol (ethanol). The general finding is that alcohol use in traffic is already risky 
at low BAC levels, especially for younger drivers who have less driving experience than older drivers. 
Alcohol affects the driving behaviour by increasing the reaction time and decreasing concentration, 
coordination and tracking.  Furthermore, alcohol leads to more risk-taking behaviour and affects 
decision making and planning, since drivers overestimate their skills and underestimate the risk due to 
the effects of alcohol (Kelly et al., 2004; Steyvers and Brookhuis, 1996). 
4.3.1.1 General results 
Alcohol (ethanol) was detected among car drivers by using breath alcohol testers or analysing blood or 
oral fluid. The breath alcohol results were converted to blood alcohol results by using a conversion 
factor of 1:2100, since most participating countries use this conversion factor in their legislation. The 
results for alcohol are presented in table 4.3.1.1 subdivided into four blood alcohol concentration 
(BAC) categories: 0.1-0.49 g/L, 0.5-0.79 g/L, 0.8-1.19 g/L, and 1.2 g/L and higher. No alcohol results 
were available for Sweden. 
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Table 4.3.1.1. Prevalence of alcohol alone by BAC (g/L) category and country; prevalence in percentages; 
95% confidence intervals in italics 
 alcohol 0.1-0.5 alcohol 0.5-0.8 alcohol 0.8-1.2 alcohol 1.2+ Total 
BE 4.27 1.33 0.42 0.41 6.42 
(n=2949) 3.59 - 5.06 0.97 - 1.81 0.24 - 0.72 0.23 - 0.71 5.59 - 7.36 
CZ 0.54 0.24 0.15 0.06 0.99 
(n=2037) 0.30 - 0.97 0.10 - 0.57 0.05 - 0.44 0.01 - 0.30 0.65 - 1.53 
DK 2.05 0.28 0.18 0.02 2.53 
(n=3002) 1.60 - 2.62 0.14 - 0.54 0.08 - 0.41 0.00 - 0.16 2.02 - 3.15 
ES 2.31 0.90 0.23 0.49 3.92 
(n=3174) 1.84 - 2.89 0.62 - 1.29 0.11 - 0.47 0.30 - 0.80 3.30 - 4.66 
FI 0.38 0.10 0.02 0.13 0.64 
(n=3842) 0.23 - 0.63 0.04 - 0.27 0.00 - 0.14 0.05 - 0.30 0.43 - 0.94 
HU 0.05 0.02 0.00 0.08 0.15 
(n=2741) 0.01 - 0.24 0.00 - 0.18 0.00 - 0.14 0.02 - 0.28 0.06 - 0.38 
IT 3.35 2.02 1.81 1.40 8.59 
(n=1311) 2.51 - 4.47 1.39 - 2.94 1.22 - 2.69 0.89 - 2.19 7.19 - 10.23 
LT 1.55 0.43 0.41 1.47 3.86 
(n=1267) 1.00 - 2.39 0.19 - 0.97 0.18 - 0.94 0.94 - 2.29 2.93 - 5.06 
NL 1.54 0.26 0.14 0.21 2.15 
(n=4822) 1.23 - 1.93 0.15 - 0.44 0.07 - 0.29 0.12 - 0.39 1.78 - 2.60 
NO 0.26 0.04 0.02 0.01 0.32 
(n=9236) 0.17 - 0.38 0.02 - 0.11 0.00 - 0.07 0.00 - 0.06 0.23 - 0.46 
PL 0.89 0.18 0.27 0.14 1.47 
(n=4008) 0.64 - 1.23 0.09 - 0.36 0.15 - 0.48 0.06 - 0.31 1.14 - 1.90 
PT 3.71 0.44 0.47 0.31 4.93 
(n=3965) 3.17 - 4.35 0.27 - 0.69 0.30 - 0.74 0.18 - 0.53 4.29 - 5.64 
 
In general the highest prevalence is present among the lower BAC categories. However, in Lithuania a 
large share of alcohol-intoxicated drivers had a BAC level of 1.2 g/L or higher. The total prevalence for 
alcohol ranged between 0.15% in Hungary and 8.59% in Italy. The average use of alcohol ≥ 0.1 g/L in 
European traffic is 3.48%. 
 
  45 
0.00
2.00
4.00
6.00
8.00
10.00
12.00
BE CZ DK ES FI HU IT LT NL NO PL PT
Alcohol >= 0.1g/L 
European mean
 
Figure 4.3.1.1. Prevalence of alcohol alone ≥ 0.1 g/L by country; prevalence in percentages 
Figure 4.3.1.1 presents an overview of the total prevalence of alcohol ≥ 0.1 g/L with a reference line 
for the European mean. Single alcohol use is most prevalent among car drivers in the three Southern 
European countries, in Belgium and in Lithuania. All other countries had a prevalence that was 
relatively far below the European mean. The prevalence for single alcohol use was the lowest in 
Hungary, Norway and Finland.  
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Figure 4.3.1.2. Prevalence of alcohol alone ≥ 0.5 g/L by country; prevalence in percentages 
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Figure 4.3.1.2 presents the distribution of those drivers who have a BAC of 0.5 g/L and higher. Seven 
European countries that participated in the roadside survey have a legal BAC limit of 0.5 g/L (Belgium, 
Denmark, Spain, Italy, the Netherlands, Portugal and Finland). Lithuania has a legal limit of 0.4 g/L, 
Poland, Norway and Sweden have a legal limit of 0.2 g/L, and Czech Republic and Hungary have a 
legal limit of 0.0 g/L.  The average prevalence for a BAC of 0.5 g/L and higher was 1.49%. 
The relative prevalence between countries for a BAC of 0.5 g/L and higher is similar to that of 0.1 g/L 
and higher. Italy (5.23%) has over twice the prevalence of the second and third ranked countries, 
Lithuania (2.31%) and Belgium (2.16%), respectively.  
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Figure 4.3.1.3. Prevalence of alcohol alone ≥ 1.2 g/L by country; prevalence in percentages 
Figure 4.3.1.3 presents the distribution of those drivers who have a BAC of 1.2 g/L and higher. Italy 
and Lithuania have the highest shares of drivers with this very high BAC. The prevalence in these two 
countries was almost three times higher than that of Spain, which had the third highest prevalence. In 
Lithuania almost 40% of all drivers with alcohol in their blood had a BAC of 1.2 g/L or higher, while for 
most other countries this share is below 15%. High BAC-drivers were virtually absent in Norway and 
Denmark. 
 
Table 4.3.1.2. Prevalence of alcohol alone and alcohol in combination with other psychoactive 
substances; prevalence in percentages 
 BE CZ DK ES FI HU IT LT NL NO PL PT SE 
Alcohol alone 6.42 0.99 2.53 3.92 0.64 0.15 8.59 3.86 2.15 0.32 1.47 6.42 NA 
Alcohol in combi 0.31 0.05 0.1 1.14 0.08 0.03 1.01 0.03 0.24 0.07 - 0.31 NA 
Total 6.73 1.04 2.63 5.06 0.72 0.18 9.6 3.89 2.39 0.39 1.47 6.73 NA 
Share 5% 5% 4% 23% 11% 17% 11% 1% 10% 18% - 5% NA 
 
Table 4.3.1.2 and figure 4.3.1.4 present the prevalence of alcohol alone together with the prevalence 
of alcohol in combination with other psychoactive substances. The relative share of alcohol in 
combination with drugs as a total of all alcohol use is between 0% (Poland) and 23% (Spain). So, in 
Spain the combination of alcohol and drugs is relatively frequent. In almost one quarter of the alcohol 
cases drugs was prevalent as well. In general, countries with a higher prevalence of alcohol and drugs 
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alone (see table 4.3) have a higher prevalence as well for the combination of alcohol and drugs. No 
alcohol data were available for Sweden. 
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Figure 4.3.1.4. Prevalence of alcohol alone ≥ 0.1 g/L and alcohol in combination with other psychoactive 
substances in 12 European countries; prevalence in percentages 
4.3.1.2 Alcohol by gender and age 
Table 4.3.1.3 presents the prevalence of single alcohol use by age group. The highest prevalence in 
Europe was detected among drivers in Italy aged 50+ (13.40%) and 18-24 (9.18%) and among young 
drivers in Portugal (8.97%). The 95% confidence intervals are very large for some countries. 
Therefore, it is difficult to assign exact differences between age groups for the participating countries. 
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Table 4.3.1.3. Prevalence of alcohol alone ≥ 0.1 g/L by age group; prevalence in percentages; 95% 
confidence intervals in italics 
Total 18-24 25-34 35-49 50+ All ages 
BE 6.58 6.62 5.20 7.68 6.42 
(n=2949) 4.28 - 10 4.92 - 8.87 4.04 - 6.67 6.12 - 9.6 5.59 - 7.36 
CZ 0.86 0.27 1.59 1.00 0.99 
(n=2037) 0.24 - 3.02 0.06 - 1.16 0.9 - 2.79 0.44 - 2.29 0.65 - 1.53 
DK 1.48 1.40 2.34 3.35 2.53 
(n=3002) 0.53 - 4.1 0.67 - 2.89 1.59 - 3.43 2.47 - 4.52 2.02 - 3.15 
ES 2.20 3.61 4.19 6.19 3.92 
(n=3174) 1.29 - 3.74 2.63 - 4.93 3.12 - 5.6 4.38 - 8.69 3.3 - 4.66 
FI 0.72 0.76 0.40 0.74 0.64 
(n=3842) 0.25 - 2.09 0.34 - 1.69 0.17 - 0.96 0.41 - 1.32 0.43 - 0.94 
HU 0.00 0.00 0.28 0.23 0.15 
(n=2741) 0 - 1.49 0 - 0.43 0.09 - 0.88 0.05 - 0.99 0.06 - 0.38 
IT 9.18 7.91 8.13 13.40 8.59 
(n=1311) 6.46 - 12.89 5.72 - 10.84 6.03 - 10.87 7.28 - 23.37 7.19 - 10.23 
LT 4.12 3.16 4.04 3.45 3.86 
(n=1267) 2.02 - 8.19 1.73 - 5.69 2.59 - 6.26 1.89 - 6.2 2.93 - 5.06 
NL 0.75 1.86 2.33 2.60 2.15 
(n=4822) 0.29 - 1.96 1.19 - 2.89 1.72 - 3.16 1.92 - 3.51 1.78 - 2.6 
NO 0.39 0.12 0.30 0.39 0.32 
(n=9236) 0.15 - 1.02 0.03 - 0.45 0.16 - 0.55 0.23 - 0.67 0.23 - 0.46 
PL 0.47 2.16 1.95 0.41 1.47 
(n=4008) 0.15 - 1.42 1.5 - 3.08 1.31 - 2.89 0.15 - 1.12 1.14 - 1.9 
PT 8.97 4.50 4.16 4.21 4.93 
(n=3965) 6.83 - 11.7 3.46 - 5.82 3.19 - 5.39 3.07 - 5.75 4.29 - 5.64 
 
Figure 4.3.1.5 presents the distribution of alcohol ≥ 0.1 g/L by age group. There is no general pattern 
in the distribution of drivers positive for alcohol over the different age groups between the countries. 
In Denmark, Czech Republic, Spain, Hungary and the Netherlands the share of drivers younger than 
35 years old is smaller than the share of older drivers. In Belgium, Finland, Italy, Lithuania, Norway 
and Poland the distributions of shares are similar, while in Portugal the share of alcohol positive 
drivers was the highest among young drivers. No results were available for Sweden.  
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Figure 4.3.1.5. Distribution of the prevalence of alcohol alone ≥ 0.1 g/L among the age groups; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various age 
groups  
 
Figure 4.3.1.6 presents an overview of the prevalence of alcohol (≥ 0.1 g/L) by gender. In all countries 
the prevalence for male drivers is higher than for female drivers. The only exceptions are Norway, 
where the prevalence of alcohol among male drivers is equal to that of female drivers, and Italy where 
the prevalence of alcohol among female drivers is even higher than that of men. 
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Figure 4.3.1.6. Prevalence of alcohol alone ≥ 0.1 g/L by gender; prevalence in percentages 
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Table 4.3.1.4 provides an overview of the distribution of alcohol by age for male drivers. 
The prevalence among male drivers is the lowest in Hungary (0.20%) and the highest in Italy (8.39%). 
The 95% confidence intervals are very large for some countries. Therefore, differences between age 
groups for the participating countries should be interpreted with care. 
 
Table 4.3.1.4. Prevalence of alcohol alone ≥ 0.1 g/L by age group for male drivers; prevalence in 
percentages; 95% confidence intervals in italics 
Male 18-24 25-34 35-49 50+ All ages 
BE 7.08 7.51 6.24 8.92 7.47 
(n=1957) 4.2 - 11.71 5.23 - 10.66 4.71 - 8.21 6.98 - 11.33 6.39 - 8.72 
CZ 1.33 0.36 1.70 1.14 1.15 
(n=1589) 0.38 - 4.62 0.08 - 1.54 0.91 - 3.15 0.5 - 2.61 0.73 - 1.81 
DK 1.31 2.19 3.25 4.50 3.47 
(n=1975) 0.35 - 4.76 1.06 - 4.5 2.15 - 4.89 3.3 - 6.11 2.75 - 4.37 
ES 2.41 3.55 4.31 6.81 4.14 
(n=2520) 1.36 - 4.24 2.48 - 5.06 3.12 - 5.92 4.78 - 9.62 3.43 - 4.98 
FI 1.08 1.19 0.44 0.85 0.82 
(n=2511) 0.37 - 3.11 0.53 - 2.62 0.15 - 1.27 0.45 - 1.6 0.54 - 1.26 
HU 0.00 0.00 0.38 0.28 0.20 
(n=2062) 0 - 2.09 0 - 0.58 0.12 - 1.18 0.06 - 1.21 0.08 - 0.51 
IT 9.48 5.38 10.08 12.32 8.39 
(n=998) 6.44 - 13.74 3.46 - 8.27 7.37 - 13.66 5.54 - 25.2 6.82 - 10.27 
LT 4.54 3.60 4.40 3.52 4.20 
(n=1130) 2.24 - 9.01 1.96 - 6.55 2.82 - 6.8 1.91 - 6.4 3.18 - 5.52 
NL 0.82 2.17 2.79 3.01 2.52 
(n=3363) 0.27 - 2.42 1.34 - 3.51 1.98 - 3.91 2.17 - 4.18 2.04 - 3.11 
NO 0.44 0.06 0.29 0.43 0.34 
(n=6520) 0.15 - 1.29 0.01 - 0.45 0.14 - 0.62 0.24 - 0.77 0.22 - 0.51 
PL 0.54 2.61 2.41 0.45 1.75 
(n=3331) 0.17 - 1.68 1.82 - 3.73 1.62 - 3.57 0.16 - 1.23 1.35 - 2.25 
PT 9.76 5.99 6.37 4.47 6.21 
(n=2541) 6.95 - 13.53 4.47 - 8 4.89 - 8.26 3.17 - 6.26 5.34 - 7.21 
 
Figure 4.3.1.7 shows that for male drivers in Portugal, Italy and Belgium the share of drivers with a 
BAC of 0.1 g/L is the highest. In most countries the share of alcohol positive male drivers is the 
highest for the two oldest age groups (35-49 and 50+). 
 
  51 
0.00
2.00
4.00
6.00
8.00
10.00
12.00
BE CZ DK ES FI HU IT LT NL NO PL PT
Agegroup 50+
Agegroup 35-49
Agegroup 25-34
Agegroup 18-24
 
Figure 4.3.1.7. Distribution of the prevalence of alcohol alone ≥ 0.1 g/L among the age groups for male 
drivers; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups.  
 
 
Table 4.3.1.5 provides an overview of the distribution of alcohol positive female drivers by age. No 
single alcohol use was detected among female drivers in Hungary. In Italy however, the share of 
alcohol positive drivers was 9.22%. In Finland, Poland, Norway and Czech Republic the share of 
female drivers positive for alcohol was beneath the 0.5%. The 95% confidence intervals are very large 
for some countries. Therefore, it is difficult to assign exact differences between age groups for the 
participating countries. 
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Table 4.3.1.5. Prevalence of alcohol alone ≥ 0.1 g/L by age group for female drivers; prevalence in 
percentages; 95% confidence intervals in italics 
Female 18-24 25-34 35-49 50+ All ages 
BE 5.77 5.32 3.10 4.31 4.28 
(n=971) 2.73 - 11.8 3.15 - 8.85 1.76 - 5.42 2.4 - 7.64 3.17 - 5.74 
CZ 0.00 0.00 1.21 0.00 0.44 
(n=448) 0 - 4.32 0 - 2.73 0.33 - 4.34 0 - 5.68 0.12 - 1.6 
DK 1.86 0.00 0.84 0.66 0.70 
(n=1015) 0.41 - 8.1 0 - 2.15 0.3 - 2.3 0.2 - 2.15 0.34 - 1.43 
ES 1.39 3.82 3.71 2.19 3.05 
(n=605) 0.34 - 5.5 1.99 - 7.2 1.84 - 7.36 0.49 - 9.21 1.96 - 4.72 
FI 0.00 0.00 0.35 0.45 0.27 
(n=1283) 0 - 2.71 0 - 1.44 0.09 - 1.38 0.12 - 1.74 0.1 - 0.74 
HU 0.00 0.00 0.00 0.00 0.00 
(n=679) 0 - 4.9 0 - 1.56 0 - 1.56 0 - 3.08 0 - 0.56 
IT 7.98 18.35 3.21 15.24 9.22 
(n=313) 3.44 - 17.41 11.54 - 27.91 1.33 - 7.58 6.02 - 33.55 6.49 - 12.94 
LT 0.00 0.76 0.00 2.25 0.64 
(n=121) 0 - 19 0.06 - 8.41 0 - 9.35 0.19 - 21.84 0.09 - 4.21 
NL 0.61 1.07 1.44 1.51 1.30 
(n=1454) 0.1 - 3.5 0.37 - 3.07 0.74 - 2.78 0.72 - 3.15 0.83 - 2.02 
NO 0.29 0.27 0.30 0.30 0.29 
(n=2709) 0.05 - 1.74 0.06 - 1.22 0.1 - 0.87 0.09 - 0.95 0.15 - 0.58 
PL 0.13 0.20 0.11 0.00 0.13 
(n=672) 0 - 3.74 0.02 - 1.87 0.01 - 1.78 0 - 4.88 0.02 - 0.81 
PT 8.00 2.44 0.29 3.14 2.59 
(n=1342) 5.05 - 12.46 1.4 - 4.22 0.06 - 1.33 1.38 - 6.97 1.88 - 3.58 
 
Figure 4.3.1.8 presents an overview of the distribution of alcohol (≥ 0.1 g/L) among the various age 
groups of female drivers. It shows that in Portugal, Italy, Spain and Belgium the shares of female 
drivers with a BAC of 0.1 g/L are the highest. As was the case for male drivers, in many countries the 
share of alcohol positive drivers is the highest for the two oldest age groups (35-49 and 50+). 
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Figure 4.3.1.8 Distribution of the prevalence of alcohol alone ≥ 0.1 g/L among the age groups for female 
drivers; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups  
 
4.3.1.3. Alcohol by time period 
Table 4.3.1.6 presents the distribution of alcohol by time period. In general alcohol use is higher during 
nighttime hours than during day time hours. However, in some Eastern European countries such as 
Hungary, Lithuania and Poland this was not the case. The highest prevalence was detected in 
Belgium during weekday nights (21.05%) and during weekend nights (16.60%). 
The 95% confidence intervals are very large for some countries. Therefore, it is difficult to assign exact 
differences between time periods for the participating countries. 
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Table 4.3.1.6. Prevalence of alcohol alone ≥ 0.1 g/L by time period; prevalence in percentages; 95% 
confidence intervals in italics 
Time 
period 
Weekdays  
04.00-21.59 
Weekday  nights 
22.00-03.59 
Weekend days 
04.00-21.59 
Weekend nights 
22.00-03.59 
All time 
periods 
BE 3.99 21.05 8.94 16.60 6.42 
(n=2949) 3.22 - 4.93 15.61 - 27.76 7 - 11.34 9.85 - 26.61 5.59 - 7.36 
CZ 0.83 1.23 1.26 3.09 0.99 
(n=2037) 0.46 - 1.47 0.13 - 10.75 0.64 - 2.44 0.39 - 20.67 0.65 - 1.53 
DK 2.25 2.46 3.31 2.45 2.53 
(n=3002) 1.69 - 2.97 0.63 - 9.1 2.25 - 4.84 0.64 - 8.89 2.02 - 3.15 
ES 2.40 8.22 5.78 11.24 3.92 
(n=3174) 1.83 - 3.15 4.59 - 14.32 4.36 - 7.63 7.22 - 17.1 3.3 - 4.66 
FI 0.49 1.08 0.83 2.03 0.64 
(n=3842) 0.29 - 0.85 0.23 - 4.79 0.43 - 1.58 0.48 - 8.14 0.43 - 0.94 
HU 0.16 0.00 0.15 0.00 0.15 
(n=2741) 0.06 - 0.46 0 - 5.75 0.03 - 0.85 0 - 6.88 0.06 - 0.38 
IT 8.51 10.64 8.60 8.90 8.59 
(n=1311) 6.89 - 10.46 3.81 - 26.37 5.97 - 12.24 2.62 - 26.17 7.19 - 10.23 
LT 3.64 3.85 4.99 0.00 3.86 
(n=1267) 2.62 - 5.03 0.76 - 17.35 2.95 - 8.31 0 - 13.37 2.93 - 5.06 
NL 1.59 9.20 2.51 6.65 2.15 
(n=4822) 1.22 - 2.06 5.49 - 15.02 1.72 - 3.64 3.49 - 12.28 1.78 - 2.6 
NO 0.34 0.00 0.27 0.79 0.32 
(n=9236) 0.22 - 0.52 0 - 0.69 0.12 - 0.58 0.3 - 2.1 0.23 - 0.46 
PL 1.41 1.72 1.70 0.86 1.47 
(n=4008) 1.04 - 1.91 0.41 - 6.9 1.05 - 2.73 0.11 - 6.32 1.14 - 1.9 
PT 5.08 3.06 4.24 9.00 4.93 
(n=3965) 4.34 - 5.94 0.9 - 9.9 3.11 - 5.76 4.37 - 17.64 4.29 - 5.64 
 
The share of alcohol use was in general the lowest at weekdays during daytime hours. However, in 
Portugal the share of alcohol drivers was higher during weekday hours than during weekday nights. 
Despite a general large share of high BAC drivers (see table 4.3.1.6 and figure 4.3.1.9), no alcohol 
use was found during weekend nights in Lithuania. In Hungary no alcohol was found at all during night 
time hours.  
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Figure 4.3.1.9. Distribution of the prevalence of alcohol alone ≥ 0.1 g/L among the time periods; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various time 
periods 
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4.3.2 Amphetamines 
Amphetamines are drugs that have a stimulating effect on mental and physical performance. Impairing 
effects on driving behaviour were mainly found at high doses, among chronic users and in the crash 
phase, when fatigue sets in. More complex tasks will be more affected by amphetamine use and a 
driving behaviour tends to be more impulsive. Negative effects of stimulants can also be expected 
when the stimulant effect is gone and users become very tired (Kelly et al., 2004; Scheers et al., 2006; 
Steyvers and Brookhuis, 1996). 
The results are presented for single use of amphetamines. The combination of amphetamines with a 
substance from an other substance group is regarded as combinational use. The share of 
combinational use in relation to single use is presented in table 4.3.2.1 and figure 4.3.2.2. 
The 95% confidence intervals can vary between countries and within countries for the different 
disaggregations. Therefore, differences between the participating countries should be interpreted with 
care, especially the differences for disaggregations by gender, age and time period. 
 
4.3.2.1 General results 
The amphetamine drugs group consisted of amphetamine, metamphetamine, MDMA, MDA, and 
MDEA. Cut-off values for these substances in blood and saliva are presented in table 2.2.  
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Figure 4.3.2.1. Prevalence of amphetamines alone by country; prevalence in percentages 
Figure 4.3.2.1 presents the prevalence of amphetamines. The prevalence is very low in most of the 13 
countries. The Czech Republic has the highest share with 0.38%, which is almost the double of the 
share of the countries that are ranked 2 and 3, Lithuania and The Netherlands with 0.22% and 0.19% 
respectively. However, most countries have a prevalence that is lower than 0.10%. No single 
amphetamines were detected in Belgium, Hungary, Italy and Portugal. The average prevalence for 
amphetamines in Europe is 0.08%. 
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Table 4.3.2.1. Prevalence of amphetamines alone and amphetamines in combination with other 
psychoactive substances; prevalence in percentages 
  BE CZ DK ES FI HU IT LT NL NO PL PT SE 
Alone - 0.36 0.02 0.11 0.05 - - 0.22 0.19 0.06 0.05 - 0.07 
Combi - 0.02 0.02 0.11 0.05 - 0.33 - 0.18 0.15 0.02 0.02 - 
Total - 0.38 0.04 0.22 0.10 - 0.33 0.22 0.37 0.21 0.07 0.02 0.07 
Share - 5% 55% 51% 48% - 100% 0% 49% 73% 29% 100% 0% 
 
Table 4.3.2.1 and figure 4.3.2.2 present the relative share of amphetamines in combination with other 
psychoactive substances. In Italy and Portugal amphetamines were only detected in combination with 
other substances, while in Lithuania and Sweden amphetamines were only detected as single 
substance. In general amphetamines are equally often detected alone as in combinations.  
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Figure 4.3.2.2. Prevalence of amphetamines alone and in combination with other psychoactive 
substances; prevalence in percentages 
4.3.2.2. Amphetamines by gender and age 
Table 4.3.2.2 provides an overview of the prevalence of amphetamines distributed by age. The 
highest prevalence was detected among drivers in Czech Republic aged 25-34 years (1.13%), and for 
drivers in Lithuania aged 18-24 years (1.06%). 
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Table 4.3.2.2. Prevalence of amphetamines alone by age group; prevalence in percentages; 95% 
confidence intervals in italics 
Total 18-24 25-34 35-49 50+ All ages 
CZ 0.41 1.13 0.00 0.00 0.36 
(n=2037) 0.07 - 2.3 0.53 - 2.4 0 - 0.53 0 - 0.74 0.17 - 0.72 
DK 0.00 0.10 0.00 0.00 0.02 
(n=3002) 0 - 1.71 0.01 - 0.98 0 - 0.36 0 - 0.32 0 - 0.16 
ES 0.40 0.08 0.02 0.00 0.11 
(n=3174) 0.12 - 1.33 0.01 - 0.52 0 - 0.41 0 - 0.78 0.04 - 0.3 
FI 0.00 0.28 0.00 0.00 0.05 
(n=3842) 0 - 0.9 0.08 - 1 0 - 0.32 0 - 0.26 0.02 - 0.19 
LT 1.06 0.27 0.00 0.00 0.22 
(n=1267) 0.28 - 3.96 0.04 - 1.67 0 - 0.83 0 - 1.28 0.07 - 0.66 
NL 0.12 0.22 0.36 0.00 0.19 
(n=4822) 0.02 - 0.98 0.07 - 0.76 0.17 - 0.78 0 - 0.24 0.1 - 0.36 
NO 0.17 0.13 0.04 0.00 0.06 
(n=9236) 0.04 - 0.68 0.04 - 0.45 0.01 - 0.2 0 - 0.11 0.02 - 0.13 
PL 0.12 0.08 0.00 0.02 0.05 
(n=4008) 0.02 - 0.86 0.02 - 0.43 0 - 0.31 0 - 0.49 0.01 - 0.18 
SE 0.00 0.09 0.14 0.02 0.07 
(n=6198) 0 - 0.78 0.01 - 0.57 0.05 - 0.43 0 - 0.17 0.03 - 0.17 
 
Figure 4.3.2.3 shows that in general amphetamines are used by drivers younger than 35 years old. In 
the Netherlands and Sweden however, the largest share was formed by drivers aged 35-49 years.  
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Figure 4.3.2.3. Distribution of the prevalence of amphetamines alone among the age groups; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various age 
groups 
 
Figure 4.3.2.4 shows that single amphetamines use is in some countries more prevalent among male 
drivers and in other countries more among female drivers. In Lithuania the prevalence of 
amphetamines among female drivers was almost 20 times higher than for male drivers. 
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Figure 4.3.2.4. Prevalence of amphetamines alone by gender; prevalence in percentages  
Table 4.3.2.3 presents the distribution of amphetamines by age group among male drivers. No single 
amphetamine use was detected among male drivers from Belgium, Hungary, Italy and Portugal. Male 
drivers in Czech Republic have the highest prevalence for single amphetamine use. The highest 
prevalence was among 25-34 years old men from Czech Republic with 1.50%. Among male drivers 
aged 50+ almost no amphetamine use was found. 
 
Table 4.3.2.3. Prevalence of amphetamines alone among male drivers by age group; prevalence in 
percentages; 95% confidence intervals in italics 
Male 18-24 25-34 35-49 50+ All ages 
CZ 0.64 1.50 0.00 0.00 0.46 
(n=1589) 0.11 - 3.52 0.7 - 3.18 0 - 0.68 0 - 0.84 0.22 - 0.93 
DK 0.00 0.16 0.00 0.00 0.03 
(n=1975) 0 - 2.56 0.02 - 1.52 0 - 0.57 0 - 0.45 0 - 0.24 
ES 0.29 0.02 0.00 0.00 0.06 
(n=2520) 0.06 - 1.33 0 - 0.52 0 - 0.46 0 - 0.9 0.01 - 0.26 
FI 0.00 0.00 0.00 0.00 0.00 
(n=2511) 0 - 1.35 0 - 0.8 0 - 0.55 0 - 0.35 0 - 0.15 
LT 0.00 0.32 0.00 0.00 0.08 
(n=1130) 0 - 2.38 0.05 - 1.98 0 - 0.9 0 - 1.36 0.01 - 0.47 
NL 0.18 0.13 0.55 0.00 0.23 
(n=3363) 0.02 - 1.41 0.02 - 0.76 0.26 - 1.17 0 - 0.34 0.12 - 0.46 
NO 0.14 0.19 0.05 0.00 0.06 
(n=6520) 0.02 - 0.81 0.05 - 0.66 0.01 - 0.27 0 - 0.15 0.03 - 0.16 
PL 0.15 0.04 0.00 0.02 0.04 
(n=3331) 0.02 - 1.04 0 - 0.42 0 - 0.39 0 - 0.53 0.01 - 0.18 
SE 0.00 0.13 0.22 0.03 0.09 
(n=4352) 0 - 1.12 0.02 - 0.85 0.07 - 0.67 0 - 0.23 0.04 - 0.24 
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Figure 4.3.2.5 presents an overview of male drivers by age group. Amphetamine use among male 
drivers is mainly found among drivers between 18 and 34 years old. However, in the Netherlands and 
Sweden users were mainly aged 35 to 50. No amphetamines were found among male drivers from 
Belgium, Finland, Hungary, Italy and Portugal. 
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Figure 4.3.2.5. Distribution of the prevalence of amphetamines alone among the age groups for male 
drivers; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups 
Table 4.3.2.4 and figure 4.3.2.6 present the prevalence of amphetamines among female drivers. 
Amphetamines among female drivers are almost without exception used by the young. The share of 
female amphetamine users was lower than the share of male users except for Lithuania, where 1.5% 
of all young female drivers (aged 18-24) were positive for amphetamines.  
 
Table 4.3.2.4. Prevalence of amphetamines alone among female drivers by age group; prevalence in 
percentages; 95% confidence intervals in italics 
Female 18-24 25-34 35-49 50+ All ages 
CZ 0.00 0.00 0.00 0.00 0.00 
(n=448) 0 - 4.32 0 - 2.73 0 - 2.31 0 - 5.68 0 - 0.85 
DK 0.00 0.00 0.00 0.00 0.00 
(n=1015) 0 - 4.97 0 - 2.15 0 - 0.94 0 - 1.05 0 - 0.38 
ES 0.86 0.29 0.09 0.00 0.30 
(n=605) 0.15 - 4.67 0.04 - 2.22 0 - 2.09 0 - 5.56 0.08 - 1.13 
FI 0.00 0.79 0.00 0.00 0.16 
(n=1283) 0 - 2.71 0.22 - 2.77 0 - 0.78 0 - 0.96 0.05 - 0.57 
LT 11.30 0.00 0.00 0.00 1.53 
(n=121) 3.02 - 34.29 0 - 7.06 0 - 9.35 0 - 18.35 0.4 - 5.63 
NL 0.00 0.46 0.00 0.00 0.09 
(n=1454) 0 – 2.42 0.1 - 2.13 0 - 0.66 0 - 0.88 0.02 - 0.42 
NO 0.24 0.00 0.02 0.00 0.04 
(n=2709) 0.03 - 1.65 0 - 0.75 0 - 0.42 0 - 0.45 0.01 - 0.21 
PL 0.00 0.29 0.00 0.00 0.11 
(n=672) 0 - 3.51 0.04 - 2.03 0 - 1.57 0 - 4.88 0.01 - 0.77 
SE 0.00 0.00 0.00 0.00 0.00 
(n=1835) 0 - 2.57 0 - 1.24 0 - 0.56 0 - 0.54 0 - 0.21 
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Figure 4.3.2.6. Distribution of the prevalence of amphetamines alone among the age groups for female 
drivers; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups 
4.3.2.3. Amphetamines by time period 
Table 4.3.2.5 presents the distribution of amphetamines by time period. The highest prevalence was 
found in weekends both during day and night time hours.  
 
Table 4.3.2.5. Prevalence of amphetamines alone by time period; prevalence in percentages; 95% 
confidence intervals in italics  
Time 
period 
Weekdays  
04.00-21.59 
Weekday  nights 
22.00-03.59 
Weekend days 
04.00-21.59 
Weekend nights 
22.00-03.59 
All time 
periods 
CZ 0.22 0.00 0.64 0.62 0.36 
(n=2037) 0.08 - 0.66 0 - 8.62 0.25 - 1.6 0.02 - 16.88 0.17 - 0.72 
DK 0.00 0.00 0.07 0.00 0.02 
(n=3002) 0 - 0.18 0 - 5.06 0.01 - 0.63 0 - 4.87 0 - 0.16 
ES 0.00 0.00 0.38 0.23 0.11 
(n=3174) 0 - 0.18 0 - 2.94 0.13 - 1.11 0.02 - 2.8 0.04 - 0.3 
FI 0.00 0.00 0.20 0.00 0.05 
(n=3842) 0 - 0.15 0 - 2.94 0.05 - 0.7 0 - 4.76 0.02 - 0.19 
LT 0.29 0.00 0.00 0.00 0.22 
(n=1267) 0.09 - 0.88 0 - 11.28 0 - 1.43 0 - 13.37 0.07 - 0.66 
NL 0.15 0.45 0.22 0.63 0.19 
(n=4822) 0.07 - 0.35 0.06 - 3.4 0.07 - 0.74 0.1 - 4 0.1 - 0.36 
NO 0.04 0.13 0.02 0.40 0.06 
(n=9236) 0.01 - 0.13 0.02 - 0.94 0 - 0.21 0.1 - 1.51 0.02 - 0.13 
PL 0.00 0.29 0.15 0.34 0.05 
(n=4008) 0 - 0.13 0.02 - 4.54 0.03 - 0.67 0.02 - 5.44 0.01 - 0.18 
SE 0.06 0.44 0.06 0.00 0.07 
(n=6198) 0.02 - 0.19 0.05 - 3.82 0.01 - 0.36 0 - 3.01 0.03 - 0.17 
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Figure 4.3.2.7 presents an overview of the distribution of amphetamines by time period. This 
distribution differs per country. In the Netherlands, Norway and Poland amphetamine is mainly used in 
night time periods. In Sweden it is detected during night times as well, but only on weekdays. In 
Denmark and Finland amphetamine use was only detected during weekend days and in Czech 
Republic and Spain it was detected primarily in the weekend both during the day and during the night. 
In Lithuania amphetamines were only detected in traffic during weekday hours. 
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Figure 4.3.2.7. Distribution of the prevalence of amphetamines alone among the time periods; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various time 
periods 
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4.3.3 Cocaine 
Cocaine is a stimulant drug with a short half life. This means that the effect of cocaine is quite short (in 
general the effect of a normal dose lasts for half an hour). A user gets more alert and feels less tired. 
The after effect is the opposite to the initial effect. A driver becomes reckless when under the influence 
of cocaine. Most negative effects of cocaine on driving behaviour are expected among heavy and 
chronic users (Kelly et al., 2004; Scheers et al., 2006; Steyvers and Brookhuis, 1996).  
The results are presented for single use of cocaine. The combination of cocaine with a substance from 
another substance group is regarded as combinational use. The share of combinational use in relation 
to single use is presented in table 4.3.3.1 and figure 4.3.3.2. 
The 95% confidence intervals can vary between countries and within countries for the different 
disaggregations. Therefore, differences between the participating countries should be interpreted with 
care, especially the differences for disaggregations by gender, age and time period. 
4.3.3.1. General results 
The cocaine group includes both drivers with cocaine and with its metabolite benzoylecgonine. Since 
cocaine has a short halflife both substances are covered by most countries with a zero-tolerance 
driving legislation.  
The cut-off levels for cocaine and benzoylecgonine are presented in table 2.2. 
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Figure 4.3.3.1. Prevalence of cocaine alone by country; prevalence in percentages 
 
Figure 4.3.3.1 shows that single cocaine use is mainly prevalent among drivers from Spain (1.49%) 
and Italy (1.25%). No cocaine was detected among drivers in Czech Republic, Denmark, Lithuania, 
Poland and Sweden. The average prevalence for cocaine in Europe is 0.42%. 
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Table 4.3.3.1. Prevalence of cocaine alone and cocaine in combination with other psychoactive 
substances; prevalence in percentages 
  BE CZ DK ES FI HU IT LT NL NO PL PT SE 
Cocaine alone 0.20 - - 1.49 0.03 0.04 1.25 - 0.30 0.06 - 0.03 - 
Cocaine in combi 0.23 0.05 0.06 1.09 - - 0.39 - 0.36 0.07 - 0.22 0.01 
Total 0.43 0.05 0.06 2.58 0.03 0.04 1.64 - 0.66 0.13 - 0.25 0.01 
Share 54% 100% 100% 42% 0% 0% 24% - 54% 52% - 87% 100% 
 
Table 4.3.3.1 and figure 4.3.3.2 present an overview of cocaine use in traffic both as a single drug and 
in combination with other psychoactive substances. When cocaine was used, it was often in 
combination with other psychoactive substances. On average around half of the times cocaine was 
detected in combination with other substances. Only in Finland and Hungary cocaine was used solely 
as a single drug. 
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Figure 4.3.3.2. Prevalence of cocaine alone and cocaine in combination with other psychoactive 
substances; prevalence in percentages 
4.3.3.2 Cocaine use by gender and age 
Table 4.3.3.2 presents the distribution of cocaine by age group. The highest prevalence was among 
25-34 and 35-49 years old drivers from Spain with 2.07% and 1.81%, respectively. Among drivers 
aged 50+ almost no cocaine use was found. 
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Table 4.3.3.2. Prevalence of cocaine alone by age group; prevalence in percentages; 95% confidence 
intervals in italics 
Total 18-24 25-34 35-49 50+ All ages 
BE 0.61 0.35 0.10 0.03 0.20 
(n=2949) 0.16 - 2.33 0.1 - 1.21 0.02 - 0.52 0 - 0.48 0.09 - 0.43 
ES 1.22 2.07 1.81 0.04 1.49 
(n=3174) 0.6 - 2.48 1.36 - 3.13 1.16 - 2.83 0 - 0.86 1.12 - 1.97 
FI 0.00 0.00 0.11 0.00 0.03 
(n=3842) 0 - 0.9 0 - 0.52 0.02 - 0.51 0 - 0.26 0.01 - 0.16 
HU 0.00 0.06 0.05 0.00 0.04 
(n=2741) 0 - 1.49 0.01 - 0.54 0.01 - 0.51 0 - 0.59 0.01 - 0.21 
IT 1.29 0.92 1.67 0.13 1.25 
(n=1311) 0.5 - 3.25 0.36 - 2.35 0.86 - 3.22 0 - 5.51 0.78 - 2.01 
NL 0.70 0.81 0.16 0.00 0.30 
(n=4822) 0.26 – 0.81 0.41 - 1.57 0.05 - 0.49 0 - 0.24 0.18 - 0.5 
NO 0.00 0.10 0.11 0.03 0.06 
(n=9236) 0 - 0.39 0.02 - 0.41 0.04 - 0.29 0 - 0.16 0.03 - 0.14 
PT 0.00 0.09 0.02 0.00 0.03 
(n=3965) 0 - 0.72 0.02 - 0.48 0 - 0.34 0 - 0.44 0.01 - 0.16 
 
Figure 4.3.3.3 shows that the use of cocaine as a single substance is the highest in Spain and Italy. In 
all other countries single cocaine use is very low or even not detected. Almost all single cocaine users 
were younger than 50.  
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Figure 4.3.3.3. Distribution of the prevalence of cocaine alone among the age groups; overall prevalences 
in percentages per country, the figure shows the relative contributions of the various age groups 
 
Figure 4.3.3.4 presents the distribution of cocaine use among drivers by gender. Cocaine is mainly 
used by male drivers. However, female drivers in Spain have a higher prevalence than most male 
users from other countries. 
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Figure 4.3.3.4. Prevalence of cocaine alone by gender; prevalence in percentages 
 
Table 4.3.3.3 presents the distribution of cocaine by age group among male drivers. The highest 
prevalence was among 25-34 years old men from Spain with 2.58% and among drivers aged 35-49 in 
Italy (2.33). Among male drivers aged 50+ almost no cocaine use was detected. 
 
Table 4.3.3.3. Prevalence of cocaine alone among male drivers by age group; prevalence in percentages; 
95% confidence intervals in italics 
Male 18-24 25-34 35-49 50+ All ages 
BE 0.97 0.58 0.15 0.04 0.29 
(n=1957) 0.25 - 3.68 0.17 - 2.02 0.03 - 0.78 0 - 0.66 0.13 - 0.65 
ES 1.49 2.58 1.84 0.05 1.69 
(n=2520) 0.72 - 3.05 1.69 - 3.92 1.12 - 3.01 0 - 0.99 1.26 - 2.27 
FI 0.00 0.00 0.00 0.00 0.00 
(n=2511) 0 - 1.35 0 - 0.8 0 - 0.55 0 - 0.35 0 - 0.15 
HU 0.00 0.08 0.07 0.00 0.05 
(n=2062) 0 - 2.09 0.01 - 0.73 0.01 - 0.68 0 - 0.72 0.01 - 0.28 
IT 1.57 1.12 2.33 0.21 1.62 
(n=998) 0.61 - 3.99 0.43 - 2.87 1.2 - 4.49 0 - 8.47 1.01 - 2.61 
NL 0.86 0.91 0.23 0.00 0.36 
(n=3363) 0.29 – 2.49 0.43 - 1.91 0.07 - 0.71 0 - 0.34 0.21 - 0.63 
NO 0.00 0.15 0.08 0.04 0.07 
(n=6520) 0 - 0.56 0.04 - 0.59 0.02 - 0.32 0.01 - 0.22 0.03 - 0.17 
PT 0.00 0.15 0.03 0.00 0.05 
(n=2541) 0 - 1.2 0.03 - 0.82 0 - 0.53 0 - 0.54 0.01 - 0.24 
 
Figure 4.3.3.5 presents the distribution of cocaine use among male drivers by age group. The highest 
prevalence of single cocaine use was found among male drivers in Spain and Italy. Almost all male 
drivers who used cocaine were younger than 50.  
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Figure 4.3.3.5. Distribution of the prevalence of cocaine alone among the age groups for male drivers; 
overall prevalences in percentages per country, the figure shows the relative contributions of the various 
age groups 
Table 4.3.3.4 presents an overview of the distribution of cocaine among female drivers by age group. 
It shows that the highest prevalence of cocaine in traffic among female drivers was in Spain (0.65%). 
Lower prevalences were found in the Netherlands, Finland, Italy and Norway. In all other countries no 
cocaine use was detected among female drivers.  The highest prevalence was detected among 35-49 
year old females in Spain (1.70%). The next two highest prevalence among female drivers were found 
in the Netherlands among female drivers aged 18-24 (0.34%) and aged 25-34 (0.53%).  
 
Table 4.3.3.4. Prevalence of cocaine alone among female drivers by age group; prevalence in 
percentages; 95% confidence intervals in italics 
Female 18-24 25-34 35-49 50+ All ages 
BE 0.00 0.00 0.00 0.00 0.00 
(n=971) 0 - 3.37 0 - 1.52 0 - 1.04 0 - 1.55 0 - 0.39 
ES 0.16 0.23 1.70 0.00 0.65 
(n=605) 0.01 - 3.45 0.02 - 2.11 0.61 - 4.63 0 - 5.56 0.26 - 1.65 
FI 0.00 0.00 0.26 0.00 0.10 
(n=1283) 0 - 2.71 0 - 1.44 0.05 - 1.24 0 - 0.96 0.02 - 0.47 
HU 0.00 0.00 0.00 0.00 0.00 
(n=679) 0 - 4.9 0 - 1.56 0 - 1.56 0 - 3.08 0 - 0.56 
IT 0.15 0.11 0.00 0.00 0.06 
(n=313) 0 - 6.1 0 - 4.55 0 - 2.65 0 - 13.07 0 - 1.32 
NL 0.34 0.53 0.04 0.00 0.15 
(n=1454) 0.04 – 3.04 0.12 - 2.25 0 - 0.73 0 - 0.88 0.05 - 0.53 
NO 0.00 0.00 0.16 0.00 0.06 
(n=2709) 0 - 1.21 0 - 0.75 0.04 - 0.64 0 - 0.45 0.01 - 0.25 
PT 0.00 0.00 0.00 0.00 0.00 
(n=1342) 0 - 1.79 0 - 0.77 0 - 0.81 0 - 2.21 0 - 0.28 
 
Figure 4.3.3.6 shows that in Finland, Spain and Norway single cocaine use was mainly detected 
among female drivers aged 35-49. In the Netherlands and Italy single cocaine use was most prevalent 
among drivers younger than 35 years. The range of cocaine use among female drivers was between 0 
and 0.15% for all countries, except for Spain. 
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Figure 4.3.3.6. Distribution of the prevalence of cocaine alone among the age groups for female drivers; 
overall prevalences in percentages per country, the figure shows the relative contributions of the various 
age groups 
 
Table 4.3.3.5 presents the distribution of cocaine by time period. The highest prevalence was during 
weekday nights (1.97%) and weekend days (1.91%) and weekend nights (2.11) in Spain. In Italy 
highest prevalence was found during weekdays at daytime (1.63%) and weekends at night time 
(1.16%). 
 
4.3.3.3. Cocaine use by time period 
Table 4.3.3.5. Prevalence of cocaine alone by time period; prevalence in percentages; 95% confidence 
intervals in italics 
Time 
period 
Weekdays  
04.00-21.59 
Weekday  nights 
22.00-03.59 
Weekend days 
04.00-21.59 
Weekend nights 
22.00-03.59 
All time 
periods 
BE 0.11 1.05 0.23 0.39 0.20 
(n=2949) 0.03 - 0.37 0.27 - 3.98 0.05 - 0.98 0.03 - 5.59 0.09 - 0.43 
ES 1.25 1.97 1.91 2.11 1.49 
(n=3174) 0.86 - 1.82 0.61 - 6.15 1.16 - 3.12 0.76 - 5.72 1.12 - 1.97 
FI 0.05 0.00 0.00 0.00 0.03 
(n=3842) 0.01 - 0.24 0 - 2.94 0 - 0.36 0 - 4.76 0.01 - 0.16 
HU 0.05 0.00 0.00 0.00 0.04 
(n=2741) 0.01 - 0.29 0 - 5.75 0 - 0.59 0 - 6.88 0.01 - 0.21 
IT 1.63 0.91 0.14 1.16 1.25 
(n=1311) 1 - 2.65 0.06 - 12.87 0.01 - 1.49 0.08 - 15.31 0.78 - 2.01 
NL 0.25 0.15 0.42 0.95 0.30 
(n=4822) 0.13 - 0.48 0.01 - 2.87 0.17 - 1.03 0.19 - 4.52 0.18 - 0.5 
NO 0.04 0.27 0.00 0.40 0.06 
(n=9236) 0.01 - 0.14 0.06 - 1.16 0 - 0.17 0.1 - 1.51 0.03 - 0.14 
PT 0.00 0.00 0.12 0.37 0.03 
(n=3965) 0 - 0.13 0 - 4.98 0.02 - 0.64 0.02 - 5.56 0.01 - 0.16 
 
Table 4.3.3.5 and figure 4.3.3.7 indicate that in Finland and Hungary cocaine use in traffic was only 
detected at weekdays during daytime hours. In Spain it was frequently detected during all time 
periods. In Italy it was detected frequently in all time periods except in the weekend at daytime hours. 
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In the Netherlands single cocaine use was primarily detected during weekend nights, while in Belgium 
it was more often detected during weekday nights. 
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Figure 4.3.3.7. Distribution of the prevalence of cocaine alone among the time periods; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various time 
periods 
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4.3.4  THC (cannabis) 
THC is the psychoactive component of cannabis. It impairs driving performance in several ways. Even 
in small amounts tasks like attention, reaction time, and hand-eye coordination are decreased by THC 
use. Furthermore, it was concluded from driving simulator experiments that various vehicle control 
tasks were impaired as well. However, THC users seem to be aware of their impairment and try to 
compensate by driving more slowly and avoiding risky manoeuvres (Kelly et al., 2004; Scheers et al., 
2006; Steyvers and Brookhuis, 1996).  
The results are presented for single use of THC. The combination of a THC with a substance from 
another substance group is regarded as combinational use. The share of combinational use in relation 
to single use is presented in table 4.3.4.1 and figure 4.3.4.2. 
The 95% confidence intervals can vary between countries and within countries for the different 
disaggregations. Therefore, differences between the participating countries should be interpreted with 
care, especially the differences for disaggregations by gender, age and time period. 
4.3.4.1 General results 
The THC substance group is formed by THC only. THC-COOH was detected as well in blood, but this 
inactive metabolite of THC will be regarded as negative. THC-COOH can not be detected in saliva 
which was used for analysis in most of the participating countries (see table 3.5). The cut-off values for 
THC are presented in table 2.2. 
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Figure 4.3.4.1. Prevalence of THC alone by country; prevalence in percentages 
Figure 4.3.4.1 shows that THC was mainly used in Spain where the prevalence was almost 4 times 
higher than in that of the second ranked country: The Netherlands. The prevalence of THC in 
Portuguese traffic was higher than the European mean as well. In Lithuania no THC was detected 
among drivers. The average prevalence in Europe for THC is 1.32%. 
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Table 4.3.4.1. Prevalence of THC alone and THC in combination with other psychoactive substances; 
prevalence in percentages 
  BE CZ DK ES FI HU IT LT NL NO PL PT SE 
THC alone 0.35 0.46 0.20 5.99 0.04 0.19 1.15 - 1.67 0.48 0.57 1.38 0.03 
THC in combi 0.14 0.11 0.11 0.90 - 0.02 0.96 - 0.43 0.16 0.02 0.41 - 
Total 0.49 0.57 0.31 6.89 0.04 0.21 2.11 - 2.10 0.64 0.59 1.79 0.03 
Share 29% 19% 36% 13% 0% 9% 46% - 21% 25% 3% 23% 0% 
 
Table 4.3.4.1 and figure 4.3.4.2 show that THC is mainly used alone. On average between 20% and 
30% of THC use was in combination with other psychoactive substances. Combinational THC use was 
the highest in the Southern European countries (Italy, Spain, Portugal) and the Netherlands. 
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Figure 4.3.4.2. Prevalence of THC alone and THC in combination with other psychoactive substances; 
prevalence in percentages 
4.3.4.2 THC use by gender and age 
Table 4.3.4.2 presents the single use of THC in traffic by age group. Prevalence was the highest 
among young drivers in Spain aged 18-24 and 25-34 with 12.44% and 9.10%, respectively. And 
among young drivers aged 18-24 in the Netherlands (4.49%). 
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Table 4.3.4.2. Prevalence of THC alone by age group; prevalence in percentages; 95% confidence 
intervals in italics 
Total 18-24 25-34 35-49 50+ All ages 
BE 2.55 0.38 0.04 0.00 0.35 
(n=2949) 1.27 - 5.04 0.11 - 1.26 0 - 0.43 0 - 0.42 0.19 - 0.64 
CZ 1.84 0.71 0.14 0.00 0.46 
(n=2037) 0.75 - 4.44 0.28 - 1.83 0.02 - 0.78 0 - 0.74 0.25 - 0.86 
DK 0.75 0.61 0.13 0.00 0.20 
(n=3002) 0.18 - 3 0.21 - 1.79 0.03 - 0.58 0 - 0.32 0.09 - 0.43 
ES 12.44 9.10 1.93 0.04 5.99 
(n=3174) 10.01 - 15.37 7.5 - 11.01 1.25 - 2.97 0 - 0.86 5.22 - 6.87 
FI 0.11 0.00 0.00 0.08 0.04 
(n=3842) 0.01 - 1.11 0 - 0.52 0 - 0.32 0.02 - 0.4 0.01 - 0.17 
HU 0.41 0.36 0.11 0.00 0.19 
(n=2741) 0.08 - 2.22 0.13 - 1.02 0.02 - 0.61 0 - 0.59 0.08 - 0.44 
IT 0.57 0.91 1.89 0.00 1.15 
(n=1311) 0.15 - 2.19 0.35 - 2.33 1.01 - 3.5 0 - 5.26 0.7 - 1.89 
NL 4.49 2.22 1.62 0.45 1.67 
(n=4822) 3 - 6.66 1.48 - 3.33 1.12 - 2.33 0.22 - 0.93 1.34 - 2.07 
NO 1.15 1.06 0.34 0.12 0.48 
(n=9236) 0.65 - 2.03 0.66 - 1.67 0.19 - 0.61 0.05 - 0.31 0.36 - 0.64 
PL 1.52 0.85 0.18 0.00 0.57 
(n=4008) 0.81 - 2.86 0.48 - 1.5 0.05 - 0.62 0 - 0.45 0.38 - 0.85 
PT 1.36 2.72 0.65 0.54 1.38 
(n=3965) 0.67 - 2.75 1.94 - 3.8 0.34 - 1.26 0.22 - 1.28 1.07 - 1.8 
SE 0.00 0.14 0.03 0.00 0.03 
(n=6198) 0 - 0.78 0.03 - 0.67 0 - 0.25 0 - 0.14 0.01 - 0.12 
 
Figure 4.3.4.3 shows that most drivers that were screened positive for THC were younger than 35 
years in all countries. 
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Figure 4.3.4.3. Distribution of the prevalence of THC alone among the age groups; overall prevalences in 
percentages per country, the figure shows the relative contributions of the various age groups 
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Figure 4.3.4.4 shows that THC is predominantly used by male drivers. Only in Italy the prevalence of 
THC is more or less the same for male and female users. Among male drivers single THC use was 
detected mainly among Spanish drivers, followed by male drivers from Portugal, the Netherlands and 
Italy. 
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Figure 4.3.4.4. Prevalence of THC by gender; prevalence in percentages 
Table 4.3.4.3 provides an overview of the use of THC by male drivers. Prevalence was the highest 
among young male drivers in Spain aged 18-24 and 25-34 with 14.93% and 11.27%, respectively, and 
among young male drivers aged 18-24 in the Netherlands (5.75%). 
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Table 4.3.4.3. Prevalence of THC alone among male drivers by age group; prevalence in percentages; 95% 
confidence intervals in italics 
Male 18-24 25-34 35-49 50+ All ages 
BE 3.91 0.64 0.06 0.00 0.51 
(n=1957) 1.93 - 7.76 0.19 - 2.11 0.01 - 0.64 0 - 0.57 0.28 - 0.93 
CZ 2.84 0.94 0.18 0.00 0.59 
(n=1589) 1.16 - 6.78 0.37 - 2.42 0.03 - 1 0 - 0.84 0.32 - 1.1 
DK 1.13 0.96 0.20 0.00 0.30 
(n=1975) 0.28 - 4.5 0.32 - 2.79 0.04 - 0.93 0 - 0.45 0.14 - 0.66 
ES 14.93 11.27 2.39 0.05 7.22 
(n=2520) 11.99 - 18.45 9.27 - 13.64 1.54 - 3.67 0 - 0.99 6.28 - 8.29 
FI 0.16 0.00 0.00 0.11 0.06 
(n=2511) 0.02 - 1.65 0 - 0.8 0 - 0.55 0.02 - 0.55 0.02 - 0.26 
HU 0.58 0.49 0.15 0.00 0.26 
(n=2062) 0.11 - 3.13 0.17 - 1.39 0.03 - 0.82 0 - 0.72 0.11 - 0.59 
IT 0.04 0.44 2.62 0.00 1.10 
(n=998) 0 - 1.58 0.1 - 1.86 1.4 - 4.86 0 - 8.08 0.61 - 1.96 
NL 5.75 2.51 2.12 0.63 2.08 
(n=3363) 3.76 - 8.69 1.6 - 3.91 1.43 - 3.13 0.31 - 1.28 1.65 - 2.62 
NO 1.54 1.34 0.41 0.16 0.59 
(n=6520) 0.85 - 2.78 0.81 - 2.18 0.22 - 0.78 0.06 - 0.42 0.43 - 0.81 
PL 1.85 1.05 0.23 0.00 0.68 
(n=3331) 0.98 - 3.46 0.59 - 1.84 0.07 - 0.78 0 - 0.5 0.46 - 1.03 
PT 2.23 4.50 1.03 0.67 2.08 
(n=2541) 1.09 - 4.52 3.2 - 6.29 0.53 - 1.98 0.28 - 1.59 1.6 - 2.71 
SE 0.00 0.21 0.04 0.00 0.04 
(n=4352) 0 - 1.12 0.05 - 0.99 0 - 0.38 0 - 0.18 0.01 - 0.16 
 
Figure 4.3.4.5 shows that in most countries THC positive male drivers were younger than 35 years old. 
However, in Italy the larger part of the male drivers positive for THC was aged 35-49.  
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Figure 4.3.4.5. Distribution of the prevalence of THC alone among the age groups for male drivers; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various age 
groups  
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Table 4.3.4.4 presents the use of THC by female drivers. Prevalence was the highest among young 
female drivers in Italy aged 18-24 and 25-34 with 2.71% and 2.83%, respectively. And among young 
female drivers aged 18-24 in Spain (2.58%). 
 
Table 4.3.4.4. Prevalence of THC alone among female drivers by age group; prevalence in percentages; 
95% confidence intervals in italics 
Female 18-24 25-34 35-49 50+ All ages 
BE 0.26 0.00 0.00 0.00 0.03 
(n=971) 0.02 - 3.86 0 - 1.52 0 - 1.04 0 - 1.55 0 - 0.45 
CZ 0.00 0.00 0.00 0.00 0.00 
(n=448) 0 - 4.32 0 - 2.73 0 - 2.31 0 - 5.68 0 - 0.85 
DK 0.00 0.00 0.00 0.00 0.00 
(n=1015) 0 - 4.97 0 - 2.15 0 - 0.94 0 - 1.05 0 - 0.38 
ES 2.58 1.31 0.00 0.00 0.96 
(n=605) 0.89 - 7.27 0.44 - 3.81 0 - 1.91 0 - 5.56 0.44 - 2.08 
FI 0.00 0.00 0.00 0.00 0.00 
(n=1283) 0 - 2.71 0 - 1.44 0 - 0.78 0 - 0.96 0 - 0.3 
HU 0.00 0.00 0.00 0.00 0.00 
(n=679) 0 - 4.9 0 - 1.56 0 - 1.56 0 - 3.08 0 - 0.56 
IT 2.71 2.83 0.03 0.00 1.32 
(n=313) 0.67 - 10.25 0.86 - 8.9 0 - 2.72 0 - 13.07 0.52 - 3.29 
NL 1.61 1.51 0.62 0.00 0.71 
(n=1454) 0.5 - 5.07 0.61 - 3.69 0.23 - 1.66 0 - 0.88 0.39 - 1.3 
NO 0.32 0.43 0.20 0.00 0.19 
(n=2709) 0.06 - 1.78 0.12 - 1.47 0.06 - 0.71 0 - 0.45 0.08 - 0.44 
PL 0.00 0.00 0.00 0.00 0.00 
(n=672) 0 - 3.51 0 - 1.51 0 - 1.57 0 - 4.88 0 - 0.57 
PT 0.09 0.24 0.00 0.00 0.10 
(n=1342) 0 - 1.96 0.05 - 1.21 0 - 0.81 0 - 2.21 0.02 - 0.46 
SE 0.00 0.00 0.00 0.00 0.00 
(n=1835) 0 - 2.57 0 - 1.24 0 – 0.56 0 – 0.54 0 - 0.21 
 
Figure 4.3.4.6 shows THC use is strongly concentrated among female drivers younger than 35 years. 
Only in the Netherlands and Norway a small share of THC positive drivers was 35 years or older. THC 
was not detected among female drivers in Czech Republic, Denmark, Finland, Hungary, Lithuania, 
Poland and Sweden. 
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Figure 4.3.4.6. Distribution of the prevalence of THC alone among the age groups for female drivers; 
overall prevalences in percentages per country, the figure shows the relative contributions of the various 
age groups  
 
4.3.4.3. THC use by time period 
Table 4.3.4.5 gives an overview of the use of THC by time period. Prevalence was the highest during 
all time periods in Spain, during weekend days in Italy and during week and weekend nights in the 
Netherlands. 
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Table 4.3.4.5. Prevalence of THC alone by time period; prevalence in percentages; 95% confidence 
intervals in italics 
Time 
period 
Weekdays  
04.00-21.59 
Weekday  nights 
22.00-03.59 
Weekend days 
04.00-21.59 
Weekend nights 
22.00-03.59 
All time 
periods 
BE 0.20 0.00 0.76 1.54 0.35 
(n=2949) 0.08 - 0.51 0 - 2.2 0.33 - 1.76 0.3 - 7.51 0.19 - 0.64 
CZ 0.43 0.00 0.51 1.85 0.46 
(n=2037) 0.19 - 0.95 0 - 8.62 0.18 - 1.42 0.15 - 18.82 0.25 - 0.86 
DK 0.24 0.00 0.00 1.22 0.20 
(n=3002) 0.1 - 0.56 0 - 5.06 0 - 0.51 0.2 - 6.99 0.09 - 0.43 
ES 5.97 7.24 5.96 5.39 5.99 
(n=3174) 5.04 - 7.07 3.88 - 13.11 4.52 - 7.83 2.81 - 10.07 5.22 - 6.87 
FI 0.05 0.36 0.00 0.00 0.04 
(n=3842) 0.01 - 0.23 0.03 - 3.6 0 - 0.36 0 - 4.76 0.01 - 0.17 
HU 0.11 0.00 0.48 0.00 0.19 
(n=2741) 0.03 - 0.38 0 - 5.75 0.17 - 1.38 0 - 6.88 0.08 - 0.44 
IT 0.00 0.30 4.72 1.16 1.15 
(n=1311) 0 - 0.41 0.01 - 11.84 2.86 - 7.67 0.08 - 15.31 0.7 - 1.89 
NL 1.44 3.26 2.04 2.85 1.67 
(n=4822) 1.1 - 1.89 1.37 - 7.58 1.34 - 3.09 1.08 - 7.32 1.34 - 2.07 
NO 0.39 0.80 0.45 1.39 0.48 
(n=9236) 0.26 - 0.58 0.33 - 1.96 0.25 - 0.83 0.65 - 2.92 0.36 - 0.64 
PL 0.52 0.86 0.61 1.54 0.57 
(n=4008) 0.31 - 0.85 0.13 - 5.53 0.28 - 1.34 0.3 - 7.44 0.38 - 0.85 
PT 1.44 2.42 0.96 3.25 1.38 
(n=3965) 1.07 - 1.94 0.62 - 8.96 0.5 - 1.84 1 - 10.08 1.07 - 1.8 
SE 0.01 0.44 0.06 0.00 0.03 
(n=6198) 0 - 0.11 0.05 - 3.82 0.01 - 0.36 0 - 3.01 0.01 - 0.12 
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Figure 4.3.4.7. Distribution of the prevalence of THC alone among the time periods; overall prevalences in 
percentages per country, the figure shows the relative contributions of the various time periods 
  78 
Figure 4.3.4.7 shows that THC is prevalent at all days of the week during all hours of the week in most 
countries. However, in Belgium, Czech Republic, Denmark, Italy and Hungary, single THC use was 
mainly detected during the weekend. 
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4.3.5 Illicit opiates 
Illicit opiates are depressants. A user has in general feelings of sleepiness, drowsiness or calmness 
and has lower sense of pain. Opiates are also used as analgesics. The depressant effect of opiates is 
most of the time that heavy that drivers don't feel able or motivated to drive a vehicle. The effects of 
illicit opiates vary per type of substance, route of administration and tolerance (Kelly et al., 2004; 
Scheers et al., 2006; Steyvers and Brookhuis, 1996). 
The results of the roadside surveys are presented for single use of illicit opiates. The combination of 
an illicit opiate with a substance from another substance group is regarded as combinational use. The 
share of combinational use in relation to single use is presented in table 4.3.5.1 and figure 4.3.5.2.  
 
The 95% confidence intervals can vary between countries and within countries for the different 
disaggregations. Therefore, differences between the participating countries should be interpreted with 
care, especially the differences for disaggregations by gender, age and time period. 
4.3.5.1. General results 
The illicit opiates group includes drivers that were positive for heroin (6-acetylmorphine) or the 
combination of morphine and codeine where the concentration of morphine is equal to or higher than 
the concentration of codeine. If the concentration of codeine is higher than that of morphine, the use 
was regarded as medicinal opiates and opioids use. The cut-off levels for heroin, morphine and 
codeine are presented in table 2.2. 
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Figure 4.3.5.1. Prevalence of illicit opiates alone by country; prevalence in percentages 
Figure 4.3.5.1 shows that illicit opiates are barely prevalent in European traffic. Italy has the highest 
share with 0.3%. In the Northern European counties no illicit opiates were detected among drivers. In 
the Eastern European countries they were only detected in Poland. The average prevalence for illicit 
opiates in Europe is 0.07%. 
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Table 4.3.5.1. Prevalence of illicit opiates alone and illicit opiates in combination with other psychoactive 
substances; prevalence in percentages 
  BE CZ DK ES FI HU IT LT NL NO PL PT SE 
Illicit opiates alone 0.09 - - 0.05 - - 0.30 - 0.01 - 0.09 0.15 - 
Illicit opiates in combi 0.07 - - 0.21 - - 0.71 - - - - 0.03 - 
Total 0.16 - - 0.26 - - 1.01 - 0.01 - 0.09 0.18 - 
Share 43% - - 82% - - 70% - 0% - 0% 16% - 
 
Table 4.3.5.1 and figure 4.3.5.2 show that Illicit opiates were relatively frequently used in combination 
with other psychoactive substances in Belgium, Spain and Italy. In Portugal around 1 in 6 illicit opiate 
users combined it with other substances. Illicit opiates use was not detected among drivers from 
Northern European countries (Denmark, Finland, Norway and Sweden) and from Czech Republic, 
Lithuania, and Hungary. 
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Figure 4.3.5.2. Prevalence of illicit opiates alone and illicit opiates in combination with other psychoactive 
substances; prevalence in percentages 
4.3.5.2. Illicit opiates use by gender and age 
Table 4.3.5.2 gives an overview of the prevalence of illicit opiates by age group. In general the 
prevalence is very low. Only Italian drivers aged 35-49 have a prevalence higher than 0.5%, namely 
0.77%. Furthermore, in Belgium young drivers aged 18-24, have a prevalence of 0.40%. 
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Table 4.3.5.2. Prevalence of illicit opiates alone by age group; prevalence in percentages; 95% confidence 
intervals in italics 
Total 18-24 25-34 35-49 50+ All ages 
BE 0.40 0.17 0.04 0.00 0.09 
(n=2949) 0.08 - 1.99 0.03 - 0.93 0 - 0.43 0 - 0.42 0.03 - 0.28 
ES 0.03 0.00 0.12 0.00 0.05 
(n=3174) 0 - 0.71 0 - 0.37 0.03 - 0.59 0 - 0.78 0.01 - 0.2 
IT 0.03 0.00 0.77 0.00 0.30 
(n=1311) 0 - 1.27 0 - 0.88 0.3 - 2.01 0 - 5.26 0.12 - 0.78 
NL 0.00 0.03 0.00 0.00 0.01 
(n=4822) 0 - 0.75 0 - 0.44 0 - 0.22 0 - 0.24 0 - 0.09 
PL 0.00 0.09 0.20 0.00 0.09 
(n=4008) 0 - 0.64 0.02 - 0.45 0.06 - 0.66 0 - 0.45 0.04 - 0.25 
PT 0.00 0.21 0.25 0.00 0.15 
(n=3965) 0 - 0.72 0.07 - 0.68 0.09 - 0.71 0 - 0.44 0.07 - 0.33 
 
Figure 4.3.5.3 shows that most users are between 35 and 49 years old, except for Belgium where 
most users were younger than 25.  
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Figure 4.3.5.3. Distribution of the prevalence of illicit opiates alone among the age groups; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various age 
groups 
 
Figure 4.3.5.4 provides an overview of the prevalence of illicit opiates by gender. It is clearly shown 
that illicit opiates are mainly used by male drivers.  
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Figure 4.3.5.4. Prevalence of illicit opiates alone by gender; prevalence in percentages 
Table 4.3.5.3 presents the use of illicit opiates among male drivers. The prevalence of Illicit opiates 
was very low or even absent among male drivers. Italy had the highest prevalence with almost 0.4% of 
the male drivers, followed by Portugal, Poland and Belgium.  
 
Table 4.3.5.3. Prevalence of illicit opiates alone among male drivers by age group; prevalence in 
percentages; 95% confidence intervals in italics 
Male 18-24 25-34 35-49 50+ All ages 
BE 0.63 0.29 0.00 0.00 0.11 
(n=1957) 0.12 - 3.15 0.05 - 1.55 0 - 0.52 0 - 0.57 0.03 - 0.39 
ES 0.00 0.00 0.15 0.00 0.05 
(n=2520) 0 - 0.82 0 - 0.47 0.03 - 0.74 0 - 0.9 0.01 - 0.24 
IT 0.04 0.00 1.08 0.00 0.39 
(n=998) 0 - 1.58 0 - 1.09 0.41 - 2.8 0 - 8.08 0.15 - 1.02 
NL 0.00 0.05 0.00 0.00 0.01 
(n=3363) 0 - 1.08 0 - 0.61 0 - 0.33 0 - 0.34 0 - 0.13 
PL 0.00 0.11 0.25 0.00 0.11 
(n=3331) 0 - 0.77 0.02 - 0.56 0.08 - 0.82 0 - 0.5 0.04 - 0.3 
PT 0.00 0.36 0.39 0.00 0.23 
(n=2541) 0 - 1.2 0.11 - 1.15 0.14 - 1.11 0 - 0.54 0.11 - 0.51 
 
Figure 4.3.5.5 shows that most male drivers who used illicit opiates were 35-49 years old, except for 
Belgium and the Netherlands where all male drivers positive for illicit opiates as a single drug were 
younger than 35 years. In Portugal illicit opiates in traffic were used by male drivers aged 25-49. 
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Figure 4.3.5.5. Distribution of the prevalence of illicit opiates alone among the age groups for male 
drivers; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups 
 
 
Table 4.3.5.4 and figure 4.3.5.6 show that illicit opiates were only used by a very small share of 35-49 
old female drivers in Belgium and by 18-24 old female drivers in Spain. In all other countries no illicit 
opiates were detected at all.  
 
Table 4.3.5.4. Prevalence of illicit opiates alone among female drivers by age group; prevalence in 
percentages; 95% confidence intervals in italics 
Female 18-24 25-34 35-49 50+ All ages 
BE 0.00 0.00 0.13 0.00 0.05 
(n=971) 0 - 3.37 0 - 1.52 0.01 - 1.27 0 - 1.55 0 - 0.48 
ES 0.16 0.00 0.00 0.00 0.03 
(n=605) 0.01 - 3.45 0 - 1.68 0 - 1.91 0 - 5.56 0 - 0.67 
IT 0.00 0.00 0.00 0.00 0.00 
(n=313) 0 - 5.82 0 - 4.35 0 - 2.65 0 - 13.07 0 - 1.21 
NL 0.00 0.00 0.00 0.00 0.00 
(n=1454) 0 - 2.42 0 - 1.33 0 - 0.66 0 - 0.88 0 - 0.26 
PL 0.00 0.00 0.00 0.00 0.00 
(n=672) 0 - 3.51 0 - 1.51 0 - 1.57 0 - 4.88 0 - 0.57 
PT 0.00 0.00 0.00 0.00 0.00 
(n=1342) 0 - 1.79 0 - 0.77 0 - 0.81 0 - 2.21 0 - 0.28 
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Figure 4.3.5.6. Distribution of the prevalence of illicit opiates alone among the age groups for female 
drivers; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups 
 
4.3.5.3 Illicit opiates use by time period 
Table 4.3.5.5 presents an overview of the prevalence of illicit opiates by time period. The highest 
prevalence was found in Italy in the weekend at night time (0.58%) and during weekdays at day time 
(0.40%).  
 
Table 4.3.5.5. Prevalence of illicit opiates alone by time period; prevalence in percentages; 95% 
confidence intervals in italics 
Time 
period 
Weekdays  
04.00-21.59 
Weekday  nights 
22.00-03.59 
Weekend days 
04.00-21.59 
Weekend nights 
22.00-03.59 
All time 
periods 
BE 0.06 0.00 0.23 0.00 0.09 
(n=2949) 0.01 - 0.29 0 - 2.2 0.05 - 0.97 0 - 4.88 0.03 - 0.28 
ES 0.00 0.00 0.16 0.12 0.05 
(n=3174) 0 - 0.18 0 - 2.94 0.03 - 0.76 0.01 - 2.59 0.01 - 0.2 
IT 0.40 0.00 0.00 0.58 0.30 
(n=1311) 0.15 - 1.05 0 - 11.31 0 - 1.22 0.02 - 14.36 0.12 - 0.78 
NL 0.00 0.00 0.03 0.00 0.01 
(n=4822) 0 - 0.11 0 - 2.59 0 - 0.42 0 - 2.87 0 - 0.09 
PL 0.13 0.00 0.00 0.00 0.09 
(n=4008) 0.05 - 0.34 0 - 4 0 - 0.4 0 - 4.81 0.04 - 0.25 
PT 0.15 0.00 0.14 0.37 0.15 
(n=3965) 0.06 - 0.38 0 - 4.98 0.03 - 0.68 0.02 - 5.56 0.07 - 0.33 
 
Figure 4.3.5.7 shows that in Italy and Portugal the largest share was during weekend nights, in 
Belgium, the Netherlands and Spain during weekend days and in Poland at weekdays during daytime. 
Illicit opiates were not found during weekday nights in any of the 13 countries. 
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Figure 4.3.5.7. Distribution of the prevalence of illicit opiates alone among the time periods; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various time 
periods 
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4.3.6 Benzodiazepines 
Benzodiazepines are sedative medicinal drugs, mainly used to treat anxiety and insomnia problems. 
The impairment effect of benzodiazepines is mainly present in the first two weeks of intake. Driving 
and simulator studies found impairment for different tasks such as steering, braking, reaction time and 
lane position (Kelly et al., 2004; Scheers et al., 2006; Steyvers and Brookhuis, 1996). 
The results of the roadside surveys are presented for single use of benzodiazepines. The combination 
of benzodiazepines with a substance from an other substance group is regarded as combinational 
use. The share of combinational use in relation to single use is presented in table 4.3.6.1 and figure 
4.3.6.2.  
The 95% confidence intervals can vary between countries and within countries for the different 
disaggregations. Therefore, differences between the participating countries should be interpreted with 
care, especially the differences for disaggregations by gender, age and time period. 
4.3.6.1. General results 
The benzodiazepines group consists of diazepam, nordiazepam, oxazepam, lorazepam, alprazolam, 
flunitrazepam, and clonazepam. The cut-off levels for these benzodiazepines are presented in table 
2.2. 
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Figure 4.3.6.1. Prevalence benzodiazepines alone by country; prevalence in percentages 
Figure 4.3.6.1 presents an overview of the use of benzodiazepines by country. Benzodiazepines were 
detected in all 13 countries. The highest prevalence was detected in Portugal (2.73%), followed by 
Belgium (2.01%), Hungary (1.50%), Lithuania (1.41%) and Spain (1.40%). The average use in Europe 
is 0.9%. 
 
Table 4.3.6.1. Prevalence of benzodiazepines alone and benzodiazepines in combination with other 
psychoactive substances; prevalence in percentages 
  BE CZ DK ES FI HU IT LT NL NO PL PT SE 
Alone 2.01 0.62 0.47 1.40 0.79 1.50 0.97 1.41 0.40 0.84 0.14 2.73 0.19 
Combi 0.27 0.04 0.04 0.32 0.29 0.25 0.75 0.03 0.04 0.20 - 0.22 0.02 
Total 2.28 0.66 0.51 1.72 1.08 1.75 1.72 1.44 0.44 1.04 0.14 2.96 0.21 
Share 12% 6% 8% 19% 27% 14% 44% 2% 9% 19% 0% 8% 10% 
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Table 4.3.6.1 and figure 4.3.6.2 provide an overview of the use of benzodiazepines among drivers 
either alone or in combination with other psychoactive substances. It shows that benzodiazepines 
were not often used in combination with other psychoactive substances. In most countries the share of 
combination use for benzodiazepines in relation to all benzodiazepine use was around 15%. However 
in Italy almost half of all benzodiazepines were used in combination. 
 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
BE CZ DK ES FI HU IT LT NL NO PO PT SE
benzodiazepines in combi
benzodiazepines alone
 
Figure 4.3.6.2. Prevalence of benzodiazepines alone and benzodiazepines in combination with other 
psychoactive substances; prevalence in percentages 
4.3.6.2 Benzodiazepine use by gender and age 
Table 4.3.6.2 gives an overview of the prevalence of benzodiazepines by age group. The prevalence 
was the highest among drivers aged 50 years and older in Lithuania (5.35%), Portugal (4.58%), Spain 
(3.84%), and Belgium (3.50%). In general benzodiazepine use is most prevalent in older age groups; 
The group of 50+ has the highest prevalence, and decreasing in age the lowest use was among the 
young drivers aged 18-24. 
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Table 4.3.6.2. Prevalence of benzodiazepines alone by age group; prevalence in percentages; 95% 
confidence intervals in italics 
Total 18-24 25-34 35-49 50+ All ages 
BE 0.00 0.57 2.17 3.50 2.01 
(n=2949) 0 - 1.28 0.21 - 1.55 1.46 - 3.21 2.49 - 4.91 1.57 - 2.59 
CZ 0.41 0.20 0.79 0.95 0.62 
(n=2037) 0.07 - 2.3 0.04 - 1.04 0.35 - 1.74 0.4 - 2.22 0.36 - 1.07 
DK 0.46 0.06 0.53 0.59 0.47 
(n=3002) 0.08 - 2.53 0 - 0.91 0.24 - 1.17 0.29 - 1.2 0.28 - 0.79 
ES 0.04 1.11 1.38 3.84 1.40 
(n=3174) 0 - 0.72 0.63 - 1.96 0.82 - 2.3 2.47 - 5.94 1.05 - 1.87 
FI 0.35 0.80 0.48 1.17 0.79 
(n=3842) 0.08 - 1.51 0.36 - 1.74 0.21 - 1.06 0.74 - 1.86 0.56 - 1.13 
HU 1.85 1.10 0.83 2.89 1.50 
(n=2741) 0.77 - 4.35 0.59 - 2.02 0.42 - 1.64 1.85 - 4.48 1.11 - 2.03 
IT 3.12 0.35 0.30 0.00 0.97 
(n=1311) 1.69 - 5.69 0.08 - 1.49 0.07 - 1.3 0 - 5.26 0.57 - 1.67 
LT 0.22 0.00 0.38 5.35 1.41 
(n=1267) 0.02 - 2.57 0 - 1.18 0.1 - 1.48 3.31 - 8.53 0.9 - 2.23 
NL 0.00 0.15 0.66 0.39 0.40 
(n=4822) 0 - 0.75 0.03 - 0.64 0.37 - 1.17 0.18 - 0.85 0.25 - 0.62 
NO 0.38 0.29 0.66 1.42 0.84 
(n=9236) 0.14 - 1 0.12 - 0.69 0.44 - 1.01 1.07 - 1.88 0.67 - 1.05 
PL 0.31 0.00 0.29 0.02 0.14 
(n=4008) 0.08 - 1.18 0 - 0.28 0.1 - 0.78 0 - 0.49 0.06 - 0.31 
PT 0.80 2.03 2.96 4.58 2.73 
(n=3965) 0.32 - 1.98 1.37 - 3 2.16 - 4.03 3.38 - 6.17 2.27 - 3.29 
SE 0.00 0.06 0.27 0.21 0.19 
(n=6198) 0 - 0.78 0.01 - 0.51 0.12 - 0.61 0.1 - 0.46 0.11 - 0.33 
 
Figure 4.3.6.3 shows that the largest shares for single benzodiazepine use were among drivers aged 
35 years and older. However, in Italy most benzodiazepines were used by young drivers aged 18-24. 
 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
BE CZ DK ES FI HU IT LT NL NO PL PT SE
Agegroup 50+
Agegroup 35-49
Agegroup 25-34
Agegroup 18-24
 
Figure 4.3.6.3. Distribution of the prevalence of benzodiazepines alone among the age groups; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various age 
groups 
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Unlike illicit drugs, benzodiazepine use is relatively more frequently detected among female drivers. 
Especially in Lithuania the share of female drivers was much higher than that of male drivers. 
However, in Denmark, Finland, and Poland the share of benzodiazepine use was higher among male 
drivers. 
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Figure 4.3.6.4. Prevalence of benzodiazepines alone by gender; prevalence in percentages 
Table 4.3.6.3 gives an overview of the prevalence of benzodiazepines among male drivers by age 
group. Highest prevalence was found in the highest age groups (50+) for Portugal (3.07%), Hungary 
(3.06%) and Belgium (3.02%). High shares in lower age groups were found in Hungary and Italy with 
2.61% and 2.38%, respectively, among drivers aged 18-24.  
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Table 4.3.6.3. Prevalence of benzodiazepines alone among male drivers by age group; prevalence in 
percentages; 95% confidence intervals in italics 
Male 18-24 25-34 35-49 50+ All ages 
BE 0.00 0.25 1.90 3.02 1.78 
(n=1957) 0 - 2.03 0.04 - 1.49 1.14 - 3.17 1.96 - 4.61 1.28 - 2.46 
CZ 0.00 0.00 0.55 0.65 0.38 
(n=1589) 0 - 2.39 0 - 0.91 0.19 - 1.58 0.22 - 1.91 0.17 - 0.82 
DK 0.69 0.10 0.62 0.75 0.60 
(n=1975) 0.12 - 3.79 0.01 - 1.41 0.25 - 1.57 0.35 - 1.59 0.34 - 1.05 
ES 0.04 1.08 1.46 2.97 1.31 
(n=2520) 0 - 0.9 0.56 - 2.06 0.83 - 2.53 1.73 - 5.05 0.94 - 1.83 
FI 0.33 1.24 0.39 1.27 0.92 
(n=2511) 0.05 - 1.93 0.57 - 2.7 0.12 - 1.19 0.76 - 2.13 0.61 - 1.37 
HU 2.61 0.96 0.41 3.06 1.46 
(n=2062) 1.09 - 6.12 0.45 - 2.05 0.14 - 1.23 1.9 - 4.9 1.02 - 2.07 
IT 2.38 0.00 0.42 0.00 0.75 
(n=998) 1.1 - 5.11 0 - 1.09 0.1 - 1.81 0 - 8.08 0.37 - 1.5 
LT 0.24 0.00 0.21 2.91 0.82 
(n=1130) 0.02 - 2.83 0 - 1.4 0.03 - 1.28 1.48 - 5.61 0.43 - 1.52 
NL 0.00 0.00 0.45 0.34 0.27 
(n=3363) 0 - 1.08 0 - 0.52 0.19 - 1.03 0.13 - 0.88 0.14 - 0.5 
NO 0.55 0.39 0.56 1.09 0.73 
(n=6520) 0.21 - 1.46 0.16 - 0.95 0.33 - 0.97 0.75 - 1.58 0.55 - 0.97 
PL 0.38 0.00 0.36 0.02 0.16 
(n=3331) 0.1 - 1.43 0 - 0.35 0.13 - 0.97 0 - 0.53 0.07 - 0.37 
PT 0.67 0.93 1.53 3.07 1.68 
(n=2541) 0.19 - 2.33 0.44 - 1.95 0.89 - 2.63 2.03 - 4.62 1.25 - 2.25 
SE 0.00 0.08 0.30 0.08 0.14 
(n=4352) 0 - 1.12 0.01 - 0.76 0.12 - 0.79 0.02 - 0.32 0.06 - 0.3 
 
Figure 4.3.6.5 shows that benzodiazepines were mainly used by male drivers of 50 years and older. 
However, in Italy, Hungary, Denmark and Poland benzodiazepines were relatively frequently detected 
among young male drivers. 
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Figure 4.3.6.5. Distribution of the prevalence of benzodiazepines alone among the age groups for male 
drivers; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups 
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Table 4.3.6.4 gives an overview of the prevalence of benzodiazepines among female drivers by age 
group. The highest prevalence was found among female drivers aged 50+ in Lithuania. Almost half 
(45.02%) of them was positive for benzodiazepines. However, the number of tested female drivers 
was very low in Lithuania so that this extremely high outcome could have been caused by chance. 
Furthermore high prevalence was detected among female drivers aged 50 and over in Portugal 
(10.83%) and Spain (9.51%).  
 
Table 4.3.6.4. Prevalence of benzodiazepines alone among female drivers by age group; prevalence in 
percentages; 95% confidence intervals in italics 
Female 18-24 25-34 35-49 50+ All ages 
BE 0.00 1.05 2.70 4.82 2.50 
(n=971) 0 - 3.37 0.33 - 3.25 1.47 - 4.91 2.77 - 8.27 1.69 - 3.69 
CZ 1.17 0.80 1.60 3.08 1.49 
(n=448) 0.21 - 6.36 0.15 - 4.14 0.51 - 4.93 0.84 - 10.65 0.71 - 3.09 
DK 0.00 0.00 0.37 0.21 0.22 
(n=1015) 0 - 4.97 0 - 2.15 0.09 - 1.59 0.03 - 1.43 0.06 - 0.75 
ES 0.00 1.24 1.06 9.51 1.78 
(n=605) 0 - 3.16 0.41 - 3.71 0.3 - 3.7 4.49 - 19.03 1 - 3.16 
FI 0.40 0.00 0.61 0.92 0.56 
(n=1283) 0.04 - 3.43 0 - 1.44 0.21 - 1.78 0.34 - 2.44 0.27 - 1.14 
HU 0.00 1.46 2.05 2.14 1.63 
(n=679) 0 - 4.9 0.54 - 3.89 0.87 - 4.72 0.68 - 6.56 0.91 - 2.89 
IT 6.11 1.77 0.00 0.00 1.69 
(n=313) 2.35 - 14.99 0.41 - 7.32 0 - 2.65 0 - 13.07 0.74 - 3.81 
LT 0.00 0.00 2.34 45.02 7.07 
(n=121) 0 - 19 0 - 7.06 0.38 - 13.23 24.6 - 67.26 3.7 - 13.06 
NL 0.00 0.53 1.09 0.55 0.70 
(n=1454) 0 - 2.42 0.12 - 2.25 0.51 - 2.31 0.17 - 1.8 0.38 - 1.28 
NO 0.00 0.09 0.88 2.37 1.10 
(n=2709) 0 - 1.21 0.01 - 0.91 0.47 - 1.66 1.54 - 3.62 0.77 - 1.57 
PL 0.00 0.00 0.00 0.00 0.00 
(n=672) 0 - 3.51 0 - 1.51 0 - 1.57 0 - 4.88 0 - 0.57 
PT 1.00 3.65 5.44 10.83 4.75 
(n=1342) 0.28 - 3.47 2.32 - 5.69 3.73 - 7.87 6.99 - 16.4 3.74 - 6 
SE 0.00 0.00 0.20 0.63 0.31 
(n=1835) 0 - 2.57 0 - 1.24 0.04 - 0.91 0.25 - 1.53 0.14 - 0.69 
 
Figure 4.3.6.6 indicates that among female drivers benzodiazepines were mostly detected among 
drivers aged 50+. In Italy benzodiazepines were most often used by young female drivers. The overall 
use of benzodiazepines was the highest in Lithuania followed by Portugal and Belgium. No 
benzodiazepines were detected among female drivers from Poland. 
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Figure 4.3.6.6. Distribution of the prevalence of benzodiazepines alone among the age groups for female 
drivers; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups 
 
4.3.6.3 Benzodiazepine use by time period 
 
Table 4.3.6.5 provides an overview of the prevalence of benzodiazepines by time period. The highest 
prevalence was found in Portugal during weekdays, weeknights, and weekend days.  
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Table 4.3.6.5. Prevalence of benzodiazepines alone by time period; prevalence in percentages; 95% 
confidence intervals in italics 
Time 
period 
Weekdays  
04.00-21.59 
Weekday  nights 
22.00-03.59 
Weekend days 
04.00-21.59 
Weekend nights 
22.00-03.59 
All time 
periods 
BE 2.12 1.05 2.03 1.16 2.01 
(n=2949) 1.58 - 2.84 0.27 - 3.98 1.21 - 3.41 0.19 - 6.9 1.57 - 2.59 
CZ 0.79 0.00 0.32 0.62 0.62 
(n=2037) 0.44 - 1.43 0 - 8.62 0.09 - 1.13 0.02 - 16.88 0.36 - 1.07 
DK 0.48 0.00 0.49 0.41 0.47 
(n=3002) 0.26 - 0.88 0 - 5.06 0.19 - 1.3 0.03 - 5.62 0.28 - 0.79 
ES 1.36 0.49 1.77 0.82 1.40 
(n=3174) 0.95 - 1.96 0.06 - 3.83 1.06 - 2.95 0.17 - 3.79 1.05 - 1.87 
FI 0.91 0.36 0.57 0.71 0.79 
(n=3842) 0.61 - 1.35 0.03 - 3.6 0.26 - 1.23 0.08 - 6.03 0.56 - 1.13 
HU 1.69 2.06 0.99 0.00 1.50 
(n=2741) 1.21 - 2.36 0.44 - 9.2 0.47 - 2.09 0 - 6.88 1.11 - 2.03 
IT 1.03 0.00 0.96 0.00 0.97 
(n=1311) 0.56 - 1.91 0 - 11.31 0.33 - 2.79 0 - 13.37 0.57 - 1.67 
LT 1.81 0.00 0.29 0.00 1.41 
(n=1267) 1.14 - 2.88 0 - 11.28 0.04 - 1.96 0 - 13.37 0.9 - 2.23 
NL 0.48 0.00 0.21 0.16 0.40 
(n=4822) 0.3 - 0.77 0 - 2.59 0.06 - 0.72 0.01 - 3.17 0.25 - 0.62 
NO 1.02 0.13 0.49 0.99 0.84 
(n=9236) 0.8 - 1.31 0.02 - 0.94 0.27 - 0.88 0.41 - 2.38 0.67 - 1.05 
PL 0.13 0.57 0.13 0.00 0.14 
(n=4008) 0.05 - 0.34 0.06 - 5.04 0.03 - 0.63 0 - 4.81 0.06 - 0.31 
PT 2.73 4.58 2.71 1.56 2.73 
(n=3965) 2.19 - 3.38 1.66 - 12.02 1.84 - 3.99 0.31 - 7.54 2.27 - 3.29 
SE 0.19 0.00 0.21 0.00 0.19 
(n=6198) 0.1 - 0.37 0 - 3.01 0.07 - 0.6 0 - 3.01 0.11 - 0.33 
 
Figure 4.3.6.7 shows that benzodiazepines were most commonly detected during daytime in many of 
the countries. Only in Poland and Portugal relatively more drivers were positive for the use of 
benzodiazepines during night time hours. 
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Figure 4.3.6.7. Distribution of the prevalence of benzodiazepines alone among the time periods; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various time 
periods 
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4.3.7 Z-drugs 
Z-drugs are hypnotic medicinal drugs, mainly used to treat insomnia problems. Z-drugs have effects 
similar to benzodiazepines, although they belong to a different pharmacological-chemical group. 
Users are recommended to comply to the prescription which means that for zolpidem no higher doses 
should be taken and that a certain number of hours of uninterrupted sleep is needed before driving. 
zopiclone use has a larger effect on driving impairment (Verster et al., 2007).  
The results of the roadside surveys are presented for single use of Z-drugs. The combination of Z-
drugs with a substance from an other substance group is regarded as combinational use. The share of 
combinational use in relation to single use is presented in table 4.3.7.1 and figure 4.3.7.2.  
The 95% confidence intervals can vary between countries and within countries for the different 
disaggregations. Therefore, differences between the participating countries should be interpreted with 
care, especially the differences for disaggregations by gender, age and time period. 
4.3.7.1. General results 
The Z-drugs group consists of zolpidem and zopiclone. The cut-off levels for these substances are 
presented in table 2.2. 
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Figure 4.3.7.1. Prevalence Z-drugs alone by country 
Figure 4.3.7.1 presents the prevalence of Z-drugs by country. Z-drugs are not commonly detected 
among European drivers. The prevalence is the highest in the Northern European countries, followed 
by Belgium, Hungary and the Netherlands. No single use of Z-drugs was detected among drivers in 
Czech Republic, Spain, Italy, Lithuania, Poland and Portugal. The average use of Z-drugs by drivers in 
Europe is 0.12%. 
 
Table 4.3.7.1 and figure 4.3.7.2 show that Z-drugs were relatively often combined with other 
psychoactive substances in Finland and Hungary. In Denmark only single use of Z-drugs was 
detected. In Belgium, Norway, Sweden and the Netherlands the relative share of combinational use of 
Z-drugs varied between 9% and 26%. 
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Table 4.3.7.1. Prevalence of Z-drugs alone and Z-drugs in combination with other psychoactive 
substances; prevalence in percentages 
 BE CZ DK ES FI HU IT LT NL NO PL PT SE 
Z-drugs alone 0.22 - 0.32 - 0.36 0.07 - - 0.04 0.69 - - 0.31 
Z-drugs in combi 0.07 - - - 0.22 0.08 - - 0.01 0.07 - - 0.11 
Total 0.29 - 0.32 - 0.58 0.15 - - 0.05 0.76 - - 0.42 
Share 24% - 0% - 38% 53% - - 19% 9% - - 26% 
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Figure 4.3.7.2. Prevalence of Z-drugs alone and Z-drugs in combination with other psychoactive 
substances; prevalence in percentages 
4.3.7.2. Z-drugs by age and gender 
Table 4.3.7.2 gives an overview of the prevalence of Z-drugs by age group. The prevalence was the 
highest among drivers aged 50 years and older in Norway (1.39%), Finland (0.73%), and Sweden 
(0.62%). 
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Table 4.3.7.2. Prevalence of Z-drugs alone by age group; prevalence in percentages; 95% confidence 
intervals in italics 
Total 18-24 25-34 35-49 50+ All ages 
BE 0.00 0.00 0.18 0.50 0.22 
(n=2949) 0 - 1.28 0 - 0.62 0.05 - 0.65 0.21 - 1.22 0.1 - 0.47 
DK 0.00 0.00 0.22 0.59 0.32 
(n=3002) 0 - 1.71 0 - 0.78 0.07 - 0.73 0.29 - 1.21 0.17 - 0.59 
FI 0.00 0.12 0.17 0.73 0.36 
(n=3842) 0 - 0.9 0.02 - 0.74 0.05 - 0.62 0.41 - 1.31 0.21 - 0.6 
HU 0.00 0.22 0.00 0.00 0.07 
(n=2741) 0 - 1.49 0.06 - 0.8 0 - 0.41 0 - 0.59 0.02 - 0.26 
NL 0.00 0.00 0.02 0.11 0.04 
(n=4822) 0 - 0.75 0 - 0.38 0 - 0.26 0.03 - 0.44 0.01 - 0.15 
NO 0.00 0.34 0.35 1.39 0.69 
(n=9236) 0 - 0.39 0.15 - 0.76 0.2 - 0.62 1.05 - 1.85 0.54 - 0.88 
SE 0.00 0.06 0.06 0.62 0.31 
(n=6198) 0 - 0.78 0.01 - 0.51 0.01 - 0.3 0.39 - 0.98 0.2 - 0.48 
 
Figure 4.3.7.3 shows that most drivers positive for Z-drugs were 50 years and older, except for 
Hungary where all drivers were between 25 and 34 years old.  
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Figure 4.3.7.3. Distribution of the prevalence of Z-drugs alone among the age groups; overall prevalences 
in percentages per country, the figure shows the relative contributions of the various age groups 
 
In general the share of female drivers who were positive for Z-drugs was higher than the share of male 
drivers. However, In the Netherlands only (a small share of) male drivers were positive for Z-drugs and 
in Sweden the share of Z-drugs users was a little bit higher among male drivers than among female 
drivers. In Hungary Z-drugs were only detected among female drivers. 
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Figure 4.3.7.4. Prevalence of Z-drugs alone by gender; prevalence in percentages 
 
Table 4.3.7.3 gives an overview of the prevalence of Z-drugs among male drivers by age group. The 
prevalence was the highest among drivers aged 50 years and older in Norway (0.95%), Sweden 
(0.64%), Denmark (0.60%) and Finland (0.56%). 
 
Table 4.3.7.3. Prevalence of Z-drugs alone among male drivers by age group; prevalence in percentages; 
95% confidence intervals in italics 
Male 18-24 25-34 35-49 50+ All ages 
BE 0.00 0.00 0.00 0.54 0.18 
(n=1957) 0 - 2.03 0 - 1.03 0 - 0.52 0.2 - 1.45 0.07 - 0.49 
DK 0.00 0.00 0.15 0.60 0.31 
(n=1975) 0 - 2.56 0 - 1.22 0.03 - 0.85 0.26 - 1.38 0.14 - 0.67 
FI 0.00 0.19 0.00 0.56 0.27 
(n=2511) 0 - 1.35 0.03 - 1.15 0 - 0.55 0.26 - 1.21 0.13 - 0.56 
HU 0.00 0.00 0.00 0.00 0.00 
(n=2062) 0 - 2.09 0 - 0.58 0 - 0.55 0 - 0.72 0 - 0.19 
NL 0.00 0.00 0.03 0.15 0.06 
(n=3363) 0 - 1.08 0 - 0.52 0 - 0.39 0.04 - 0.61 0.02 - 0.22 
NO 0.00 0.22 0.17 0.95 0.46 
(n=6520) 0 - 0.56 0.07 - 0.7 0.06 - 0.44 0.64 - 1.42 0.32 - 0.66 
SE 0.00 0.00 0.04 0.64 0.32 
(n=4352) 0 - 1.12 0 - 0.61 0 - 0.38 0.38 - 1.08 0.19 - 0.54 
 
Figure 4.3.7.5 indicates that most male users were older than 50 years. Only in Finland and Norway 
male users were younger than 35 years. Contrary to benzodiazepines, no Z-drugs were found among 
young male drivers aged 18-24.  
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Figure 4.3.7.5. Distribution of the prevalence of Z-drugs alone among the age groups for male drivers; 
overall prevalences in percentages per country, the figure shows the relative contributions of the various 
age groups 
 
 
Table 4.3.7.4 provides an overview of the prevalence of Z-drugs among female drivers by age group. 
The prevalence was the highest among drivers aged 50 years and older in Norway (2.62%), Finland 
(1.21%), Denmark (0.58%) and Sweden (0.55%). 
 
Table 4.3.7.4. Prevalence of Z-drugs alone among female drivers by age group; prevalence in 
percentages; 95% confidence intervals in italics 
Female 18-24 25-34 35-49 50+ All ages 
BE 0.00 0.00 0.53 0.40 0.30 
(n=971) 0 - 3.37 0 - 1.52 0.14 - 1.94 0.07 - 2.26 0.1 - 0.89 
DK 0.00 0.00 0.33 0.58 0.34 
(n=1015) 0 - 4.97 0 - 2.15 0.07 - 1.53 0.16 - 2.03 0.12 - 0.92 
FI 0.00 0.00 0.42 1.21 0.53 
(n=1283) 0 - 2.71 0 - 1.44 0.12 - 1.49 0.51 - 2.85 0.26 - 1.1 
HU 0.00 0.80 0.00 0.00 0.28 
(n=679) 0 - 4.9 0.21 - 2.92 0 - 1.56 0 - 3.08 0.08 - 1.05 
NL 0.00 0.00 0.00 0.00 0.00 
(n=1454) 0 - 2.42 0 - 1.33 0 - 0.66 0 - 0.88 0 - 0.26 
NO 0.00 0.61 0.74 2.62 1.22 
(n=2709) 0 - 1.21 0.21 - 1.74 0.37 - 1.48 1.74 - 3.92 0.87 - 1.71 
SE 0.00 0.17 0.08 0.55 0.27 
(n=1835) 0 - 2.57 0.02 - 1.56 0.01 - 0.71 0.21 - 1.43 0.11 - 0.63 
 
Figure 4.3.7.6 shows that most Z-drugs are used by older female drivers, and that Z-drugs are not 
used by the youngest drivers (18-24).  
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Figure 4.3.7.6 Distribution of the prevalence of Z-drugs alone among the age groups for female drivers; 
overall prevalences in percentages per country, the figure shows the relative contributions of the various 
age groups 
 
 
4.3.7.3. Z-drugs use by time period 
Table 4.3.7.5 presents an overview of the prevalence of Z-drugs by time period. The prevalence was 
the highest at weekdays during daytime hours in Norway (0.92%) and in Finland (0.46%), in the 
weekend at daytime hours in Denmark (0.46%) and during weekday nights in Sweden (0.44%). 
 
Table 4.3.7.5. Prevalence of Z-drugs alone by time period; prevalence in percentages; 95% confidence 
intervals in italics 
Time 
period 
Weekdays  
04.00-21.59 
Weekday  nights 
22.00-03.59 
Weekend days 
04.00-21.59 
Weekend nights 
22.00-03.59 
All time 
periods 
BE 0.30 0.00 0.07 0.00 0.22 
(n=2949) 0.14 - 0.65 0 - 2.2 0.01 - 0.7 0 - 4.88 0.1 - 0.47 
DK 0.29 0.00 0.46 0.00 0.32 
(n=3002) 0.13 - 0.63 0 - 5.06 0.17 - 1.26 0 - 4.87 0.17 - 0.59 
FI 0.46 0.36 0.15 0.00 0.36 
(n=3842) 0.26 - 0.8 0.03 - 3.6 0.03 - 0.62 0 - 4.76 0.21 - 0.6 
HU 0.10 0.00 0.00 0.00 0.07 
(n=2741) 0.03 - 0.36 0 - 5.75 0 - 0.59 0 - 6.88 0.02 - 0.26 
NL 0.05 0.00 0.03 0.00 0.04 
(n=4822) 0.01 - 0.2 0 - 2.59 0 - 0.42 0 - 2.87 0.01 - 0.15 
NO 0.92 0.13 0.35 0.00 0.69 
(n=9236) 0.71 - 1.19 0.02 - 0.94 0.18 - 0.7 0 - 0.83 0.54 - 0.88 
SE 0.39 0.44 0.08 0.00 0.31 
(n=6198) 0.25 - 0.62 0.05 - 3.82 0.01 - 0.39 0 - 3.01 0.2 - 0.48 
 
Figure 4.3.7.7 shows that Z-drugs were most often used during daytime hours at weekdays. In 
Denmark however, most Z-drugs were detected during daytime hours in the weekend and in Sweden 
most Z-drugs were detected during night time hours at weekdays. In none of the countries Z-drugs 
were found in weekend nights. 
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Figure 4.3.7.7. Distribution of the prevalence of Z-drugs alone among the time periods; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various time 
periods 
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4.3.8 Medicinal opiates and opioids 
Medicinal opiates and opioids are medicinal drugs that are used as antitussives or pain-killers. A user 
has in general feelings of sleepiness, drowsiness or calmness and has lower sense of pain. The 
depressant effect of opiates can be that heavy that drivers don't feel able or motivated to drive a 
vehicle. The effects of medicinal opiates and opioids vary per type of substance (Kelly et al., 2004; 
Scheers et al., 2006; Steyvers and Brookhuis, 1996). 
The results of the roadside surveys are presented for single use of medicinal opiates and opioids. The 
combination of medicinal opiates and opioids with a substance from another substance group is 
regarded as combinational use. The share of combinational use in relation to single use is presented 
in table 4.3.8.1 and figure 4.3.8.2.  
The 95% confidence intervals can vary between countries and within countries for the different 
disaggregations. Therefore, differences between the participating countries should be interpreted with 
care, especially the differences for disaggregations by gender, age and time period. 
4.3.8.1. General results 
The medicinal opiates and opioids group consists of morphine, codeine, methadone and tramadol. 
The cut-off levels for these substances are presented in table 2.2. As tramadol was originally not part 
of the core drugs, it was not measured in Finland and the Netherlands. 
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Figure 4.3.8.1. Prevalence of medicinal opiates and opioids alone by country; prevalence in percentages 
 
Figure 4.3.8.1 presents the prevalence of medicinal opiates and opioids by country. The highest 
prevalence is found in Denmark, Belgium, Sweden, Finland and Italy. No medicinal opiates and 
opioids were detected among drivers in Lithuania. The average use of medicinal opiates and opioids 
by drivers in Europe is 0.35%. 
 
 
Table 4.3.8.1 and figure 4.3.8.2 show that in Hungary, Italy and Portugal medicinal opiates and opioids 
are relatively often used in combination with other psychoactive substances. In Czech Republic, 
Spain, and Poland only single use was detected.  
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Table 4.3.8.1. Prevalence of medicinal opiates and opioids alone and medicinal opiates and opioids in 
combination with other psychoactive substances; prevalence in percentages 
  BE CZ DK ES FI HU IT LT NL NO PL PT SE 
Med. opiates and 
opioids alone 0.75 0.21 0.79 0.19 0.56 0.11 0.53 - 0.16 0.16 0.03 0.11 0.63 
Med. opiates and 
opioids in combi 0.23 - 0.01 - 0.09 0.19 0.70 - 0.05 0.08 - 0.09 0.11 
Total 0.98 0.21 0.80 0.19 0.65 0.30 1.23 - 0.21 0.24 0.03 0.19 0.74 
Share 23% 0% 1% 0% 14% 63% 57% - 24% 33% 0% 45% 15% 
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Figure 4.3.8.2. Prevalence of medicinal opiates and opioids alone and medicinal opiates and opioids in 
combination with other psychoactive substances; prevalence in percentages 
4.3.8.2 Medicinal opiates and opioids use by gender and age 
Table 4.3.8.2 provides an overview of the prevalence of medicinal opiates and opioids distributed by 
age. The highest prevalence was detected among drivers in Denmark and Finland aged 50+, 1.03% 
and 1.10% respectively, and for drivers in Belgium aged 34-49 years (0.96%). 
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Table 4.3.8.2. Prevalence of medicinal opiates and opioids alone by age group; prevalence in 
percentages; 95% confidence intervals in italics 
 
Total 18-24 25-34 35-49 50+ All ages 
BE 0.72 0.00 0.96 0.79 0.75 
(n=2949) 0.21 - 2.5 0 - 0.62 0.53 - 1.73 0.39 - 1.61 0.5 - 1.13 
CZ 0.00 0.38 0.00 0.41 0.21 
(n=2037) 0 - 1.56 0.11 - 1.33 0 - 0.53 0.12 - 1.43 0.08 - 0.52 
DK 0.00 0.90 0.56 1.10 0.79 
(n=3002) 0 - 1.71 0.36 - 2.2 0.26 - 1.21 0.65 - 1.86 0.53 - 1.18 
ES 0.00 0.16 0.42 0.00 0.19 
(n=3174) 0 - 0.65 0.04 - 0.65 0.17 - 1.05 0 - 0.78 0.09 - 0.41 
FI 0.00 0.68 0.09 1.03 0.56 
(n=3842) 0 - 0.9 0.29 - 1.58 0.02 - 0.49 0.63 - 1.69 0.37 - 0.85 
HU 0.00 0.11 0.09 0.16 0.11 
(n=2741) 0 - 1.49 0.02 - 0.63 0.01 - 0.57 0.03 - 0.87 0.04 - 0.32 
IT 0.00 0.00 1.39 0.00 0.53 
(n=1311) 0 - 1.21 0 - 0.88 0.67 - 2.85 0 - 5.26 0.25 - 1.09 
NL 0.04 0.00 0.12 0.36 0.16 
(n=4822) 0 - 0.83 0 - 0.38 0.03 - 0.43 0.16 - 0.8 0.08 - 0.32 
NO 0.00 0.00 0.21 0.25 0.16 
(n=9236) 0 - 0.39 0 - 0.23 0.1 - 0.44 0.13 - 0.48 0.1 - 0.27 
PL 0.00 0.00 0.10 0.00 0.03 
(n=4008) 0 - 0.64 0 - 0.28 0.02 - 0.49 0 - 0.45 0.01 - 0.15 
PT 0.00 0.00 0.28 0.07 0.11 
(n=3965) 0 - 0.72 0 - 0.32 0.11 - 0.75 0.01 - 0.57 0.04 - 0.27 
SE 0.12 0.23 0.43 0.98 0.63 
(n=6198) 0.01 - 1 0.07 - 0.81 0.22 - 0.83 0.68 - 1.42 0.46 - 0.86 
 
Figure 4.3.8.3 shows that in all countries medicinal opiates and opioids were mainly detected among 
drivers of 35 years and older. 
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Figure 4.3.8.3. Distribution of the prevalence of medicinal opiates and opioids alone among the age 
groups; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups 
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Figure 4.3.8.4 presents an overview of the prevalence of medicinal opiates and opioids by gender. In 
most countries the share of female drivers is larger, except for Spain, Finland, Norway and Portugal 
where the share of male drivers positive for medicinal opiates and opioids was larger. 
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Figure 4.3.8.4. Prevalence of medicinal opiates and opioids alone by gender; prevalence in percentages 
Table 4.3.8.3 provides an overview of the prevalence of medicinal opiates and opioids among male 
drivers distributed by age. The highest prevalence was detected among male drivers in Finland aged 
25-34 years (1.06%), and for drivers in Denmark aged 50+ (1.00%). 
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Table 4.3.8.3. Prevalence of medicinal opiates and opioids alone among male drivers by age group; 
prevalence in percentages; 95% confidence intervals in italics 
Male 18-24 25-34 35-49 50+ All ages 
BE 0.63 0.00 0.61 0.32 0.51 
(n=1957) 0.12 - 3.15 0 - 1.03 0.25 - 1.49 0.09 - 1.12 0.28 - 0.93 
CZ 0.00 0.00 0.00 0.47 0.13 
(n=1589) 0 - 2.39 0 - 0.91 0 - 0.68 0.13 - 1.63 0.04 - 0.47 
DK 0.00 0.00 0.05 1.00 0.45 
(n=1975) 0 - 2.56 0 - 1.22 0 - 0.66 0.52 - 1.93 0.23 - 0.85 
ES 0.00 0.20 0.52 0.00 0.23 
(n=2520) 0 - 0.82 0.05 - 0.83 0.21 - 1.29 0 - 0.9 0.11 - 0.51 
FI 0.00 1.06 0.07 0.88 0.59 
(n=2511) 0 - 1.35 0.46 - 2.46 0.01 - 0.67 0.47 - 1.64 0.36 - 0.97 
HU 0.00 0.08 0.05 0.19 0.09 
(n=2062) 0 - 2.09 0.01 - 0.73 0 - 0.63 0.03 - 1.07 0.02 - 0.34 
IT 0.00 0.00 0.84 0.00 0.30 
(n=998) 0 - 1.51 0 - 1.09 0.29 - 2.45 0 - 8.08 0.1 - 0.88 
NL 0.06 0.00 0.00 0.32 0.11 
(n=3363) 0 - 1.2 0 - 0.52 0 - 0.33 0.12 - 0.85 0.04 - 0.3 
NO 0.00 0.00 0.26 0.23 0.18 
(n=6520) 0 - 0.56 0 - 0.34 0.12 - 0.58 0.1 - 0.5 0.1 - 0.31 
PL 0.00 0.00 0.05 0.00 0.01 
(n=3331) 0 - 0.77 0 - 0.35 0.01 - 0.48 0 - 0.5 0 - 0.14 
PT 0.00 0.00 0.30 0.09 0.12 
(n=2541) 0 - 1.2 0 - 0.54 0.09 - 0.97 0.01 - 0.71 0.04 - 0.35 
SE 0.00 0.09 0.28 0.89 0.53 
(n=4352) 0 - 1.12 0.01 - 0.77 0.1 - 0.75 0.57 - 1.39 0.35 - 0.79 
 
Figure 4.3.8.5 shows that only in Belgium and the Netherlands young male drivers were detected for 
medicinal opiates and opioids. In all other countries except for Finland, the largest shares were found 
for male drivers aged 35 and older. 
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Figure 4.3.8.5. Distribution of the prevalence of medicinal opiates and opioids alone among the age 
groups for male drivers; overall prevalences in percentages per country, the figure shows the relative 
contributions of the various age groups 
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Table 4.3.8.4 presents an overview of the prevalence of medicinal opiates and opioids among female 
drivers distributed by age. The highest prevalence was detected among female drivers in Italy aged 
35-49 (2.76%), in Denmark aged 25-34 years (2.50%), drivers in Belgium aged 50 years and older 
(2.06%). 
 
Table 4.3.8.4. Prevalence of medicinal opiates and opioids alone among female drivers by age group; 
prevalence in percentages; 95% confidence intervals in italics 
Female 18-24 25-34 35-49 50+ All ages 
BE 0.88 0.00 1.66 2.06 1.25 
(n=971) 0.15 - 4.92 0 - 1.52 0.77 - 3.56 0.89 - 4.72 0.72 - 2.16 
CZ 0.00 1.53 0.00 0.00 0.47 
(n=448) 0 - 4.32 0.43 - 5.27 0 - 2.31 0 - 5.68 0.13 - 1.64 
DK 0.00 2.50 1.41 1.34 1.46 
(n=1015) 0 - 4.97 1.01 - 6.02 0.63 - 3.1 0.56 - 3.13 0.89 - 2.4 
ES 0.00 0.00 0.00 0.00 0.00 
(n=605) 0 - 3.16 0 - 1.68 0 - 1.91 0 - 5.56 0 - 0.61 
FI 0.00 0.00 0.14 1.46 0.50 
(n=1283) 0 - 2.71 0 - 1.44 0.02 - 1.03 0.66 - 3.2 0.24 - 1.06 
HU 0.00 0.21 0.21 0.00 0.15 
(n=679) 0 - 4.9 0.02 - 1.96 0.02 - 1.96 0 - 3.08 0.03 - 0.84 
IT 0.00 0.00 2.76 0.00 1.24 
(n=313) 0 - 5.82 0 - 4.35 1.07 - 6.96 0 - 13.07 0.48 - 3.19 
NL 0.00 0.00 0.35 0.47 0.28 
(n=1454) 0 - 2.42 0 - 1.33 0.1 - 1.26 0.13 - 1.68 0.11 - 0.71 
NO 0.00 0.00 0.10 0.30 0.13 
(n=2709) 0 - 1.21 0 - 0.75 0.02 - 0.56 0.09 - 0.95 0.05 - 0.36 
PL 0.00 0.00 0.30 0.00 0.11 
(n=672) 0 - 3.51 0 - 1.51 0.04 - 2.12 0 - 4.88 0.01 - 0.77 
PT 0.00 0.00 0.25 0.00 0.09 
(n=1342) 0 - 1.79 0 - 0.77 0.05 - 1.26 0 - 2.21 0.02 - 0.43 
SE 0.39 0.53 0.72 1.25 0.87 
(n=1835) 0.04 - 3.28 0.13 - 2.16 0.3 - 1.68 0.66 - 2.38 0.53 - 1.4 
 
Figure 4.3.8.6 shows that in Czech Republic all female drivers that had been detected using medicinal 
opiates and opioids were aged 25-34, whereas all positive men were aged 50 and older. In general 
the usage was most prevalent among female drivers aged 35 and older. However, in Czech Republic, 
Denmark, Sweden and Hungary the relative share of drivers aged below 35 years of age was large. 
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Figure 4.3.8.6. Distribution of the prevalence of medicinal opiates and opioids alone among the age 
groups for female drivers; overall prevalences in percentages per country, the figure shows the relative 
contributions of the various age groups 
4.3.8.3 Medicinal opiates and opioids use by time period 
 
Table 4.3.8.5 provides an overview of the prevalence of medicinal opiates and opioids by time period. 
The highest prevalences by far were detected among drivers in Denmark during weekend nights 
(2.86%). 
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Table 4.3.8.5. Prevalence of medicinal opiates and opioids alone by time period; prevalence in 
percentages; 95% confidence intervals in italics 
Time 
period 
Weekdays  
04.00-21.59 
Weekday  nights 
22.00-03.59 
Weekend days 
04.00-21.59 
Weekend nights 
22.00-03.59 
All time 
periods 
BE 0.98 0.00 0.30 0.39 0.75 
(n=2949) 0.63 - 1.5 0 - 2.2 0.08 - 1.08 0.03 - 5.59 0.5 - 1.13 
CZ 0.07 0.00 0.51 0.00 0.21 
(n=2037) 0.01 - 0.41 0 - 8.62 0.18 - 1.42 0 - 15.86 0.08 - 0.52 
DK 0.72 0.49 0.81 2.86 0.79 
(n=3002) 0.44 - 1.18 0.04 - 5.96 0.37 - 1.74 0.82 - 9.49 0.53 - 1.18 
ES 0.14 0.16 0.32 0.23 0.19 
(n=3174) 0.05 - 0.41 0.01 - 3.25 0.1 - 1.01 0.02 - 2.8 0.09 - 0.41 
FI 0.69 0.72 0.27 0.00 0.56 
(n=3842) 0.43 - 1.09 0.12 - 4.21 0.09 - 0.82 0 - 4.76 0.37 - 0.85 
HU 0.13 0.52 0.00 0.00 0.11 
(n=2741) 0.04 - 0.41 0.04 - 6.69 0 - 0.59 0 - 6.88 0.04 - 0.32 
IT 0.73 0.00 0.00 0.00 0.53 
(n=1311) 0.35 - 1.51 0 - 11.31 0 - 1.22 0 - 13.37 0.25 - 1.09 
NL 0.20 0.15 0.08 0.00 0.16 
(n=4822) 0.09 - 0.41 0.01 - 2.87 0.01 - 0.51 0 - 2.87 0.08 - 0.32 
NO 0.21 0.00 0.11 0.00 0.16 
(n=9236) 0.12 - 0.36 0 - 0.69 0.03 - 0.35 0 - 0.83 0.1 - 0.27 
PL 0.00 0.00 0.13 0.00 0.03 
(n=4008) 0 - 0.13 0 - 4 0.03 - 0.63 0 - 4.81 0.01 - 0.15 
PT 0.08 0.00 0.20 0.00 0.11 
(n=3965) 0.03 - 0.27 0 - 4.98 0.05 - 0.77 0 - 4.89 0.04 - 0.27 
SE 0.68 0.00 0.56 0.00 0.63 
(n=6198) 0.48 - 0.97 0 - 3.01 0.29 - 1.08 0 - 3.01 0.46 - 0.86 
 
Figure 4.3.8.7 shows that the distribution over the four different DRUID time periods varies largely, but 
in general medicinal opiates and opiods were detected most often during daytime hours. However, in 
Denmark most medicinal opiates and opioids were detected in weekend nights and in Finland during 
weeknights.  
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Figure 4.3.8.7. Distribution of the prevalence of medicinal opiates and opioids alone among the time 
periods; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various time periods 
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4.3.9 Alcohol and drugs 
In the previous sections we have provided an overview of the results for alcohol and drug use 
separately. In this section we will present the results of the use of alcohol and drugs in combination 
with each other. The combination of alcohol and drugs can cause larger impairing effects than one of 
the substances alone (Kelly et al., 2004; Scheers et al., 2006; Steyvers and Brookhuis, 1996). 
The 95% confidence intervals can vary between countries and within countries for the different 
disaggregations. Therefore, differences between the participating countries should be interpreted with 
care, especially the differences for disaggregations by gender, age and time period. 
 
4.3.9.1 General results 
The group alcohol and drugs consist of alcohol ≥ 0.1 g/L in combination with one or more other 
psychoactive substances, excluding THC-COOH which is regarded as negative. The cut-off levels for 
the psychoactive substances are presented in table 2.2. 
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Figure 4.3.9.1. Combined use of alcohol and drugs by country 
Figure 4.3.9.1 presents the prevalence of combined use of alcohol and drugs for 12 of the 13 
countries, since no alcohol results were available for Sweden. The prevalence was the highest in 
Spain and Italy, followed by Portugal and Belgium. No combined use of alcohol and drugs was 
detected among drivers in Hungary and Poland. The average prevalence for alcohol-drug 
combinations in Europe is 0.37%. 
No alcohol-drug combinations were encountered in Hungary, Poland and Sweden (the latter because 
no Swedish alcohol data were available). 
4.3.9.2 Use of alcohol-drugs combinations by gender and age 
Table 4.3.9.1 presents an overview of the prevalence of alcohol-drugs combinations among drivers by 
age. The highest prevalence was detected among drivers in Spain aged 18-24 (1.82%) and 25-34 
years (1.52%), drivers in Italy aged 25-34 years (1.27%) and 35-49 years (1.49%), and drivers in 
Portugal aged 18-24 (1.22%). 
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Table 4.3.9.1. Prevalence of alcohol-drugs combinations by age group; prevalence in percentages; 95% 
confidence intervals in italics 
Total 18-24 25-34 35-49 50+ All ages 
BE 0.83 0.22 0.11 0.43 0.31 
(n=2949) 0.26 - 2.67 0.05 - 1.01 0.02 - 0.55 0.17 - 1.11 0.16 - 0.58 
CZ 0.41 0.00 0.00 0.00 0.05 
(n=2037) 0.07 - 2.3 0 - 0.69 0 - 0.53 0 - 0.74 0.01 - 0.28 
DK 0.00 0.34 0.13 0.00 0.10 
(n=3002) 0 - 1.71 0.08 - 1.37 0.03 - 0.59 0 - 0.32 0.03 - 0.3 
ES 1.82 1.52 0.90 0.15 1.14 
(n=3174) 1.01 - 3.27 0.93 - 2.47 0.48 - 1.7 0.02 - 1.06 0.83 - 1.58 
FI 0.00 0.00 0.11 0.12 0.08 
(n=3842) 0 - 0.9 0 - 0.52 0.02 - 0.51 0.03 - 0.47 0.03 - 0.23 
IT 0.09 1.27 1.49 0.13 1.01 
(n=1311) 0.01 - 1.38 0.57 - 2.84 0.73 - 2.98 0 - 5.51 0.59 - 1.71 
LT 0.00 0.00 0.00 0.13 0.03 
(n=1267) 0 - 2.16 0 - 1.18 0 - 0.83 0.01 - 1.53 0 - 0.36 
NL 0.53 0.60 0.13 0.02 0.24 
(n=4822) 0.17 - 1.63 0.28 - 1.3 0.04 - 0.45 0 - 0.28 0.13 - 0.42 
NO 0.08 0.12 0.03 0.08 0.07 
(n=9236) 0.01 - 0.53 0.03 - 0.45 0 - 0.17 0.02 - 0.24 0.03 - 0.15 
PT 1.22 0.75 0.03 0.05 0.42 
(n=3965) 0.58 - 2.56 0.39 - 1.42 0 - 0.35 0 - 0.53 0.26 - 0.67 
 
Figure 4.3.9.2 shows that most drivers were younger than 35 years old, except for Italy, where the 
drugs-alcohol combination was relatively more prevalent among drivers over 35 years old. 
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Figure 4.3.9.2. Distribution of the prevalence alcohol-drugs combinations among the age groups; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various age 
groups 
Figure 4.3.9.3 presents the distribution of alcohol-drugs combinations among drivers by gender. In 
most countries the share of male drivers positive for alcohol-drugs combinations is much higher than 
the share of female drivers. However, in Italy the share is almost the same. 
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Figure 4.3.9.3. Alcohol-drugs combinations by gender 
Table 4.3.9.2 presents an overview of the prevalence of alcohol-drug combinations among male 
drivers distributed by age group. The highest prevalence was detected among young males aged 18-
24 in Spain (2.22%) and Portugal (2.05%). In Italy the prevalence was the highest among male drivers 
aged 25-34 (1.55%). In Hungary and Poland no male drivers were positive for alcohol-drugs 
combinations. 
 
Table 4.3.9.2. Prevalence of alcohol-drugs combinations among male drivers by age group; prevalence in 
percentages; 95% confidence intervals in italics 
Male 18-24 25-34 35-49 50+ All ages 
BE 1.33 0.37 0.13 0.59 0.44 
(n=1957) 0.41 - 4.22 0.08 - 1.69 0.02 - 0.75 0.23 - 1.52 0.23 - 0.85 
CZ 0.63 0.00 0.00 0.00 0.06 
(n=1589) 0.11 - 3.51 0 - 0.91 0 - 0.68 0 - 0.84 0.01 - 0.35 
DK 0.00 0.53 0.10 0.00 0.12 
(n=1975) 0 - 2.56 0.13 - 2.14 0.01 - 0.76 0 - 0.45 0.03 - 0.39 
ES 2.22 1.86 1.03 0.18 1.35 
(n=2520) 1.22 - 3.99 1.13 - 3.04 0.53 - 1.99 0.03 - 1.22 0.97 - 1.88 
FI 0.00 0.00 0.18 0.17 0.12 
(n=2511) 0 - 1.35 0 - 0.8 0.04 - 0.87 0.04 - 0.65 0.04 - 0.35 
IT 0.11 1.55 1.24 0.21 1.02 
(n=998) 0.01 - 1.72 0.69 - 3.48 0.5 - 3.01 0 - 8.47 0.56 - 1.86 
LT 0.00 0.00 0.00 0.14 0.03 
(n=1130) 0 - 2.38 0 - 1.4 0 - 0.9 0.01 - 1.62 0 - 0.4 
NL 0.67 0.81 0.20 0.03 0.32 
(n=3363) 0.2 - 2.2 0.37 - 1.77 0.06 - 0.67 0 - 0.39 0.18 - 0.58 
NO 0.11 0.18 0.04 0.06 0.08 
(n=6520) 0.02 - 0.77 0.05 - 0.64 0.01 - 0.25 0.01 - 0.26 0.03 - 0.18 
PT 2.05 1.28 0.04 0.03 0.64 
(n=2541) 0.97 - 4.28 0.68 - 2.42 0 - 0.54 0 - 0.61 0.39 - 1.03 
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Figure 4.3.9.4. shows that alcohol-drugs combinations are especially prevalent among drivers aged 
18-34 from Southern European countries. In Finland and Lithuania, most drivers positive for these 
combinations were 35 years and older. 
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Figure 4.3.9.4. Distribution of the prevalence alcohol-drugs combinations among the age groups for male 
drivers; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups 
Table 4.3.9.3 presents an overview of the prevalence of alcohol-drugs combinations among female 
drivers distributed by age. The highest prevalence by far was detected among female drivers in Italy 
aged 35-49 (2.12%). 
Table 4.3.9.3. Prevalence of alcohol-drugs combinations among female drivers by age group; prevalence 
in percentages; 95% confidence intervals in italics 
Female 18-24 25-34 35-49 50+ All ages 
BE 0.00 0.00 0.08 0.00 0.03 
(n=971) 0 - 3.37 0 - 1.52 0.01 - 1.19 0 - 1.55 0 - 0.45 
CZ 0.00 0.00 0.00 0.00 0.00 
(n=448) 0 - 4.32 0 - 2.73 0 - 2.31 0 - 5.68 0 - 0.85 
DK 0.00 0.00 0.19 0.00 0.07 
(n=1015) 0 - 4.97 0 - 2.15 0.03 - 1.28 0 - 1.05 0.01 - 0.51 
ES 0.28 0.31 0.37 0.00 0.28 
(n=605) 0.02 - 3.68 0.04 - 2.25 0.05 - 2.58 0 - 5.56 0.07 - 1.1 
FI 0.00 0.00 0.00 0.00 0.00 
(n=1283) 0 - 2.71 0 - 1.44 0 - 0.78 0 - 0.96 0 - 0.3 
IT 0.00 0.11 2.12 0.00 0.99 
(n=313) 0 - 5.82 0 - 4.56 0.72 - 6.05 0 - 13.07 0.34 - 2.82 
LT 0.00 0.00 0.00 0.00 0.00 
(n=121) 0 - 19 0 - 7.06 0 - 9.35 0 - 18.35 0 - 3.07 
NL 0.21 0.08 0.00 0.00 0.04 
(n=1454) 0.02 - 2.82 0 - 1.47 0 - 0.66 0 - 0.88 0 - 0.33 
NO 0.00 0.00 0.00 0.13 0.04 
(n=2709) 0 - 1.21 0 - 0.75 0 - 0.37 0.02 - 0.67 0.01 - 0.21 
PT 0.00 0.00 0.00 0.11 0.01 
(n=1342) 0 - 1.79 0 - 0.77 0 - 0.81 0.01 - 2.43 0 - 0.31 
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Figure 4.3.9.5 shows that the share of drugs-alcohol combinations is relatively large among female 
drivers of 35 years and older. 
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Figure 4.3.9.5. Distribution of the prevalence alcohol-drugs combinations among the age groups for 
female drivers; overall prevalences in percentages per country, the figure shows the relative 
contributions of the various age groups 
4.3.9.3 Use of alcohol-drugs combinations by time period 
Table 4.3.9.4 presents an overview of the prevalence of drugs-alcohol combinations by time period. 
The highest prevalence was detected during night time hours in Spain (4.11% in weekday nights and 
4.10% in weekend nights), and in night time hours in Italy (1.82% in weekday nights and 2.13% in 
weekend nights). 
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Table 4.3.9.4. Prevalence of alcohol-drugs combinations by time period; prevalence in percentages; 95% 
confidence intervals in italics 
Time 
period 
Weekdays  
04.00-21.59 
Weekday  nights 
22.00-03.59 
Weekend days 
04.00-21.59 
Weekend nights 
22.00-03.59 
All time 
periods 
BE 0.14 0.00 0.78 1.16 0.31 
(n=2949) 0.05 - 0.43 0 - 2.2 0.34 - 1.79 0.19 - 6.9 0.16 - 0.58 
CZ 0.07 0.00 0.00 0.00 0.05 
(n=2037) 0.01 - 0.42 0 - 8.62 0 - 0.59 0 - 15.86 0.01 - 0.28 
DK 0.06 0.49 0.10 0.82 0.10 
(n=3002) 0.01 - 0.3 0.04 - 5.96 0.01 - 0.69 0.1 - 6.32 0.03 - 0.3 
ES 0.66 4.11 1.37 4.10 1.14 
(n=3174) 0.39 - 1.1 1.8 - 9.12 0.76 - 2.44 1.95 - 8.42 0.83 - 1.58 
FI 0.12 0.00 0.00 0.00 0.08 
(n=3842) 0.04 - 0.35 0 - 2.94 0 - 0.36 0 - 4.76 0.03 - 0.23 
IT 1.03 1.82 0.77 2.13 1.01 
(n=1311) 0.56 - 1.91 0.21 - 14.34 0.23 - 2.5 0.23 - 16.82 0.59 - 1.71 
LT 0.00 0.00 0.15 0.00 0.03 
(n=1267) 0 - 0.4 0 - 11.28 0.01 - 1.7 0 - 13.37 0 - 0.36 
NL 0.19 0.74 0.24 0.95 0.24 
(n=4822) 0.09 - 0.4 0.14 - 3.89 0.07 - 0.76 0.19 - 4.52 0.13 - 0.42 
NO 0.06 0.13 0.04 0.20 0.07 
(n=9236) 0.02 - 0.17 0.02 - 0.94 0.01 - 0.25 0.03 - 1.19 0.03 - 0.15 
PT 0.45 0.51 0.31 0.50 0.42 
(n=3965) 0.26 - 0.76 0.04 - 5.9 0.1 - 0.94 0.04 - 5.8 0.26 - 0.67 
 
Figure 4.3.9.6 shows that the combined use of alcohol and drugs was mainly detected during night 
time hours. However, in Finland, Czech Republic and Belgium relatively large shares were found 
during daytime hours as well. 
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Figure 4.3.9.6. Distribution of the prevalence alcohol-drugs combinations among the time periods; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various time 
periods 
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4.3.10 Drug-drug combinations 
In the previous sections we have provided an overview of the results for drug use separately. In this 
section we will present the results of the multiple drug use. The effect of drug-drug combinations 
differs per the substances included and can cause larger impairing effects than one of the substances 
alone (Kelly et al., 2004; Scheers et al., 2006; Steyvers and Brookhuis, 1996). 
The 95% confidence intervals can vary between countries and within countries for the different 
disaggregations. Therefore, differences between the participating countries should be interpreted with 
care, especially the differences for disaggregations by gender, age and time period. 
 
4.3.10.1 General results 
The group drug-drug combinations consist of the combination of two or more other psychoactive 
substances other than alcohol from at least two different groups of drugs, excluding THC-COOH which 
is regarded as negative. The cut-off levels for the psychoactive substances are presented in table 2.2. 
Figure 4.3.10.1 presents the prevalence of multiple drug use for the 13 countries. The prevalence was 
the highest in Italy and Spain, which were the only two countries with a prevalence that was higher 
than the European mean of 0.39%. Most commonly used drugs in drug-drug combinations are THC, 
cocaine, and benzodiazepines.  
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Figure 4.3.10.1. Prevalence of drug-drug combinations by country; prevalence in percentages 
 
Table 4.3.10.1 and figure 4.3.10.2 give an overview of single drug use by drivers in comparison to 
multi-drug use. The share of multi-drug use is on average around 10% of all drug use. Italy has the 
highest share of multi-drug use: in 22% of the drivers that solely used drugs (and not alcohol and 
drugs) 2 or more drugs were detected.  
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Table 4.3.10.1. Prevalence of single drug use and drug-drug combinations; prevalence in percentages 
 BE CZ DK ES FI HU IT LT NL NO PL PT SE 
Drugs alone 3.62 1.65 1.80 9.23 1.83 1.91 4.19 1.63 2.77 2.27 0.88 4.41 1.23 
Drugs in combi 0.30 0.11 0.06 0.57 0.29 0.27 1.22 - 0.35 0.28 0.02 0.23 0.12 
Total  3.92 1.76 1.86 9.80 2.12 2.18 5.41 1.63 3.12 2.55 0.90 4.64 1.35 
Share 8% 6% 3% 6% 14% 12% 22% - 11% 11% 2% 5% 9% 
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Figure 4.3.10.2. Prevalence of single drug use and drug-drug combinations; prevalence in percentages 
 
4.3.10.2 Use of drug-drug combinations by gender and age 
Table 4.3.10.2 presents an overview of the prevalence of drug-drug combinations by age. The highest 
prevalence was detected among drivers in Italy aged 18-49 (between 1.21 and 1.34% for the three 
age groups), and in the Netherlands by drivers aged 25-34 (0.96%). 
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Table 4.3.10.2. Prevalence of drug-drug combinations by age group; prevalence in percentages; 95% 
confidence intervals in italics 
Total 18-24 25-34 35-49 50+ All ages 
BE 0.85 0.43 0.00 0.42 0.30 
(n=2949) 0.27 - 2.7 0.14 - 1.33 0 - 0.35 0.16 - 1.1 0.16 - 0.58 
CZ 0.05 0.38 0.00 0.00 0.11 
(n=2037) 0 - 1.66 0.11 - 1.34 0 - 0.53 0 - 0.74 0.03 - 0.38 
DK 0.62 0.00 0.05 0.00 0.06 
(n=3002) 0.14 - 2.8 0 - 0.78 0 - 0.44 0 - 0.32 0.02 - 0.24 
ES 0.54 0.62 0.80 0.04 0.57 
(n=3174) 0.19 - 1.54 0.29 - 1.31 0.41 - 1.57 0 - 0.85 0.36 - 0.89 
FI 0.00 0.28 0.29 0.38 0.29 
(n=3842) 0 - 0.9 0.08 - 1 0.11 - 0.8 0.17 - 0.84 0.16 - 0.52 
HU 0.00 0.54 0.26 0.00 0.27 
(n=2741) 0 - 1.49 0.23 - 1.28 0.08 - 0.84 0 - 0.59 0.13 - 0.54 
IT 1.21 1.34 1.28 0.00 1.22 
(n=1311) 0.46 - 3.15 0.61 - 2.93 0.6 - 2.71 0 - 5.26 0.75 - 1.97 
NL 0.42 0.96 0.16 0.15 0.35 
(n=4822) 0.12 - 1.47 0.52 - 1.77 0.05 - 0.49 0.04 - 0.49 0.22 - 0.56 
NO 0.33 0.44 0.25 0.23 0.28 
(n=9236) 0.12 - 0.93 0.22 - 0.89 0.13 - 0.49 0.11 - 0.46 0.19 - 0.42 
PL 0.12 0.01 0.00 0.00 0.02 
(n=4008) 0.02 - 0.86 0 - 0.3 0 - 0.31 0 - 0.45 0 - 0.14 
PT 0.64 0.06 0.31 0.01 0.23 
(n=3965) 0.23 - 1.76 0.01 - 0.43 0.12 - 0.79 0 - 0.45 0.12 - 0.44 
SE 0.00 0.25 0.03 0.17 0.12 
(n=6198) 0 - 0.78 0.08 - 0.84 0 - 0.25 0.07 - 0.4 0.06 - 0.25 
 
Figure 4.3.10.3 shows that multi-drug combinations are used mostly by drivers younger than 50 years. 
The distribution over the four age groups varies largely between the different countries. 
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Figure 4.3.10.3. Distribution of the prevalence drug-drug combinations among the age groups; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various age 
groups 
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Figure 4.3.10.4 shows that in general multi-drug use is more common among male than among female 
drivers. However, in Czech Republic, Sweden and especially in Hungary, the share of female users is 
larger. 
 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
BE CZ DK ES FI HU IT LT NL NO PL PT SE
male drivers
female drivers
 
Figure 4.3.10.4. Prevalence of drug-drug combinations by gender; prevalence in percentages 
 
Table 4.3.10.3 provides an overview of the prevalence of drug-drug combinations among male drivers 
distributed by age. The highest prevalence was detected among male drivers in Italy aged 18-24 
(1.51%) and 25-34 (1.66%), in Belgium aged 18-24 years (1.36%), and among drivers in the 
Netherlands aged 25-34 (1.30%). 
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Table 4.3.10.3. Prevalence of drug-drug combinations among male drivers by age group; prevalence in 
percentages; 95% confidence intervals in italics 
Male 18-24 25-34 35-49 50+ All ages 
BE 1.36 0.72 0.00 0.51 0.43 
(n=1957) 0.42 - 4.27 0.23 - 2.23 0 - 0.52 0.18 - 1.4 0.22 - 0.83 
CZ 0.08 0.27 0.00 0.00 0.08 
(n=1589) 0 - 2.55 0.05 - 1.39 0 - 0.68 0 - 0.84 0.02 - 0.38 
DK 0.94 0.00 0.07 0.00 0.09 
(n=1975) 0.21 - 4.19 0 - 1.22 0.01 - 0.71 0 - 0.45 0.02 - 0.36 
ES 0.37 0.79 1.00 0.04 0.65 
(n=2520) 0.09 - 1.46 0.37 - 1.67 0.51 - 1.94 0 - 0.98 0.4 - 1.04 
FI 0.00 0.44 0.30 0.44 0.35 
(n=2511) 0 - 1.35 0.12 - 1.55 0.08 - 1.05 0.18 - 1.04 0.18 - 0.66 
HU 0.00 0.08 0.00 0.00 0.02 
(n=2062) 0 - 2.09 0.01 - 0.73 0 - 0.55 0 - 0.72 0 - 0.23 
IT 1.51 1.66 0.95 0.00 1.30 
(n=998) 0.58 - 3.91 0.75 - 3.63 0.34 - 2.6 0 - 8.08 0.76 - 2.21 
NL 0.61 1.30 0.24 0.20 0.50 
(n=3363) 0.17 - 2.11 0.7 - 2.42 0.08 - 0.74 0.06 - 0.68 0.31 - 0.8 
NO 0.49 0.49 0.33 0.18 0.32 
(n=6520) 0.17 - 1.36 0.22 - 1.1 0.16 - 0.67 0.08 - 0.44 0.21 - 0.49 
PL 0.15 0.01 0.00 0.00 0.03 
(n=3331) 0.02 - 1.05 0 - 0.37 0 - 0.39 0 - 0.5 0 - 0.16 
PT 1.08 0.11 0.49 0.01 0.32 
(n=2541) 0.39 - 2.94 0.02 - 0.74 0.19 - 1.25 0 - 0.56 0.16 - 0.62 
SE 0.00 0.00 0.04 0.20 0.11 
(n=4352) 0 - 1.12 0 - 0.61 0 - 0.38 0.08 - 0.49 0.04 - 0.26 
 
Figure 4.3.10.5 shows that drug-drug combinations are used mostly by male drivers younger than 50 
years, except for Sweden. The distribution over the three lower age groups varies largely between the 
different countries. 
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Figure 4.3.10.5. Distribution of the prevalence drug-drug combinations among the age groups for male 
drivers; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups 
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Table 4.3.10.4 presents an overview of the prevalence of drug-drug combinations among female 
drivers distributed by age. The highest prevalence was detected among female drivers in Italy aged 
35-49 (2.12%), and in Hungary among female drivers aged 25-34 (1.79%). 
 
Table 4.3.10.4. Prevalence of drug-drug combinations among female drivers by age group; prevalence in 
percentages; 95% confidence intervals in italics 
Female 18-24 25-34 35-49 50+ All ages 
BE 0.00 0.00 0.00 0.19 0.05 
(n=971) 0 - 3.37 0 - 1.52 0 - 1.04 0.02 - 1.9 0 - 0.48 
CZ 0.00 0.72 0.00 0.00 0.22 
(n=448) 0 - 4.32 0.13 - 4.01 0 - 2.31 0 - 5.68 0.04 - 1.25 
DK 0.00 0.00 0.00 0.00 0.00 
(n=1015) 0 - 4.97 0 - 2.15 0 - 0.94 0 - 1.05 0 - 0.38 
ES 1.24 0.00 0.00 0.00 0.23 
(n=605) 0.28 - 5.27 0 - 1.68 0 - 1.91 0 - 5.56 0.05 - 1.03 
FI 0.00 0.00 0.29 0.23 0.18 
(n=1283) 0 - 2.71 0 - 1.44 0.07 - 1.29 0.04 - 1.38 0.05 - 0.61 
HU 0.00 1.79 1.01 0.00 1.00 
(n=679) 0 - 4.9 0.73 - 4.37 0.31 - 3.24 0 - 3.08 0.48 - 2.07 
IT 0.00 0.00 2.12 0.00 0.95 
(n=313) 0 - 5.82 0 - 4.35 0.72 - 6.05 0 - 13.07 0.32 - 2.77 
NL 0.00 0.07 0.00 0.00 0.01 
(n=1454) 0 - 2.42 0 - 1.46 0 - 0.66 0 - 0.88 0 - 0.29 
NO 0.00 0.31 0.07 0.36 0.20 
(n=2709) 0 - 1.21 0.08 - 1.29 0.01 - 0.5 0.13 - 1.04 0.09 - 0.45 
PL 0.00 0.00 0.00 0.00 0.00 
(n=672) 0 - 3.51 0 - 1.51 0 - 1.57 0 - 4.88 0 - 0.57 
PT 0.00 0.00 0.00 0.00 0.08 
(n=1342) 0 - 1.79 0 - 0.77 0 - 0.81 0 - 2.21 0.01 - 0.42 
SE 0.00 0.78 0.00 0.07 0.16 
(n=1835) 0 - 2.57 0.24 - 2.55 0 - 0.56 0.01 - 0.68 0.05 - 0.47 
 
Figure 4.3.10.6 shows that Spain was the only country in which drug-drug combinations were detected 
among young women aged 18-24.  
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Figure 4.3.10.6. Distribution of the prevalence drug-drug combinations among the age groups for female 
drivers; overall prevalences in percentages per country, the figure shows the relative contributions of the 
various age groups 
 
4.3.10.3 Use of drug-drug combinations by time period 
Table 4.3.10.5 presents an overview of the prevalence of drug-drug combinations by time period. The 
highest prevalence was detected in weekend nights in the Czech Republic (1.85%), in Spain during 
weekday nights (1.64%), and in Italy at weekdays during daytime hours (1.44%). 
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Table 4.3.10.5. Prevalence of drug-drug combinations by time period; prevalence in percentages; 95% 
confidence intervals in italics 
Time 
period 
Weekdays  
04.00-21.59 
Weekday  nights 
22.00-03.59 
Weekend days 
04.00-21.59 
Weekend nights 
22.00-03.59 
All time 
periods 
BE 0.31 0.00 0.37 0.39 0.30 
(n=2949) 0.14 - 0.66 0 - 2.2 0.11 - 1.19 0.03 - 5.59 0.16 - 0.58 
CZ 0.14 0.00 0.00 1.85 0.11 
(n=2037) 0.04 - 0.53 0 - 8.62 0 - 0.59 0.15 - 18.82 0.03 - 0.38 
DK 0.00 0.00 0.25 0.00 0.06 
(n=3002) 0 - 0.18 0 - 5.06 0.07 - 0.93 0 - 4.87 0.02 - 0.24 
ES 0.38 1.64 0.84 0.70 0.57 
(n=3174) 0.2 - 0.75 0.46 - 5.67 0.4 - 1.76 0.13 - 3.6 0.36 - 0.89 
FI 0.20 0.00 0.52 0.68 0.29 
(n=3842) 0.09 - 0.46 0 - 2.94 0.23 - 1.17 0.07 - 5.97 0.16 - 0.52 
HU 0.37 0.00 0.00 0.00 0.27 
(n=2741) 0.18 - 0.75 0 - 5.75 0 - 0.59 0 - 6.88 0.13 - 0.54 
IT 1.44 0.91 0.62 0.58 1.22 
(n=1311) 0.85 - 2.42 0.06 - 12.87 0.17 - 2.28 0.02 - 14.36 0.75 - 1.97 
NL 0.32 0.15 0.33 1.42 0.35 
(n=4822) 0.18 - 0.58 0.01 - 2.87 0.12 - 0.9 0.37 - 5.26 0.22 - 0.56 
NO 0.23 0.80 0.33 0.20 0.28 
(n=9236) 0.13 - 0.38 0.33 - 1.96 0.16 - 0.67 0.03 - 1.19 0.19 - 0.42 
PL 0.00 0.14 0.08 0.00 0.02 
(n=4008) 0 - 0.13 0 - 4.27 0.01 - 0.54 0 - 4.81 0 - 0.14 
PT 0.23 0.53 0.19 0.43 0.23 
(n=3965) 0.11 - 0.49 0.05 - 5.95 0.05 - 0.74 0.03 - 5.67 0.12 - 0.44 
SE 0.10 0.00 0.22 0.00 0.12 
(n=6198) 0.04 - 0.24 0 - 3.01 0.08 - 0.61 0 - 3.01 0.06 - 0.25 
 
Figure 4.3.10.7 shows that the distribution of drug-drug combinations by time period varies 
considerable between the different countries.  
In Southern European countries and in Norway drug-drug combinations were relatively often detected 
during night time hours at weekdays. During daytime hours at weekdays the largest shares were found 
in Italy and Hungary.  
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Figure 4.3.10.7. Distribution of the prevalence drug-drug combinations among the time periods; overall 
prevalences in percentages per country, the figure shows the relative contributions of the various time 
periods 
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5. Influencing factors: The effects of time, age, gender 
and country on prevalence 
 
The aim of this chapter is to reveal the underlying factors that are of influence on the prevalence of the 
various substances in the driving population.  In this chapter, we assess which factors influence the 
occurrence of positive cases for alcohol, cocaine, THC  benzodiazepines, medicinal opioids, alcohol-
drug in combination and multiple drugs across all collected data (i.e. across countries), in order to 
reveal general prevalence patterns across countries.  For example: Is use of alcohol or 
benzodiazepines higher in certain time periods, or not? And what is the influence of age or gender on 
the prevalence?   
 
These questions were investigated by applying the logistic regression method. Logistic regression is a 
method that reveals (significant) relations between given explanatory variables (quantitative or 
qualitative) such as time period, age, gender and a binary response variable; in this case: positive or 
negative cases. Cf. annex 5 for further details on the modelling procedure.  
 
Logistic regression models were constructed to describe differences in independent variables 
explaining prevalence. The models were to include all countries where samples had been taken so 
that prevalence patterns across countries could be revealed. Prevalence of the various substance 
groups was related to time, age, driver gender, country and interactions of these variables. 
 
Time was divided into the eight time periods that were selected in the road side surveys, as indicated 
in table 5.1, see also section 3.1. 
 
Table 5.1. DRUID time periods 
Weekdays Weekend 
1 Monday – Friday        04:00 - 09:59 5 Saturday and Sunday        04:00 - 09:59 
2 Monday – Friday        10:00 - 15:59 6 Saturday and Sunday        10:00 - 15:59 
3 Monday –Thursday    16:00 - 21:59 7 Friday – Sunday                 16:00 - 21:59 
4 Monday – Thursday   22:00 - 00:00 Tuesday - Friday        00:00 - 03:59 8 
Friday – Sunday                 22:00 - 00:00 
Saturday – Monday            00:00 - 03:59 
 
 
Age of the driver was a semi quantitative variable divided into the four groups that were decided upon 
for the prevalence calculations based on the road side surveys, as indicated in table 5.2: 
 
Table 5.2. DRUID age groups 
                         Age group 
1 18-24 years 
2 25-34 years 
3 35-49 years 
4 50+ years 
 
 
Driver gender and country were qualitative variables.   
 
Models were constructed for all substance groups except amphetamine, THCCOOH, illicit opiates and 
z-drugs because of too few positive observations in these groups. Furthermore, it was not possible to 
include all countries in all the models because of missing data in one or more cells or lack of positive 
observations. 
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5.1 Factors influencing the prevalence of alcohol at and above 0.1 
g/L 
 
To determine which factors influenced the prevalence of alcohol in the driving population across 
Europe a logistic regression model was constructed.  
 
Two different models were constructed for alcohol. In the first one a sample was considered positive if 
the alcohol level was above or equal to 0.1 g/L which is the analytical cut off value.  
 
Sweden was not included in the model since the information of alcohol level for the test persons was 
not available. Hungary had only four positive samples and Lithuania had too many time periods 
without samples, which is why these countries could not be included in the model either. 
 
The total number of observations is 37,991 with 1,168 positive. The logistic regression was performed 
on the remaining countries and it was found that the following interactions: age group × gender and 
gender × country were not significant and therefore removed from the model. Hence the final model 
included the significant independent variables and interactions as shown in table 5.1. 
 
The model included the data of the following countries: Belgium, Czech Republic, Denmark, Spain, 
Finland, Italy, Norway, the Netherlands, Poland and Portugal. 
 
In table 5.1.1 the independent variables are shown in the left column. The coefficient estimates in the 
next column relate to the various levels of the independent variable in question; a minus sign means 
that prevalence is lower at that level than at the reference level (which always is set to zero), a positive 
sign means the opposite. The P-value in the right column shows the significance of the effect in 
explaining a part of the variation in the prevalence when adjusting for the other effects in the model.  
 
Table 5.1.1  Logistic regression model for the prevalence of alcohol at and above 0.1 g/L. The left column 
shows the effects that have been included in the model, coefficient estimates scale the different levels of 
the effects and P indicates the significance level of the effect when correcting for all other effects in the 
model. 
Effect Coefficient estimates DF Wald Chi-square P 
Time 
period 
1: -0.3393 
2: -1.0737 
3: -1.0275 
4: -0.6267 
5: -0.9295 
6: -1.4286 
7: -0.7387 
8: Reference 
 
7 80.85 <0.0001 
Age 
group 
18-24:  0.1901 
25-34:  0.2983 
35-49:  0.4277 
50+:  reference 
 
3 1.03 0.7935 
Gender Men:  0.1641 
Women: reference 
 
1 50.45 <0.0001 
Country BE:  1.1172 
CZ: -0.8082 
DK: -1.0765 
ES:  0.9969 
FI: -1.3092 
IT: -0.5617 
NO: -2.1848 
NL: -0.0378 
PL: -3.3302 
PT: reference 
 
9 230.52 <0.0001 
Time 
period × 
Age 
group 
 18-24 25-34 35-49 50+ 
1:  1.1604   0.5639 -0.3349 reference 
2: -1.2355 -1.8799 -0.7977 reference 
3: -1.0751  -0.9324 -0.4580 reference 
4: -0.3302 -0.0995 -0.3026 reference 
5:  2.2138  1.5244  0.6572 reference 
6: -0.1082 -0.1934 -0.2281 reference 
21 112.17 <0.0001 
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Effect Coefficient estimates DF Wald Chi-square P 
7: -1.8487 -1.1306 -0.8311 reference 
8: reference reference reference reference 
 
Time 
period × 
Gender 
 Men women 
1:  0.3065 reference 
2:  0.6901 reference 
3:  1.1242 reference 
4: -0.2085 reference 
5:  0.0404 reference 
6:  1.0189 reference 
7:  0.8940 reference 
8: reference reference 
 
7 33.61 <0.0001 
Time 
period × 
Country 
 BE CZ DK ES FI 
1: -2.2166 -0.9969 -1.0936 -1.1201 -1.1407 
2: -0.5582 -0.7045  0.6084 -1.6069 -0.3735 
3: -0.6806 -1.3356  1.1854 -1.3901 -1.0940 
4:  1.2534 -0.0808  0.9397  0.5776  0.3189 
5: -1.0686 -1.3765 -0.2445 -0.6857 -0.4258 
6: -0.1423 -0.5101  1.0080 -0.4472 -0.4111 
7:  0.1153 -0.0980  1.0818 -0.1693 -0.1014 
8: reference reference reference reference reference 
 
 IT NO NL PL PT 
1: -1.4639 -0.2136 -1.5199  1.2065 reference 
2:  1.6529 -0.3235 -1.0322  0.6422 reference 
3:  1.2130 -0.7232 -0.7509  0.4866 reference 
4:  1.1853 -11.9950  1.2863  1.6939 reference 
5: -0.7517 -0.5563 -0.6198 -0.5385 reference 
6:  0.5441  0.6563 -2.7471  1.7218 reference 
7:  1.5298 -12.2713  0.3042  1.4187 reference 
8: reference reference reference reference reference 
 
63 185.96  <0.0001 
Age 
group × 
Country 
 BE CZ DK ES FI 
18-24: -0.3782 -0.3529 -0.0685 -1.2114 -0.2698 
25-34: -0.2935 -0.8755 -0.4805 -0.5182  0.1209 
35-49: -0.4485  0.2021 -0.1828 -0.4804 -0.5778 
50+: reference reference reference reference reference 
 
 IT NO NL PL PT 
18-24:  1.0420  0.1208 -0.8545 0.9478 reference 
25-34:  0.8428 -0.5197 -0.2178 0.9760 reference 
35-49: -0.0346 -0.4692 -0.0145 1.1441 reference 
50+: reference reference reference reference reference 
 
27 55.74 0.0009 
 
 
 
 
 
 
 
 
 
 
 
As table 5.1.1 shows, several factors had a significant influence on the prevalence of alcohol across 
countries.  
 
Alcohol prevalence was significantly different in different time periods. As expected, the highest 
prevalence was on weekend nights (time period 8, i.e. Friday to Sunday 22:00-03:59), the lowest was 
on weekend days (time period 6, i.e. Saturday and Sunday 10:00-15:59).  
 
As expected, prevalence was significantly higher for male drivers than for female drivers.  
 
Prevalence differed significantly among countries with Belgium and Spain having the highest 
prevalence and Norway and Poland the lowest (besides Hungary where prevalence was too low to be 
modeled, and Sweden where information on alcohol prevalence was not available).  
Even when corrected for time period and age group there was a significant interaction between these 
two variables.  
 
The main effect age group is insignificant but it is a part of the interaction time period × age group and 
is therefore included in the final model.  
 
Not surprisingly, prevalence was highest among 18-24 year old drivers on weekend mornings, (time 
period 5, i.e. Saturday and Sunday 04:00-09:59). The lowest alcohol prevalence was found among 25-
34 year old drivers on weekdays (time period 2, i.e. Monday to Friday 10:00-15:59). There was a 
significant interaction between time period and gender, also when correcting for the two variables 
separately. The lowest alcohol prevalence was found among female drivers in time period 4, i.e. 
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weekday nights (22:00-03:59). Surprisingly, the highest prevalence was also found among female 
drivers, at weekdays 16:00-21:59.  
 
When correcting for the differences in alcohol prevalence in time periods and countries, there was a 
significant effect of the interaction term between the two. Amazingly low was alcohol prevalence in 
Norway in time period 7, i.e. Friday, Saturday and Sunday 16:00-21:59. The highest prevalence was 
found in Poland in time period 6, i.e. Saturday and Sunday 10:00-15:59. The interaction term between 
age group and country was significant even when correcting for the two single variables.  Young 
drivers in Spain (18-24 years of age) had the lowest alcohol prevalence, whereas mature drivers (aged 
35-49) in Poland had the highest. 
 
5.2 Model for the prevalence of alcohol at and above 0.5 g/L 
 
In order to clarify if other factors determine prevalence of higher alcohol concentrations than 
prevalence of higher and lower alcohol concentrations together, prevalence of higher concentrations 
of alcohol was tested.  
 
In the second model for alcohol prevalence, the cut-off for alcohol concentration was set to 0.5 g/L, 
which is the legal limit in most countries. Due to a low number of positive samples, time periods 1, 2 
and 3 were merged, 4 remained, 5, 6 and 7 were merged and 8 remained. This way, time periods 
were: 1, 2 and 3:  weekday, daytime; 4: weekday, nighttime; 5, 6 and 7: weekend, daytime; 8: 
weekend, nighttime, forming the variable time period new. 
 
A model was constructed including Belgium, Denmark, Spain, Italy, Lithuania, the Netherlands and 
Portugal. Sweden and Hungary could not be included in the model for the same reasons as described 
under the model for alcohol concentrations at and above 0.1 g/L. Furthermore, the positive samples 
for Czech Republic and Poland were very unequally distributed by age and gender whereas Finland 
and Norway had too few positive samples.  
 
It was found that the interactions gender × country, age group × gender and age group × time period 
new were insignificant. Consequently, these interactions were removed from the model. By making the 
assumption that these interactions were not significant for Czech Republic and Poland either, it was 
possible to include them in the model.  
 
The logistic regression procedure was run and here it was found that – unlike the model for the 
prevalence of alcohol at and above 0.1 g/L – the interaction age group × country and the main effect 
age group were insignificant. The total number of observations was 26,421 with 449 positive. Hence 
the final model included the significant independent variables and interactions as shown in table 5.2.1. 
 
The model included the following countries: Belgium, Czech Republic, Denmark, Spain, Italy, 
Lithuania, the Netherlands, Poland and Portugal. 
 
Table 5.2.1  Logistic regression model for the prevalence of alcohol at and above 0.5 g/L. The left column 
shows the effects that have been included in the model, coefficient estimates scale the different levels of 
the effects and P indicates the significance level of the effect when correcting for all other effects in the 
model. 
Effect Coefficient estimates DF Wald Chi-square P 
Time 
period 
new 
1-3: -0.5203 
4: -1.0101 
5-7: -0.8354 
8: reference 
 
3 3.14 0.3712 
Gender Men:  0.3683 
Women: reference 
 
1 14.61 0.0001 
Country BE:    1.6858 
CZ:   -0.3541 
DK:   -1.4221 
ES:    0.9157 
IT:    1.5150 
LT: -10.6601 
NL:   -0.3023 
8 210.63 <0.0001 
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PL:   -1.6595 
PT: reference 
 
 
Time 
period 
new 
×Country 
 BE CZ DK ES IT 
1-3: -1.7902 -0.8015 0.00094 -1.0952 -0.2110 
4:   1.0906   1.4742 2.2730   0.9388  1.5839 
5-7: -0.7376 -0.2911 1.6599 -0.3790  0.2029 
8: reference reference reference reference reference 
 
 LT NL PL PT 
1-3: 11.5426 -0.7965 -0.0405 reference 
4:   0.4818   2.1274  2.0189 reference 
5-7: 10.9727 -0.0634  0.8580 reference 
8: reference reference reference reference 
 
3 
 
 
 
 
12.70 0.0053 
Time 
period 
new × 
Gender 
 men women 
1-3:   0.4839 reference 
4: -0.5863 reference 
5-7:   0.6659 reference 
8: reference reference 
 
24 54.34 0.0004 
 
A priori one would expect the same maxima/minima prevalence groups as the previous analysis for 
alcohol prevalence equal to and above 0.1 g/L. However, the present model reveals exclusively that 
higher alcohol concentrations (equal to and above 0.5 g/l) are not necessarily prevalent in the same 
groups as the lower and higher concentrations together (concentrations equal to and above 0.1 g/L).  
 
Like for the alcohol concentrations equal to and above 0.1 g/L, the higher concentrations are 
significantly more prevalent in male than in female drivers. There were significant differences in 
prevalence of alcohol concentrations at and above 0.5 g/L among countries; Belgium having the 
highest prevalence (as for concentrations equal to and above 0.1 g/L) and Lithuania having the lowest 
prevalence.  
 
When corrected for the variations in time period and country, the interaction term of these two 
variables was significant. The highest prevalence was found in Lithuania and the lowest in Belgium. 
Both were found in time period 1-3; i.e. weekdays 04:00-21:59. 
 
The interaction term between time period and gender was significant even when correcting for the two 
variables separately. Contrary to the model that also included lower alcohol concentrations, both the 
highest and the lowest prevalence of alcohol concentrations equal to and above 0.5 g/l were for male 
drivers; the former being in time period 5-7 (weekend days 04:00-21:59) and the latter in time period 4 
(weekday nights, i.e. Monday through Friday 22:00-03:59). 
 
The clearest difference between prevalence of all concentrations of alcohol and the high 
concentrations of alcohol is that the difference in prevalence between the genders is larger in the latter 
case. Thus, prevalence of alcohol is in any case higher in male than in female drivers, but for high 
concentrations of alcohol, the difference in prevalence is larger than for all concentrations put 
together. 
 
Surprisingly, there was no difference in prevalence of high concentrations of alcohol over the various 
time periods. This is in contrast to prevalence of all concentrations of alcohol that showed a clear 
pattern being most prevalent on weekend nights and least prevalent on weekend days.  
 
5.3 Factors influencing the prevalence of cocaine  
 
To determine which factors influenced the prevalence of cocaine a logistic regression model was 
constructed.  
  
Because of very few positive samples for female drivers, this model was constructed for male drivers 
only. Time periods 1, 2 and 3 were merged to one, 4 remained, 5, 6 and 7 were merged and 8 
remained, forming the variable time period new. 
 
A model was built including the data of Spain, Italy and the Netherlands that were the only countries 
with a sufficient number of positive samples for male drivers to run the complete model. It was 
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assumed that time period new x age group was insignificant. The logistic regression procedure was 
run and it was found that the interaction terms time period new x country and age group x country was 
insignificant. Furthermore, the main effect time period new was found insignificant.  
 
Here it was also necessary to exclude the six interactions from the model and only make a model were 
the four main effects are included. From the logistic procedure it was found that the main effects time 
period and gender was not significant and therefore removed. By assuming that the above conclusion 
is true for the excluded countries as well, it was possible to include four more countries to the final 
model (Belgium, Norway, Hungary, and Portugal). The remaining six countries (Czech Republic, 
Denmark, Finland, Lithuania, Poland and Sweden) could not be included in the final model because 
there were no positive samples for male drivers. The final model included the significant independent 
variables as shown in table 5.3.1. 
 
Table 5.3.1  Logistic regression model for the prevalence of cocaine. The left column shows the effects 
that have been included in the model, coefficient estimates scale the different levels of the effects and P 
indicates the significance level of the effect when correcting for all other effects in the model. 
Effect Coefficient estimates DF Wald Chi-square P 
Age group 18-24:  1.3887 
25-34:  1.8967 
35-49:  1.6046 
50+:  reference 
 
3 14.14 0.0027 
Country BE: 1.3484 
ES: 3.2402 
HU: 0.2625 
IT: 2.6456 
NO: 0.2049 
NL: 2.0020 
PT: reference 
 
6 84.52 <0.0001 
 
 
The total number of observations was 20,111 with 94 positive. Countries included in the model for 
cocaine: Belgium, Spain, Hungary, Italy, Norway, the Netherlands and Portugal. 
 
The general prevalence of cocaine for male drivers was very low. It varied significantly with age and 
among countries, being most prevalent among male drivers aged 25-34 years and in Spain and Italy. 
The lowest prevalence was found in the 50+ age group and in Portugal, Norway and Hungary. 
 
5.4 Factors influencing the prevalence of THC 
 
To determine which factors influenced the prevalence of THC a logistic regression model was 
constructed. A model was constructed including the data of four countries: Spain, Norway, the 
Netherlands and Portugal that were the only countries with a sufficient number of positive samples to 
run the complete model. The logistic regression procedure was run and it was found that no 
interactions were significant (age group × gender, time period × age group, time period × gender, time 
period × country, gender × country and age group × country). Consequently, they were excluded.  
 
By assuming that the above conclusion is true for the excluded countries as well, it was possible to 
include eight of the excluded countries to the final model. However, as there were no positive samples 
in Lithuania, this country could not be included in the final model. 
 
The total number of observations is 46,937 with 485 samples positive for THC.  The final model 
included the significant independent variables as shown in table 5.4.1. 
 
The following twelve countries were included in the THC model: Belgium, Denmark, Czech Republic, 
Finland, Hungary, Italy, Sweden, the Netherlands, Norway, Poland, Portugal and Spain.  
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Table 5.4.1  Logistic regression model for the prevalence of THC. The left column shows the effects that 
have been included in the model, coefficient estimates scale the different levels of the effects and P 
indicates the significance level of the effect when correcting for all other effects in the model. 
Effect Coefficient estimates DF Wald Chi-square P 
Time period 1: -0.1370 
2: -0.4363 
3: -0.1142 
4:  0.0566 
5: -0.0227 
6: -0.5716 
7:  0.1481 
8: reference 
 
7 17.36 0.0152 
Age group 18-24:  3.0586 
25-34:  2.5873 
35-49:  1.5984 
50+:  reference 
 
3 197.14 <0.0001 
Gender Men:  1.5984 
Women: reference 
 
1 79.03 <0.0001 
Country BE:  1.8900 
CZ:  1.7897 
DK:  1.2486 
ES:   3.8041 
FI: -0.2938 
HU:   0.4969 
IT:   1.8794 
NO:   1.9204 
NL:  3.2061 
PL:  1.8885 
PT:  2.7146 
S: reference 
 
9 335.12 <0.0001 
 
THC seems to be a weekend drug mainly used by young male drivers. There is a significant difference 
in its prevalence in different time periods; in period 7 (Saturday and Sunday 16:00-21:59) it was most 
prevalent and in period 6 (Saturday and Sunday 10:00-15:59) it was least prevalent.  
 
THC was most prevalent in 18-24 year olds, significantly more prevalent than in the 50+ group where 
it was least prevalent. THC was significantly more prevalent in male than in female drivers.  
 
The prevalence of THC was significantly different among countries with a tentative north-south 
gradient; it was most prevalent in Spain, Portugal and the Netherlands and least prevalent in Sweden, 
Denmark and Hungary. 
 
5.5 Factors influencing the prevalence of benzodiazepines 
 
Due the low number of positive observations in the age group 18-24, age group 18-24 and age group 
25-34 were merged, 35-49 remained and 50+ remained, thus forming the new variable age group 
new.  
 
The following six countries were included in the model: Belgium, Spain, Hungary, Finland, Norway and 
Portugal. For the remaining seven countries, the positive samples were very unequally distributed by 
time period, age and gender to be included in the complete model.  
 
With logistic regression it was found that the following interactions were not significant: time period × 
age group new, time period × country and age group new × country. It was now possible to add the 
original age groups. The logistic regression procedure was run again and it was found that the 
interaction terms age group × gender and time period × gender were not significant. 
 
By assuming that the above conclusions are true for the excluded countries as well, it was possible to 
include the following four countries: Denmark, the Netherlands, Sweden and Czech Republic. But 
Italy, Lithuania and Poland had still too few positive samples to be included in the final model. Hence 
the final model included the significant independent variables and interaction, as shown in table 5.5.1. 
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The total number of observations is 41,715 with 383 positive. This model included the following ten 
countries: Belgium, Czech Republic, Denmark, Finland, Hungary, the Netherlands, Norway, Portugal, 
Spain and Sweden. 
 
Table 5.5.1  Logistic regression model for the prevalence of benzodiazepines. The left column shows the 
effects that have been included in the model, coefficient estimates scale the different levels of the effects 
and P indicates the significance level of the effect when correcting for all other effects in the model. 
Effect Coefficient estimates DF Wald Chi-square P 
Time period 1:  0.1892 
2:  0.4702 
3: -0.0284 
4: -0.1097 
5:  0.1700 
6: -0.0867 
7:  0.3048 
8: Reference 
 
7 17.39 0.0150 
Age group 18-24:  -1.8326 
25-34:  -1.0884 
35-49:  -0.5638 
50+:  reference 
 
3 80.58 <0.0001 
Gender Men:  -0.7897 
Women: reference 
 
1 18.12 <0.0001 
Country BE: 2.3795 
CZ: 2.1308 
DK: 0.0390 
ES: 2.2200 
FI: 0.7178 
HU: 1.7913 
NO: 1.4080 
NL: 0.8343 
PT: 3.1136 
S: reference 
 
9   206.78 <0.0001 
Country ×Gender 
 
 
 
 Men Women 
BE:  0.1363 reference 
CZ: -1.1651 reference 
DK:  1.3779 reference 
ES:  0.3263 reference 
FI:  1.2151 reference 
HU:  0.5904 reference 
NO:  0.2389 reference 
NL: -0.5757 reference 
PT: -0.3621 reference 
S: reference reference 
 
9 24.11 0.0041 
 
In contrast to THC, benzodiazepines are drugs occurring in traffic mainly in mature female drivers and 
during daytime. Thus, prevalence was significantly different over the time periods; it was most 
prevalent in time period 2, i.e. Monday through Friday 10:00-15:59 and least prevalent in period 4, i.e. 
Monday through Friday 22:00-03:59.  
 
Benzodiazepines were most prevalent in drivers aged 50+; significantly more prevalent than in the 
youngest age group (18-24) where they were least prevalent.  
 
As for THC, there was a tentative north-south gradient in prevalence, benzodiazepines being most 
prevalent in Spain, Portugal, Czech Republic and Belgium and least prevalent in Denmark, Finland 
and Sweden. 
 
5.6 Factors influencing the prevalence of medicinal opioids 
 
Due to a small number of positives, the three youngest age groups were merged resulting in two new 
age groups 18-49 and 50+. This formed the variable age group new2. 
 
Furthermore, due to a low number of positive samples, time periods 1, 2 and 3 were merged to one, 4 
remained, 5, 6 and 7 were merged and 8 remained (variable time period new). The procedure was run 
for Belgium, Denmark, Finland, Norway and Sweden. There were no positive samples for Lithuania, 
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and for the other seven countries the positive samples were too few and too unequally distributed by 
time period, gender and age to run the complete model.  
 
The model was run, but no estimates could be calculated. However, the P values for the various main 
effects and interactions could be calculated. Based on the P values, the assumption was made that 
the interactions time period new × country and time period new × gender were not significant, i.e. the 
interactions with the highest P values. 
 
The model was run again under these assumptions. It was found that the remaining four interactions 
were not significant: time period new × age group new2, age group new2 × gender, age group new2 × 
country and gender × country. Moreover, the main effect time period new was insignificant.  
 
By making the assumptions that these effects were insignificant for the rest of the countries with 
positive samples, it was possible to include Czech Republic, the Netherlands, Hungary, Spain, Poland, 
Italy and Portugal into the model. Finally it was possible to include the original variable age group in 
the model. Hence the final model included the significant independent variables, as shown in table 
5.6.1. 
 
The total number of observations is 47,053 with 165 positives. This model included the following 
twelve countries: Belgium, Denmark, Czech Republic, Finland, Hungary, Italy, the Netherlands, 
Norway, Spain, Poland, Portugal and Sweden. 
 
Table 5.6.1 Logistic regression model for the prevalence of medicinal opioids. The left column shows the 
effects that have been included in the model, coefficient estimates scale the different levels of the effects 
and P indicates the significance level of the effect when correcting for all other effects in the model. 
Effect Coefficient estimates DF Wald Chi-square P 
Age group 18-24:  -1.9167 
25-34:  -0.9974 
35-49:  -0.4682 
50+:  reference 
 
3 27.32 <0.0001 
Gender Men:  -0.5578 
Women: reference 
 
1 12.10 0.0005 
Country BE:  0.0343 
CZ: -1.4068 
DK:  0.1206 
ES: -0.9136 
FI: -0.2512 
HU: -0.7456 
IT: -1.7997 
NO: -1.4956 
NL: -1.5357 
PL: -2.3602 
PT: -1.7624 
S: reference 
 
11 67.23 <0.0001 
 
Medicinal opioids are drugs similar in distribution to benzodiazepines: their prevalence differed 
significantly with age, being most prevalent in the 50+ age group and least prevalent in the youngest 
age group (18-24).  Like benzodiazepines, they were significantly more prevalent by female than by 
male drivers.  
 
Prevalence of medicinal opioids was significantly differently distributed among countries, but the 
tentative gradient was the opposite as for benzodiazepines: Medicinal opioids were most prevalent in 
Belgium and the northern countries (Denmark, Sweden) and least prevalent in Poland and the 
southern countries (Italy, Portugal). There was no significant difference in prevalence of medicinal 
opioids over the time periods. 
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5.7 Factors influencing prevalence of alcohol in combination with 
drugs 
 
This model was constructed exclusively for male drivers due to a very small number of positive female 
drivers. Moreover, due to a low number of positive samples, time periods 1, 2 and 3 were merged, 4 
remained, 5, 6 and 7 were merged and 8 remained (variable time period new). A model was run 
including Belgium, Spain, Italy, Norway, the Netherlands and Portugal. There were no positive 
samples for male drivers in Hungary, Poland and Sweden, so these countries could not be included, 
and for the remaining four countries (Czech Republic, Denmark, Finland and Lithuania) the positive 
samples for male drivers were too few and too unequally distributed by time period and age to run the 
complete model.  
 
The following interaction terms turned out to be insignificant: age group x country, time period new x 
country and were consequently removed from the model. Under the assumption that the same 
interaction terms were not significantly explaining alcohol-drug prevalence for male drivers in 
Denmark, Czech Republic, Finland and Lithuania, these four countries were included in the model. 
Hence the final model included the significant independent variables and interaction, as shown in table 
5.7.1. 
 
The final model contained 25,466 observations with 161 positives. The model predicts prevalence in 
male drivers only. It includes the following ten countries: Belgium, Czech Republic, Denmark, Finland, 
Lithuania, Spain, Italy, Norway, the Netherlands and Portugal. 
 
Table 5.7.1 Logistic regression model for the prevalence of alcohol in combination with drugs. The left 
column shows the effects that have been included in the model, coefficient estimates scale the different 
levels of the effects and P indicates the significance level of the effect when correcting for all other 
effects in the model.  
Effect Coefficient estimates DF Wald Chi-square P 
Time period new 1-3: -0.1098 
4:  1.1223 
5-7:  0.8193 
8: reference 
 
3 16.12 0.0011 
Age group 18-24:  1.1159 
25-34:  2.1274 
35-49:  1.8743 
50+:  reference 
 
3 18.18 0.0004 
Country BE:  0.1226 
CZ: -2.0512 
DK: -0.8557 
ES:  1.2655 
FI: -1.3898 
IT:  0.6802 
LT: -1.7766 
NO: -1.7086 
NL: -0.0690 
PT: reference 
 
9 102.95 <0.0001 
Time period 
new× 
Age group 
 18-24: 25-34: 35-49: 50+: 
1-3:  0.1177 -1.2156 -1.9904 reference 
4: -0-6058 -1-6406 -1-3277 reference 
5-7: -0.8201 -1.1826 -2.9136 reference 
8: reference reference reference reference 
 
9 19.94 0.0183 
 
The combination of alcohol, drug(s) and driving is typically a male driver phenomenon, since there 
were too few positive samples for female drivers to include them in the prevalence model.  
 
There was a significant difference in prevalence over the time periods; thus the combination of alcohol 
and drug(s) was most prevalent in time period 5-7, i.e. Saturday and Sunday during daytime, and least 
prevalent in period 1-3, i.e. Monday through Friday during daytime.  
 
Prevalence was significantly different among age groups; the age group of 25-34 years had the 
highest prevalence and the 50+ year olds the lowest.  
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There was no clear gradient in the country prevalence, although the prevalence of alcohol in 
combination with drug(s) differed significantly among countries. Prevalence was highest in Spain and 
lowest in Czech Republic, Lithuania and Norway. 
 
5.8 Factors influencing the prevalence of multiple drugs 
 
If a person was tested positive for more than one drug, but negative for alcohol, the sample was 
considered positive for multiple drugs. 
 
This model was constructed exclusively for male drivers due to a very small number of positive female 
drivers. Moreover, due to a low number of positive samples, time periods 1, 2 and 3 were merged to 
one, 4 remained, 5, 6 and 7 were merged and 8 remained (variable time period new). A model was run 
including Spain, Norway and the Netherlands. Lithuania could not be included because there were no 
positive samples for multiple drugs. For the remaining nine countries, the positive samples were too 
few and too unequally distributed by time period new and age to run the complete model. 
 
The logistic regression was run and it was found that the interactions time period new × age group, 
age group × country and time period new × country were insignificant. It was now possible to import 
gender in the model. The procedure was run again for the same three countries and it was now found 
that the interaction terms time period new × gender, age group × gender and gender × country were 
insignificant. Furthermore, the main effect time period new was found insignificant. 
 
Hereafter all the remaining countries with positive samples for multiple drugs, that is Belgium, 
Denmark, Czech Republic, Hungary, Poland, Finland, Sweden, Italy and Portugal could be included in 
the model under the assumptions that all the abovementioned interactions and the main effect were 
not significant for these countries either. Hence the final model includes the significant independent 
variables, as shown in table 5.8.1. 
 
In the final model, the total number of observations is 47,062 with 139 positive. This model included all 
countries except Lithuania, that is Belgium, Czech Republic, Denmark, Spain, Finland, Hungary, Italy, 
Norway, the Netherlands, Poland, Portugal and Sweden. 
  
Table 5.8.1 Logistic regression model for the prevalence of multiple drugs. The left column shows the 
effects that have been included in the model, coefficient estimates scale the different levels of the effects 
and P indicates the significance level of the effect when correcting for all other effects in the model. 
Effect Coefficient estimates DF Wald Chi-square P 
Age group 18-24:  0.7576 
25-34:  0.7550 
35-49:  0.2040 
50+:  reference 
 
3 13.43 0.0038 
Gender Men:  1.0220 
Women: reference 
 
1 15.41 <0.0001 
Country BE:  1.4554 
CZ:  1.2228 
DK: -0.2158 
ES:  1.9676 
FI:  1.1140 
HU:  0.0845 
IT:  2.0807 
NO:  1.2383 
NL:  1.6815 
PL: -0.8190 
PT:  0.8472 
S: reference 
 
11 48.76 <0.0001 
 
Multiple drugs were prevalent in both male and female drivers, although significantly more prevalent in 
male than in female drivers. There was a clear age gradient in multiple drug prevalence: the older the 
driver, the smaller the prevalence.  
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Multiple drug prevalence was significantly different among countries; it was most prevalent in Spain 
and Italy and least prevalent in Denmark, Poland and Sweden. There was no significant difference in 
prevalence over time periods. 
 
5.9 Conclusion 
 
There are two opposing prevalence patterns represented in this sample:  
 
1. The first one applies to alcohol, THC, alcohol and drugs in combination and drugs in 
combination with other drugs. In this group, prevalence was highest in young male drivers in 
the weekend and lowest in female drivers during daytime. For THC there was an age gradient: 
the younger the driver, the higher the prevalence. Both alcohol, cocaine, THC, alcohol in 
combination with drug and multiple drugs were highly prevalent in Spain. Alcohol was highly 
prevalent in Belgium and sparse in Norway, Poland, Lithuania and Hungary. 
 
2. The second pattern applies to benzodiazepines and medicinal opioids. These drugs are most 
prevalent in female drivers, their prevalence is higher the older the driver, and they are most 
prevalent during daytime and least during nighttime. The prevalence of benzodiazepines 
showed a clear north-south gradient in that these drugs were most prevalent in Czech 
Republic, Belgium and southern countries (Spain, Portugal) and least prevalent in Denmark, 
Finland and Sweden. The prevalence of medicinal opioids showed the opposite being highest 
in Denmark, Sweden and Belgium and lowest in Italy, Poland and Portugal. 
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6. Discussion and conclusions 
 
The main aim of this study was to obtain more insight in the use of psychoactive substances among 
drivers in European traffic. Thirteen countries participated in this study by conducting roadside surveys 
according to a general design. In total almost 50,000 randomly selected drivers participated between 
January 2007 and July 2009. 
 
6.1 Main findings 
. 
• Alcohol is still by far the number one psychoactive substance on European roads, 
followed by illicit drugs and medicinal drugs. 
 
• On a European level alcohol is estimated to be used by 3.48% of the drivers, illicit drugs 
by 1.90% of the drivers, medicinal drugs by 1.36% of the drivers, drug-drug combinations 
by 0.39% of the drivers and alcohol-drug combinations by 0.37% of the drivers. 
 
• For illicit drugs THC is the most frequently detected drug in traffic, followed by cocaine. 
Amphetamines and illicit opiates were less frequently detected. 
 
• Illicit drugs were in general mainly detected among young male drivers, during all times of 
the day but mainly in the weekend  
 
• Medicinal drugs were in general mainly detected among older female drivers during 
daytime hours.  
 
• Benzodiazepines were the most prevalent medicinal drug in traffic, Z-drugs were less 
prevalent. However, considerable differences between countries were present. 
 
• The use of substances among drivers in the general driving population in Europe 
(prevalence) varies very much per country, but general patterns can be distinguished on 
the level of European regions: 
 
o The medicinal drugs Z-drugs and medicinal opiates and opioids were in general 
relatively frequently detected in Northern European countries.  
 
o Illicit drugs, alcohol and benzodiazepines are relatively frequently detected in 
Southern European countries.  
 
o In Eastern Europe the prevalence of alcohol and drugs was relatively low compared to 
the other European regions.  
 
o In Western Europe, drug use is more or less on the European average. 
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6.2 General results 
Tables 6.1- 6.3 provide an overview of the main results per substance. Information is provided on the 
average European prevalence, the rank of the substance in European traffic and the country in which 
the highest prevalence was detected. Furthermore, information is presented on the European region in 
which the substance use was dominant and the gender, age and time period for which the highest 
prevalence was predominantly found. 
The estimated average of psychoactive use in European traffic was calculated by means weighted 
distributions over the European subregions.  
  
6.2.1 Illicit drugs 
Illicit drugs were most frequently detected in Southern and Western Europe. Especially in Spain the 
prevalence of illicit drugs was very high. More than 8% of all drivers (approximately 1 in 12) were 
positive for one or more illicit drugs. In Northern and Eastern Europe the prevalence of illicit drugs was 
on average below 1%. 
 
Table 6.1 Overview of general results for illicit drugs 
  Amphetamines Cocaine THC Illicit opiates 
     
Mean prevalence: 0.08% 0.42% 1.32% 0.07% 
          
Prevalence ranking: #9 #4 #2 #10 
          
Highest prevalence:  Czech Republic (0.38%) Spain (1.49%) Spain (5.99%) Italy (0.3%) 
          
Main European region: No specific region Southern Europe Southern Europe Southern Europe 
          
Main gender effect: Differs per country Male drivers Male drivers Male drivers 
          
Main age effect: Young drivers (18-34) Drivers 18-49 Young drivers (18-34) Drivers 35-49 
          
Main time period effect Differs per country Differs per country Differs per country Differs per country 
 
Amphetamines  
Amphetamines were far less frequently detected than THC and cocaine. The prevalence of 
amphetamines is very low in most of the 13 countries. The Czech Republic has the highest share with 
0.38% which is almost the double of the share of the countries that are ranked second and third: 
Lithuania and The Netherlands with 0.22% and 0.19% respectively. Most countries have a prevalence 
which is lower than 0.10%.  
In general amphetamines are equally often detected alone as in combinations. 
Amphetamines are mainly used by drivers younger than 35 years old. It is in some countries more 
prevalent among male drivers and in other countries more among female drivers. In Lithuania the 
prevalence of amphetamines among female drivers was almost 20 times higher than for male drivers. 
This large difference between male and female drivers could partially be caused by the small sample 
size of female drivers (n = 121). 
The distribution of amphetamines by time period differs per country. In the Netherlands, Norway and 
Poland amphetamine is mainly used in night time periods. In Sweden it is detected during night times 
as well, but only on weekdays. In Denmark and Finland amphetamine use was only detected during 
weekend days and in Czech Republic and Spain it was detected primarily in the weekend both during 
the day and during the night. In Lithuania amphetamines were only detected in traffic during weekday 
hours. 
 
Cocaine 
The second most frequently detected illicit drug among drivers was cocaine. The highest prevalence 
for cocaine was found in Spain and Italy.  
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Cocaine was often used in combination with other psychoactive substances. On average around half 
of the cocaine was detected in combination with other substances. Only in Finland and Hungary 
cocaine was solely detected in single drug use.  
Almost all cocaine users were younger than 50 and predominantly male. However, it should be taken 
into account that female drivers in Spain have a higher prevalence for cocaine than most male users in 
other countries. 
Cocaine was detected during all time periods. However, large differences in the distribution by time 
period exist on a country level. In Finland and Hungary cocaine was only detected at weekdays during 
daytime hours. In Spain it was frequently detected during all time periods. In Italy it was detected 
frequently in all time periods except in the weekend at daytime hours. In the Netherlands single 
cocaine use was primarily detected during weekend nights, while in Belgium it was more frequently 
detected during weekday nights. 
The results of the logistic regression as presented in chapter 5 based on the data of Belgium, Norway, 
Hungary and Portugal suggest that the highest prevalence would be found among the age group 25-
34. 
 
THC 
THC was the most frequently detected illicit drug in traffic. It was mainly used in Spain where the 
prevalence was almost four times higher than in that of the second ranked country: the Netherlands. 
On average between 20% and 30% of THC use was in combination with other psychoactive 
substances. Combinational THC use was the highest in the Southern European countries (Italy, Spain, 
Portugal) and the Netherlands. In general drivers who had been using THC were males younger than 
35 years. 
THC was prevalent at all days of the week during all hours of the week in most countries. However, in 
Belgium, Czech Republic, Denmark, Italy and Hungary, single THC use was mainly detected during 
the weekend. 
The trend of THC use in weekends by young male drivers was confirmed by the logistic regression 
analysis (see chapter 5). 
 
Illicit opiates 
Illicit opiates are barely prevalent in European traffic. Italy has the highest share with 0.3%. In the 
Northern European counties no illicit opiates were detected among drivers. In the Eastern European 
countries Illicit opiates were only detected in Poland. 
Illicit opiates were relatively frequently used in combination with other psychoactive substances. In 
Italy the prevalence of illicit opiates in combination with other substances was 0.71% which was far 
higher than the single use (0.3%). 
Most users of illicit opiates are between 35 and 49 years old, except for Belgium where most users 
were younger than 25. Illicit opiate use was not detected among drivers from Northern European 
countries (Denmark, Finland, Norway and Sweden) and from Czech Republic, Lithuania, and Hungary. 
Illicit opiates are mainly used by male drivers. 
Illicit opiates were not found during weekday nights in any of the 13 countries. In Italy and Portugal the 
prevalence was the highest during weekend nights, in Belgium, the Netherlands and Spain during 
weekend days and in Poland at weekdays during daytime. 
 
6.2.2 Medicinal drugs 
Medicinal drugs were detected most frequently in Belgium and Portugal with prevalence just below 
3%. Most countries had a prevalence rate of 1.4 - 1.8%.  
 
In general benzodiazepines were the most prevalent medicinal drug in traffic. However, in Denmark 
and Sweden medicinal opiates and opioids were more frequently detected. Z-drugs were less 
prevalent, except in Norway where they were detected among 0.69% of all drivers. 
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Table 6.2 Overview of general results for medicinal drugs 
  Benzodiazepines Z-drugs Medicinal opiates and opioids 
    
Mean prevalence: 0.90% 0.12% 0.35% 
        
Prevalence ranking: #3 #8 #7 
        
Highest prevalence:  Portugal (2.73%) Norway (0.69%) Denmark (0.79%) 
     
Main European region: Southern Europe Northern Europe Northern Europe 
        
Main gender effect: Female drivers Female drivers Female drivers 
        
Main age effect: 35 years and older Drivers 50 years and older 35 years and older 
        
Main time period effect Daytime hours Daytime hours at weekdays Daytime hours 
 
 
Benzodiazepines 
Benzodiazepines were detected in all 13 countries. The highest prevalence was detected in Portugal, 
followed by Belgium, Hungary, Spain and Lithuania. The average European mean was 0.9%. 
Benzodiazepines were not often used in combination with other psychoactive substances. In most 
countries the share was around 15%. However in Italy almost half of all benzodiazepines were used in 
combination. 
The highest prevalence for single benzodiazepine use was detected among drivers aged 35 years and 
older. However, in Italy most benzodiazepines were used by young drivers aged 18-24. 
Unlike for illicit drugs, benzodiazepine use is relatively more frequently detected among female drivers. 
Especially in Lithuania the share of female drivers was much higher than that of male drivers. In 
Denmark, Finland, and Poland the share of benzodiazepine use was higher among male drivers 
though. 
Benzodiazepines were most commonly detected during daytime in many of the countries. Only in 
Poland and Portugal relatively more drivers were positive for the use of benzodiazepines during night 
time hours. 
This trend was generally confirmed by the logistic regression analysis. 
 
Z-drugs 
Z-drugs were not commonly detected among European drivers. The prevalence is the highest in the 
Northern European countries, followed by Belgium, Hungary and the Netherlands. In all other 
countries no Z-drugs were detected among drivers. 
Z-drugs were relatively often combined with other psychoactive substances in Finland and Hungary. In 
Denmark only single use of Z-drugs was detected. In Belgium, Norway, Sweden and the Netherlands 
the relative share of combinational use of Z-drugs varied between 9% and 26%. 
Most drivers positive for Z-drugs were 50 years and older, except for Hungary where all drivers were 
between 25 and 34 years old.  
In general the share of female drivers who were positive for Z-drugs was higher than the share of male 
drivers. However, In the Netherlands only (a small share of) male drivers were positive for Z-drugs and 
in Sweden the share of Z-drugs users was a little bit higher among male drivers than among female 
drivers. In Hungary Z-drugs were only detected among female drivers. 
Z-drugs were most often detected during daytime hours at weekdays. In Denmark however, most Z-
drugs were detected during daytime hours in the weekend and in Sweden most Z-drugs were detected 
during night time hours at weekdays. In none of the countries Z-drugs were found in weekend nights. 
 
Medicinal opiates and opioids 
In Hungary, Italy and Portugal medicinal opiates and opioids are relatively often used in combination 
with other psychoactive substances. In Czech Republic, Spain, and Poland only single use was 
detected. 
Medicinal opiates and opioids were mainly detected among drivers of 35 years and older. 
  142 
In most countries the share of female drivers is larger, except for Spain, Finland, Norway and Portugal 
where the share of male drivers positive for medicinal opiates and opioids was larger. The logistic 
regression results indicate a general higher prevalence among female drivers as well. 
The distribution over the four different DRUID time periods varies largely, but in general highest 
prevalence was detected during daytime hours. In Denmark though, most medicinal opiates and 
opioids were detected in weekend nights and in Finland during weeknights.  
6.2.3 Alcohol, alcohol-drugs and drug-drug combinations 
Alcohol is the most frequently detected psychoactive substance in Europe. Alcohol-drugs 
combinations and drug-drug combination were relatively prevalent as well. All these groups are mainly 
prevalent in the Southern part of Europe. 
 
Table 6.3 Overview of general results for alcohol, alcohol-drugs combinations and drug-drug 
combinations 
  Alcohol alone (≥ 0.1 g/L)  Alcohol (≥ 0.1 g/L) and drugs Drug-drug combinations 
    
Mean prevalence: 3.48% 0.37% 0.39% 
        
Prevalence ranking: #1 #6 #5 
        
Highest prevalence:  Italy (8.59%) Spain (1.14%) Italy (1.22%) 
     
Main European region: Southern Europe Southern Europe Southern Europe 
        
Main gender effect: Male drivers Male drivers Male drivers 
        
Main age effect: Differs per country Young drivers (18-34) Drivers younger than 50 
        
Main time period effect 
Weekday nights and 
weekends Nighttime hours Differs per country 
 
Single alcohol use 
The prevalence of single alcohol use in twelve of the thirteen countries ranged between 0.15% in 
Hungary and 8.59% in Italy. As stated before, no alcohol data was available for Sweden. 
In general the largest prevalence for alcohol is present at the low BAC categories. In Denmark even 
81% of the alcohol drivers had a BAC between 0.1 and 0.5 g/L. However, in Lithuania almost 40% of 
all alcohol intoxicated drivers had a BAC level of 1.2 g/L or higher, while for most other countries this 
share is below 15%. The total prevalence for alcohol ranged between 0.15% in Hungary and 8.59% in 
Italy.  
In most countries the share of alcohol-positive drivers was the highest for the two oldest age groups 
(35-49 and 50+). This is both the case for male and for female drivers. 
The prevalence of alcohol was in general the lowest at weekdays during daytime hours. However, in 
Portugal the share of alcohol drivers was higher during weekday hours than during weekday nights. 
Despite a large share of high BAC drivers, no alcohol use was found during weekend nights in 
Lithuania. In Hungary no alcohol was found at all during night time hours. 
 
Alcohol-drugs combination 
The Northern and Eastern European countries all had lower prevalence for the combined use of 
alcohol and drugs than the European average. In Western Europe the prevalence was around the 
average, while relatively the most drivers positive for alcohol and drugs were detected in Southern 
Europe. The highest prevalence was detected in Spain and Italy with prevalence rates just over the 
1%. 
The relative share of alcohol in combination with drugs as a total of all alcohol use varies between 0% 
(Hungary) and 23% (Spain). Countries with higher prevalence for single alcohol and single drug use 
have, as expected, higher prevalence for combined use of alcohol and drugs. 
In general the prevalence for alcohol-drugs combinations for male drivers is higher than for female 
drivers. The only exceptions are Norway, where the prevalence of alcohol among male drivers was 
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equal to that of female drivers, and Italy where the prevalence of alcohol among female drivers was 
even higher than that in men. 
Most drivers who used alcohol and drugs in combination with each other were younger than 35 years 
old, except for Italy, where the drugs-alcohol combination was relatively more prevalent among drivers 
over 35 years old. 
The combined use of alcohol and drugs was mainly detected during night time hours. However, in 
Finland, Czech Republic and Belgium the prevalence during daytime hours was relatively high as well. 
 
Drug-drug combinations 
The prevalence of drug-drug combinations among drivers was the highest in Italy and Spain, which 
were the only two countries with a prevalence higher than the European mean of 0.39%. Most 
commonly used drugs in multi-drug combinations are THC, cocaine, and benzodiazepines, which are 
also the most frequently detected single psychoactive substances after alcohol.  
The share of multi-drug use is on average around 10% of all drug use. Italy had the highest share of 
multi-drug use: 22% of the drug using had been using two or more different drugs. 
Drug-drug combinations were most frequently detected among drivers younger than 50 years. The 
distribution over the four age groups varies largely though over the different countries. 
In general multi-drug use is more common among male than among female drivers. However, in 
Czech Republic, Sweden and especially in Hungary, the share of female users is larger. 
The distribution of multi-drug use by time period varies considerable between the different countries. In 
Southern European countries and in Norway the prevalence of drug-drug combinations was relatively 
high during night time hours at weekdays. The prevalence during daytime hours at weekdays was the 
highest in Italy and Hungary. The results of the logistic regression analysis also indicate no significant 
overall trend of time period. 
6.3 Interpretation of the results 
The results show that the prevalence of psychoactive substances varies per country, but that in 
general the highest prevalence of alcohol and illicit drugs (except for amphetamines) was found in 
Southern European countries and the highest prevalence of medicinal drugs in Northern European 
countries. These findings are in line with the prevalence of psychoactive substances in the general 
population (Ravera and De Gier, 2008). 
Alcohol (≥ 0.1 g/L) was the most commonly detected psychoactive substance in European traffic. In 
most of the participating countries, the legal alcohol limit was higher than the 0.1 g/L cut-off level in 
this study. Only in Czech Republic and Hungary a zero tolerance limit for alcohol is present.  
However, when a cut-off level of 0.5 g/L would have been applied, alcohol would still have been the 
most prevalent substance in European traffic with an average prevalence of 1.49%.  
Figure 6.1 shows the prevalence of alcohol of 0.5 g/L and higher for twelve participating countries. No 
alcohol data was available for Sweden. The results in this figure show that those countries with the 
highest prevalence for alcohol have a legal BAC-limit of 0.4 or higher. However, a direct relationship 
between the height of the prevalence and the legal limit can not be concluded from this figure since 
other factors such as the general and specific deterrence effect from enforcement will influence the 
prevalence level as well (Veisten et al., 2010).  
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Figure 6.1. Prevalence alcohol ≥ 0.5 g/L by legal BAC limit in percentages 
Previous case-control studies (Borkenstein et al., 1974; Compton et al., 2002; Keall et al., 2001; 
Krüger and Vollrath, 2004; Mathijssen and Houwing, 2005) have shown that the relative accident and 
injury risk increases drastically at high BAC levels. Therefore, from the viewpoint of traffic safety 
drivers with a BAC of 1.2 g/L and higher form the most important target group of alcohol intoxicated 
drivers. 
The prevalence of the heavy alcohol intoxicated drivers is the highest in Italy and Lithuania, and 
therefore high prevalence among injured drivers would have been expected as well. The results from 
the DRUID hospital studies (Isalberti et al, 2011) show, however, that the prevalence of alcohol among 
injured drivers in Italy and Lithuania are actually relatively low, as compared to other participating 
European countries.  
Both Lithuania and Italy had a relatively low number of participants and therefore chance could have 
had some influence on the results of the roadside survey. On the other hand, for the other 
psychoactive substances the relative share was in both countries as would be expected from the 
results of the hospital study.  
Another possible explanation for the relatively high share of high BAC drivers in traffic compared to the 
share of high BAC drivers in the hospital is that the police has not always tested randomly. In the 
Italian country report (see Part 2 of this report) it was stated that the police may have applied a 
preselection, but that the results were in line with other studies on the prevalence of alcohol and drugs 
in Italy. In the Lithuanian country report no reference to possible bias was made and no other studies 
were available for comparison. 
 
The results of chapter 4 and 5 differ from each other on some effects of factors such as gender, age 
and time period distributions. The reason for this is that the logistic regression method applied in 
chapter 5 is a different method than standard prevalence calculation on which the results of chapter 4 
were based. For example, logistic regression calculation is only possible for those countries where 
sufficient positive samples are available. This means that effects are not based on the results of all 
countries that were included in the standard prevalence calculations, but on a subselection of the 
participating countries.  
Another difference is caused by the use of different time periods. The results in chapter 4 show that 
the prevalence of illicit drugs is not mainly limited to nighttime hours as is the case for, e.g., the 
combination of alcohol and drugs. However, the results from chapter 5 indicate that there is a strong 
relationship between time period and the prevalence of illicit drug use. This difference between results 
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can be explained by differences in the applied distribution of time-periods. The logistic regression 
method of chapter 5 includes for the most prevalent substances the original eight 6-hour time periods 
that were selected at the beginning of the project, whereas the analysis in chapter 4 did not. Both 
choices have advantages as well as disadvantages. The reason for using four 6-hour time periods in 
the result section (chapter 4) was that some countries only had a few samples in some of the time 
periods and in one country no data at all was available for one of the time periods. Low numbers result 
in low statistical power and increased confidence intervals. As explained in section 3.1, clustering was 
used to cover for most of the issues regarding low numbers of samples. The disadvantage of 
clustering is that the level of detail is decreasing. The daytime period covers the morning (04.00-
09.59), the afternoon (10.00-15.59) and the evening (16.00-21.59). It is not likely that these time 
periods are very similar concerning the prevalence of psychoactive substances. E.g. in Italy the 
highest prevalence for total substance use was detected in evening hours both during weekdays and 
in the weekend. During these hours the total prevalence of psychoactive substances was around 20% 
while it was around 15% during the other time periods, except for weekday mornings when the 
prevalence was below the 10%. After clustering, the total prevalence of psychoactive substance was 
around 15% in all four time periods. 
In Italy the prevalence of alcohol was the highest during weekday and weekend mornings. However, 
after clustering the highest prevalence for alcohol was found in weekend nights. 
These two examples show that the results by time period should be interpreted with care and that the 
loss of information due to clustering will sometimes lead to other conclusions.  
 
Despite the common design, differences in the set up of the study were still present between the 
thirteen participating countries. These differences sometimes had an effect on the response rate as 
well. The non response in the thirteen countries varied between 0 and 52%. Mandatory drug testing 
resulted in very low refusal rates, but voluntary drug testing not always resulted in high refusal rates. 
The need for informed consent varied per country. In six countries written informed consent was 
needed and in six others it was not. In Italy written informed consent was no issue since participation 
was mandatory. Based on the non-response rates it can be concluded that written informed consent 
was not always associated with increased non-response.  
In all countries where the police performed a mandatory drug test or where drug testing by 
researchers preceded the mandatory breath test for alcohol, non-response was very low (0-5%). In 
countries where the police performed the mandatory breath test for alcohol before the voluntary drug 
test was performed by a researcher, the non-response range was relatively broad: 5-52%. Only in two 
out of seven countries (Denmark and Norway) a non-response below 10% was achieved. 
 
Weighting was based on the distribution of traffic by the eight DRUID time periods in the participating 
countries. For those countries who did not have data available on traffic by time period, an average 
score was computed based on the distribution of 4 OECD countries. Additional weighting by region 
was possible as well in case all time periods were covered in all of the regions, and in case the 
distribution of both the prevalence and the traffic differed over the time periods by region.  
Another possible way of calculating weight factors by time period is by means of traffic counts during 
the roadside survey sessions. The use of this method has been discussed within the WP. Traffic 
counts seem to provide the most up-to-date information on traffic, however the collection of these data 
is not that straightforward. The first issue is that roadside surveys during night time hours are generally 
planned at roads with relative much traffic in order to include sufficient samples during hours with low 
traffic densities. If traffic counts would be used for weighting purposes, it would be likely that traffic 
proportions during night time hours would be overestimated.  
Furthermore, the traffic volume is not always the same, due to e.g. local events, weather conditions, 
and roadworks. Therefore, it would be better to use more than one traffic count per location and have 
the other traffic counts at the same day of the week during the same time of the day as that of the 
roadside survey and then calculate the average traffic volume based on the results. 
Both methods have their pros and cons. For comparability reasons it was decided that national traffic 
distribution data was used for calculating the weight factors.  
 
When comparing the results of the DRUID study with the findings of a American national roadside 
survey of alcohol and drug use by drivers that was conducted in 2007 (Lacey et al., 2009), under the 
authority of the National Highway Traffic Safety Administration (NHTSA), some interesting similaties in 
the results can be observed.  
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The main differences between the two studies were that in general more substances were included in 
the NHTSA study and that other cut-offs were applied. Therefore, it is only useful to compare patterns 
of drug use and not to compare prevalence rates. 
The general patters of drug and alcohol use in the United States and in Europe are in line with 
eachother; both studies show that illicit substance use is more common among young male drivers 
and that the use of medicinal drugs is more common among older female drivers. 
As well as in the European DRUID study, alcohol was the most frequently detected psychoactive 
substance in the United States followed by THC. Furthermore, the NHTSA study found that 
benzodiazepines were thirdly ranked during daytime hours whereas cocaine was thirdly ranked during 
night time hours. These substances were also the most prevalent substances after THC in the DRUID 
study. 
The NHTSA study provides information on drug use for the combination gender, age and timeperiod. 
However in the DRUID study this disaggregation was not presented, although it could provide some 
interesting additional information for identifying specific user groups. However, a disadvantage of such 
disaggregations is that they lead to smaller cell numbers and therefore, larger confidence intervals and 
thus less reliable figures. 
 
6.4 Strengths and limitations of the study 
 
Strengths 
The main strength of this study is that for the first time a road side survey was conducted throughout 
Europe, and that samples were collected in thirteen different European countries by applying to a 
large extent the same method. To this end practical guidelines have been developed within the 
project. In the first stage, one or more regions per country were selected. These regions were meant 
to be representative for the country with regard to substance use and traffic distribution. Within these 
regions smaller research areas were selected, and within these areas, survey locations were selected, 
where subjects were stopped at random, and were requested to participate in the study. With regard to 
days of the week and times of the day, the study population sample was stratified into eight time 
periods over the week, for each of the survey areas. The time periods did not overlap each other and 
covered all the days of the week and all times of the day. 
 
Another strength of this study is the proficiency testing that was required for all participating 
laboratories. Both for blood and saliva 4 rounds of proficiency tests were included to assure the validity 
of the results.  
 
Limitations 
The European mean that was estimated should be used with care because it was based on the results 
of 'only' thirteen countries. The representativeness on a national level varies per country. In order to 
correct for large under representations in one of the eight time periods, clustering of the data was 
needed. Clustering does certainly not solve all representativity issues, but at least it would improve the 
validity of the data to some extent. The results from countries with relatively small sample sizes, such 
as Italy, Lithuania and Czech Republic will theoretically have benefited the most from this clustering. 
 
The population of Southern EU countries are best represented in this prevalence study. The countries 
that are involved in the roadside survey account for 89% of the Southern European population, the 
population from Eastern EU countries is represented for almost two-thirds (63%). The population of 
the Northern EU countries together with Norway are represented for only 29% due to the absence of a 
roadside survey in the United Kingdom which accounts for 63% of the total Northern EU population. 
Finally, the population of the Western Member States are only represented for 11%, since large 
Member States like Germany and France, together accounting for 80% of the total Western EU 
population, did not participate in the DRUID roadside surveys. 
The results from Western Europe weight the most with a weight factor of 181.4/500, although barely 
27 million of the 181.4 million inhabitants were represented. On average the results from Western 
Europe are very close to the European mean. Therefore, despite the relative heavy weight of Western 
Europe in the European average, the underrepresentation is not expected to have a substantial effect 
on the results for the European mean. 
 
A limitation of this study is the use of different body fluids. The use of psychoactive substances will 
lead to different concentrations in blood and saliva and the correlation between these concentrations 
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is poor. We tried to compensate for this by using equivalent cut-offs to correct for differences in 
sample collection method. In general the substance concentrations in saliva are higher than in blood 
and therefore the limit of quantitation was more easily met by substances in saliva. The use of the limit 
of quantitation as the cut-off value would therefore have led to relatively higher prevalences in 
countries that collected saliva samples. In order to compensate for this possible bias, equivalent cut-
offs were introduced in the analysis. However, when applied in the countries where only saliva 
samples were used for the roadside survey, the results will in general give an underrepresentation of 
the prevalence. In combination with the collection of blood samples at the roadside or for comparison 
with the results in hospital studies among injured or killed drivers, a correction for the different body 
fluids will be needed. 
 
6.5 Recommendations  
The results of this study can generally be used in selecting overall activities and target groups in the 
policy field of psychoactive substance use in traffic across Europe. The results indicate, however, that 
the prevalence of psychoactive substances by gender, age and time period varies largely per country. 
Therefore, recommendations for national activities regarding, e.g., policy issues, enforcement, 
education or campaigns, should primarily be based on the results of the country reports, rather than on 
the general report.  
 
Alcohol is still the most prevalent substance in traffic, as well as it is among injured and killed drivers 
(Isalberti et al., 2011). Therefore, with regard to enforcement on psychoactive substances it is 
recommended that this would remain to be mainly focused on alcohol use among drivers.  Since 
enforcement of drug driving legislation is costly in terms of time and money, selective drug testing is 
recommended above random drug testing. However, drug enforcement should not go at cost of 
alcohol enforcement (Veisten et al., 2010). 
  
The thirteen roadside surveys that were conducted within the DRUID-project provided a very valuable 
insight in the prevalence of psychoactive substances among car drivers in Europe. In the near future 
new legislations on drug driving will be applied in several European countries (e.g. the Netherlands) 
and the results from the DRUID project may affect future policies towards drink and drug driving. 
Therefore, it would be very valuable to monitor if these changes will indeed have a positive effect on 
the use of psychoactive substances in traffic. National roadside surveys on the prevalence of 
substance use in traffic on a regular, say, annual or bi-annual base would be a helpful tool to monitor 
the trend of drink and drug driving. It is recommended that these monitoring surveys would be carried 
out in more countries than the thirteen European countries that participated in the DRUID roadside 
surveys, in order to get a more representative European overview. 
Since the main purpose of this roadside survey would be to monitor the trend of drug driving, the 
number of samples per country might be smaller than in the present study. A power study should be 
conducted to estimate the required number of samples from randomly selected car drivers.  
 
In order to compare the results from new roadside surveys in Europe with the data collected in DRUID 
it is recommended to follow the study design guidelines from the DRUID roadside surveys (See annex 
1) as much as possible.  
 
It is recommended to collect saliva samples when the roadside surveys are solely used for monitoring 
the prevalence of drug use in traffic, since higher non-response rates are to be expected when 
collecting blood samples.  
 
If the roadside survey is part of a case-control study, it is recommended to use the same sample 
collection method at the roadside as is used in the hospital, in order to be able to make good 
comparisons between cases and controls. 
 
Furthermore, in order to reduce non-response researchers should invite the participants of the survey 
before the police tests the driver for alcohol.  
 
It is mandatory to have permission of the various national Medical Ethics Commission to conduct a 
roadside survey like this. The process of getting this permission can take a lot of time in some 
countries, this should be taken into account when planning future prevalence studies on psychoactive 
substances.  
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Annex 1 Guidelines for roadside surveys  
Terje Assum, TOI, Giampietro Frison, TFA-UNPD, Tove Hels and Inger Marie Bernhoft, DTF,  Sjoerd 
Houwing and René Mathijssen, SWOV 
 
Introduction 
The guidelines for the roadside survey are derived from DRUID Deliverable 2.1.2: Working paper 
“Uniform design and protocols for carrying out case-control studies”. 
 
In order to be able to calculate the relative risk and to compare the prevalence as well as the relative 
risk in the various countries, a uniform study design has been set up for roadside surveys and hospital 
studies. This annex contains the guidelines for the roadside surveys only. Guidelines for the hospital 
study are included as an annex in Deliverable 2.2.5 of DRUID "Prevalence of alcohol and other 
psychoactive substances in injured drivers, based on hospital surveys in seven member states". 
 
Furthermore, uniform guidelines regarding collection of specimen, transport of specimen as well as 
analysis of specimen have been derived. 
 
Finally, a decision has been made regarding a core list of 23 substances, including alcohol, to be 
analysed for in all countries.  
 
This annex includes all decisions taken as part of the uniform design. The following partners have 
contributed to the various guidelines: DTF, UGent, SWOV, TOI, KTL, UKL-HD and TFA-UNDP.  
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Background 
During the DRUID WP2 meeting at SWOV on January 9-10, 2007, a group was appointed to outline 
how to ensure representativeness of the roadside survey results.  The aim of this document is to 
establish a joint background for planning roadside surveys among participants in WP2. This joint 
background will increase the generalization of the results and ensure comparability between results 
from various countries. DRUID WP2 is a unique possibility to have scientifically valid estimates for 
prevalence of drink-and-drug driving in various European countries.  
 
Purpose and principles 
A major purpose of the DRUID roadside surveys is to compare the prevalence of psychoactive 
substance use in traffic between countries.  This comparison requires national representativeness. 
The problem is how to achieve this goal with the practical limitations implied by roadside surveys. 
These limitations vary between the countries, and may cause limited comparability in the results 
unless utmost care is taken to ensure comparability. 
 
The general hypothesis of DRUID is that drug use increases accident risk. Consequently the surveys 
should cover drug use among road users who may cause road accidents. Ideally, all active road users, 
in all regions of each country, on all roads, in all vehicles, at all times of the year, week and day should 
be represented in the survey, in order to have the road traffic in each country surveyed in a 
representative way. For practical reasons, however, covering all aspects of road traffic may be difficult. 
Roadside surveys will usually require co-operation between the police and researchers. The principles 
of police work are different from those of research, and the police as well as the researchers have 
practical and economic restraints. 
 
Consequently, deviations from the ideal principle may be necessary. Deviations from general, national 
representativeness should preferably be agreed within the DRUID consortium to ensure comparability 
between countries. 
 
This document describes, how representativeness and comparability can be guaranteed within a 
practically feasible research design.  
 
Recommendations 
Deviations from this design by individual research institutes will have to be substantiated, and 
approved by the Task and WP leader.  
 
Representativeness factors 
Taking a completely random sample of all road users in a country is impossible since it would include 
random sampling of road users at a random sample of locations and times. A first simplification which 
is generally applied to roadside surveys into impaired traffic is a limitation with regard to road user 
type. Usually only car drivers are included, since it is assumed that psychoactive substance use by 
this road user category has the greatest impact on road safety consequences. Generally a systematic 
sample of research locations and times is used. Traffic at the selected research locations and times 
should be representative of traffic on all roads at all times. At the selected research locations, drivers 
are generally taken at random from moving traffic. It is important that selected drivers in all countries 
are tested for alcohol and drugs in a uniform way.   
 
Selection of research locations and times 
Both traffic exposure and the prevalence of psychoactive substance use may vary considerably by 
place (region, research area, road type, research location) and time (year, season, day of the week, 
time of the day). Therefore, sample fractions by place and time should be proportional to traffic 
exposure fractions by place and time. Examples of traffic exposure indicators for car drivers are: 
population, number of cars, number of license holders, distance travelled (vehicle mileage), time spent 
in traffic, number of trips. 
 
The research locations and times should be systematically selected in such a way that it is plausible 
that the resulting sample of car drivers is representative of all car drivers in a country, if necessary 
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after weighting. It is recommended that the selection in all participating countries is made in a (more or 
less) uniform way.  
 
When subpopulations, such as regions or road types, vary considerably, it is advantageous to sample 
each subpopulation (stratum) independently. Stratification is the process of grouping members of the 
population into relatively homogeneous subgroups before sampling, thus ensuring the representation 
of all subpopulations. Then sampling is applied within each stratum (Wikipedia1). For the nationwide 
result to be valid, samples within each stratum must be weighted by a factor relating to the actual 
proportion of the whole stratum that the sample constitutes.  
 
To have the road traffic surveyed in a way that represents the whole country, certain factors need to 
be considered.   
 
These factors are:  
• Nation - stratified into regions 
• Road network stratified into road types 
• Time – stratified into year (season), week, day 
• Vehicles - foreign versus only domestic vehicles, motorized vs. non-motorized, two-wheelers 
versus four-wheelers, etc. 
• Road users – pedestrians, riders, drivers, professional drivers vs non-professional drivers, 
genders, age categories, etc.  
• Weighting for traffic volumes  
 
The theoretical principle is that the results of the survey should be representative of the country or 
nation in question. For practical reasons, such as co-operation with the police, long travel distances, 
very low traffic volumes in sparsely populated areas, or hospital catchment areas in case/control 
studies, this may not be possible. Ideally, recording efforts should be equal in all regions and all 
regions equal in size (expressed by population size or mileage driven). If not, the results in the various 
regions should be multiplied with different weight factors to ensure equal representation of regions.  
 
Recommendations 
It will be accepted that a less representative area is chosen. The reason for this choice, however, 
should be stated and explained. More importantly, the representativeness of the chosen region or area 
should be assessed, based on e.g. the population percentage of the region. The group recommends 
weighting the results according to a factor that is available in all participating countries, i.e. population 
size. Statistical estimates for the whole country should be made.   
 
Weighting of strata (if stratified sampling) 
If a stratified statistical sampling procedure is used, the strata should be weighted together in the end 
by their size according to the stratification variable.  If regions are used as strata according to their 
population, the regions should be weighted according to population when they are added together.   
 
Road network  
The theoretical principle is that the survey samples should represent the total road traffic in each 
country, a requirement which normally means that all road types should be included, i.e. the same 
road categories as constitute the basis of the national road accident statistics. This may be impossible 
for practical reasons such as extremely low traffic volumes on certain road categories, high speed 
limits making the stopping of cars unsafe, too little space in many city or village streets, the reluctance 
of the police to spend time on low traffic volume roads, etc.  On the one hand, collecting a sufficient 
number of samples on such roads is extremely expensive. Moreover, samples from such low-volume 
roads will have a marginal impact on the national averages, as the national averages will statistically 
be dominated by high-volume roads.  On the other hand, some people claim that drivers under the 
influence of drugs and alcohol will choose low-volume byroads, because police checks are infrequent 
there, and consequently it is important to include such roads. The same arguments may apply to small 
                                                 
1 http :.wikipedia.org/wiki/Stratified_ sampling 
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city, town and village streets in addition to the lack of space which may make it difficult to arrange 
traffic controls there.  
 
After road types have been surveyed, results must be weighted according to the proportion that traffic 
volume on the different road types make up of the total traffic volume within the region.   
 
Recommendations 
It will be accepted that extremely low-volume roads and streets may be excluded from the survey. The 
kinds of roads included in and excluded from the survey should be stated and substantiated. 
Preferably estimates should be made for the whole road network.   
 
How to weight for varying traffic volumes? 
To have a representative sample of the road users, the samples from each road section should be 
weighted according to the road traffic volume of the particular road section as well as month, weekday 
and hour.  
 
Recommendations 
Two different ways of weighting for traffic volume will be accepted. Either the road traffic can be 
counted when the samples are collected, which is the simplest and most reliable, but more expensive 
method or existing traffic volume data can be used.  The method used should be explained in the 
national report.    
 
Time  
Road traffic occurs all year, all week and 24 hours a day. Consequently, the roadside surveys should 
also cover all the year, all week and all day. Moreover, the extent of alcohol and drug use or driving 
under the influence of alcohol and drugs may vary considerably around the year, week and day. 
 
Some people claim that alcohol and drug use vary mostly between week days and weekend days and 
between day time and night time.  Consequently, it would be sufficient to cover week days and week 
nights, as well as weekend days and weekend nights. The cooperation with the police may also 
require certain limitations as to times of the year, the week and the day. An important point is that at 
least both week days and week nights as well as weekend days and weekend nights should be 
sufficiently covered in the survey to make four-ways significant comparisons, see following example.  
 
Example:  Prevalence of alcohol and drugs among drivers of motor vehicles. Per cent (fictional 
figures). 
 Weekdays Weekends N 
Daytime 0. 2 0.4  
Night time  0.8 1.6  
N    
 
Week and weekend – day and night is defined in the following 8 time intervals of the week to ensure 
comparability. 
 
Recommendations 
It is recommended to include all times of the year, the week and the day in the surveys. However, 
there may be variation in travel patterns between countries which may substantiate different 
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definitions. Deviations should be stated and substantiated, and preferably estimations as to whole 
year, week and day should be made.  
  
Vehicles  
All vehicles using the roads and streets make up the road traffic that in total creates the road 
accidents.  Even non-motorized vehicles like pedal bicycles are part of this road traffic. However, the 
motor vehicles pose more threat to other road users than the non-motorized ones. There may be 
reason to limit the surveys to certain types of vehicles, such as passenger cars and small vans, 
excluding heavy vehicles, motor cycles, taxis, mopeds and pedal bicycles. There is also the question 
of foreign versus domestic vehicles. On the one hand, there is no doubt that foreign vehicles 
contribute to the accident number in each country. Accidents involving foreign vehicles are recorded in 
the accident statistics of the country where the accident occurs rather than in the country where the 
vehicles are registered. On the other hand the national authorities may claim that it is impossible to 
enforce the national Highway Code to foreign vehicles, even though the national Highway Code 
applies to foreign vehicles. Including foreign vehicles may also pose language problems in the data 
collection.  
 
Recommendations 
It is recommended to include passenger cars (no more than eight passengers) and small vans (up to 
3,500 kilos – demands driving license B) in the surveys, including taxis. It is recommended to include 
both foreign and domestic vehicles. When conducting the survey, the type of vehicle must be 
recorded. This way, results can be compared between countries for passenger cars and small vans no 
matter which types of vehicles are included in the various countries.                                                                 
 
Road users  
All drivers of passenger cars (no more than eight passengers) and small vans should be included, 
professional as well as non-professional drivers, foreign and domestic drivers etc. As mentioned 
before, type of vehicle must be recorded in order to be able to compare the recommended vehicle 
types between countries.    
 
Recommendations 
Drivers of the above vehicles are recommended for inclusion. Deviations should be stated and 
substantiated. Men and women, young, middle aged and elderly people as well as different ethnic 
groups should be represented in the proportion that they are represented in the road user categories 
to be included in the roadside surveys. Since the vehicles are stopped at random, the sample should 
be representative according to these factors. However, when pooling the collected data, results can 
and should be adjusted later to match the composition of the population in question.  It is important to 
instruct the police to stop vehicles according to some random mechanism rather than according to 
suspicion of alcohol and drug use, e.g. young men in old vehicles.  A random mechanism could be 
stopping the next vehicle or vehicles when the research personnel are ready for new samples or 
according to the last digits of the license plate number, etc.   
        
 
Information to be recorded from the roadside surveys  
Information needed on all randomly selected subjects 
The following data are needed on all randomly selected subjects in order to be able to identify high-
risk groups, roads and times 
• Identification number (for sample collection device and recorded data) 
• Date (year, season)  
• Time and day (8 time intervals of the week) 
• Gender 
• Age 
• Vehicle type 
• Road type 
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• Clinical signs of impairment* 
• Self-reported drug use and time of consumption* 
 
Recommendations 
This is the recommended information. However we are aware that it may not be possible to collect all 
information in some countries. 
 
In addition to this, some partners might want to collect the below data in order to estimate the potential 
bias resulting from non-response and to assess the sensitivity of saliva testing: 
 
Information needed on refusers 
Some people will refuse to take part in the survey by refusing to give a sample of blood or saliva. It is 
extremely important to count the number of refusers.  For those road users the following information is 
needed: 
• Identification number 
• Date (year, season)  
• Time and day (8 time intervals of the week) 
• Gender 
• App. age 
• Vehicle type 
• Road type 
• The reason of refusal, e.g.:  No time 
Other reason…….. ………………………….. 
 
Recommendations 
This is the recommended core information.  
 
In addition to this, some partners might want to collect the below data in order to estimate the potential 
bias resulting from non-response and to assess the sensitivity of saliva testing: 
• Clinical signs of impairment* 
• Self-reported drug use and time of consumption* 
_________________ 
* If subjects are tested for drug use on a voluntary basis, self-reported drug use (and signs of 
impairment) might help to estimate the non-response bias. This is especially of importance for the 
relative risk estimates, based on comparing blood-tested cases and saliva-tested controls. Without 
additional information, comparing blood and saliva testing results may lead to incredibly high relative 
risks. It is not very likely that subjects will report drug use, if they didn't use any. So the risk of over-
reporting is negligible. On the other hand, some underreporting is to be expected. Therefore, the self-
reported drug use will have to be considered as a lower drug use limit.  
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Annex 2 Toxicology 
 
Body fluid collection 
It was decided to use oral fluid or whole blood as matrix for the substance analyses. 
Table 1 shows which country uses which matrix.  
Table 1: body fluids used in DRUID WP 2 
Country Oral Fluid Blood 
Belgium X X 
Czech Republic X  
Denmark X  
Finland  X  
Hungary X  
Italy X X 
Lithuania  X 
Norway X  
Poland X  
Portugal X  
Spain X  
Sweden X  
The Netherlands X X 
 
Method of body fluid collection: 
 
1. Blood samples 
Summary: 
- 5-10 mL whole blood collection in vacuum tubes containing sodium fluoride and potassium oxalate 
- Transportation at 4°C (max 48 hours) 
- Storage in laboratory at -20°C. 
Sample collection: 
All laboratories analyzing blood samples within WP2 performed analysis on whole blood.  
Blood was most commonly obtained from the median cubital vein on the anterior forearm. It could be 
drawn by venipuncture with vacuum tubes (tubes that contain a vacuum that aspirates blood into the 
tube.). 
A tourniquet was placed on the arm where blood was to be collected. The vein to be used was 
palpated to determine its size, depth and direction. The skin was wiped with a disinfectant swab; an 
alcohol swab was not used due to possible contamination of the sample.  The tourniquet was 
loosened or removed once blood started to enter the tube. As agreed at the Leidschendam meeting 
(January 2007) a collection tube containing potassium oxalate and sodium fluoride (grey tops) were 
used. Blood collection tubes had to be filled completely to ensure that proper additive concentrations 
were maintained. The tubes were gently mixed by inverting 5 to 10 times immediately after collection 
to prevent coagulation. 
All appropriate documents had to be filled in using the same identification number as used to label the 
collection tubes. Labelling had to be unambiguous. 
If more than one container was taken from the same subject, these containers had to be identified with 
the same identification label, but the labels should specify how many containers were drawn from the 
same subject. 
Storage and transportation  
Data on the stability of commonly used illicit drugs were scattered over various publications, and a 
uniform study design had not been applied. The stability of drugs in blood was reviewed by Levine and 
Smith in 1990 (Forensic Science Reviews, 2:147-157) and Skopp and Pötsch in 2002 (Rechtsmedizin, 
12: 195-202, in German). Since stability of even the most labile compounds (especially cocaine) had 
to be ensured, transportation measures had to be strict. Enzymatic degradation was slowed down by 
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the presence of preservatives in the tubes. Chemical hydrolysis was decreased by low temperature 
during transportation. Therefore the blood samples had be transported cooled down or frozen. 
Direct transportation of the samples to the laboratory was preferred. If this was impossible due to 
geographical reasons, samples could be shipped under specific conditions. Before shipping, national 
and international regulations had to be ascertained. Specimens had to be sent as diagnostic 
specimens and in two containers: the primary container had to be wrapped with Parafilm® or sealing 
tape around the lid, placed into a plastic bag or a screw cap container with enough absorbent material 
to absorb all of the fluid in the primary container, and be wrapped by a secondary container such as a 
cardboard box or mailing tube. This container had to prevent crushing of the specimen during 
transport. 
Dry ice had to be placed between the plastic bag and the outer shipping container. It hat to be shipped 
in insulated outer packaging, and could not be shipped in airtight container. Useful information and 
appropriate shipping containers were available from most contractors. 
Upon arrival in the laboratory, samples had to be stored at -20°C. 
Since the maximum time for storage at 4°C (= time between sampling at the roadside and freezing) 
was 2 days, and transportation to the laboratory was not always easy to organize in some countries 
depending on the design of the studies (e.g. the presence of researchers at the roadside, the 
availability of a motor home, geographical situation, presence of dedicated personnel at the 
hospital,…) it was recommended to store samples frozen in the hospitals for e.g. one month and 
transport them to the laboratory in one shipment. During this transportation insulation and time were 
important, so that the samples were still frozen when they arrived at the laboratory since the 
consequences of multiple freeze-thaw cycles for the recovery of drugs in blood samples were 
unknown.  
 
 
2. Oral fluid samples 
Summary: 
- 1mL oral fluid collected using StatSure Saliva Sampler. 
- Collection according to guidelines by manufacturer 
- Transportation at 2-8°C (max 48 hours) 
- Storage in laboratory at -20°C 
 
Sample collection: 
Oral fluid was collected using the StatSure Saliva Sampler device. Collection had to be done 
according to the guidelines printed on the instruction leaflet: 
- Do not use device beyond expiration date printed on package  
- Record identification number on tube label 
- Stand tube upright on flat surface. Check level of buffer fluid; if adequate (see fluid level line), 
place tube in tube rack. Discard kit if fluid is below fluid line. 
- Remove collector form pouch. 
- Do not rinse mouth. Gather saliva in mouth, do not swallow. Position collector under tongue. 
Close mouth. Do not chew or suck on pad. Do no move pad around during collection. 
- The collector should remain under the tongue until the indicator turns completely blue. Blue 
colour indicates collector is saturated with a volume of 1mL saliva. The collection time is 
variable and may take 2 to 15 minutes; if the indicator has not turned blue within 15 minutes, 
the pad should be removed from the mouth and discarded; recollection with a new device may 
begin immediately but only after saliva has first accumulated in the mouth. The collector may 
be placed in the same position. 
- Open mouth and lift tongue. Remove collector from mouth. 
- Remove cap from transport tube. Insert saturated collector into tube. Do not place collector in 
mouth after it has been in buffer liquid. 
- Carefully place cap over top of collector stem in tube. Forcefully push cap downward until cap 
“snaps”. 
- Mix saturated collector with buffer by gently shaking tube. 
Storage and transportation  
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According to the guidelines on the instruction leaflet, saliva specimens had to be shipped to the 
laboratory at 2 to 8°C as soon as possible. 
Guidelines on packaging and transportation were the same as for whole blood (see above). Upon 
arrival at the laboratory, samples had to be frozen until analysis. 
After thawing, a plastic column with white centerpiece bottom and a rubber band (delivered together 
with every device) was pushed down the collection tube. The saliva:buffer mixture could then easily be 
recovered and analysed. 
UGent had contacted StatSure to determine a time frame in which the devices can be stored safely at 
4 °C (based on their experience). They stated this time had to be determined empirically for each 
analyte. However in their experience they had never seen degradation of any analyte when it was left 
out a room temperature for <2 hours or <72 hours if kept at 2-8°C. 
Therefore it was decided that the same time frame as used for whole blood transportation (max. 48 
hours at cooled temperature) could be used for oral fluid. 
 
Toxicological analysis of body fluids an applied methods 
Table 2 shows the analytical methods used by the WP2-road side partners. Extraction was based on 
liquid-liquid (LLE) or solid phase (SPE), chromatographic separation was performed by gas 
chromatography (GC) or liquid chromatography (LC): High Performance (HPLC) or Ultra Performance 
(UPLC). Detection was done by mass spectrometry (MS). 
 
Table 2: Analytical methods used in WP2 
Country Extraction Chromatography Detection 
Belgium 
Oral fluid: 
Blood: 
 
LLE 
SPE (LLE for THC) 
 
UPLC 
UPLC (GC for THC) 
 
MSMS 
MSMS (MS for THC) 
Czech Republic  
Oral fluid: 
 
LLE UPLC MSMS 
Denmark 
Oral fluid: SPE UPLC MSMS 
Finland 
Oral fluid: LLE,SPE GC MS 
Hungary  
Oral fluid: LLE GC MS 
Italy 
Oral fluid: 
Blood: 
 
SPE +LLE (for THC) 
SPE +LLE (for THC) 
 
HPLC 
GC for THC 
 
MSMS 
MS for THC 
Lithuania 
Blood: LLE GC MS 
Norway 
Oral fluid: LLE HPLC MSMS 
Poland 
Oral fluid: SPE HPLC MSMS 
Portugal 
Oral fluid: LLE LC MSMS 
Spain 
Oral fluid: SPE HPLC MSMS 
Sweden 
Oral fluid: SPE UPLC MSMS 
The Netherlands 
Oral fluid: 
Blood: 
 
PP 
PP 
UPLC MSMS 
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DRUID core and extra substances 
 
1. Core substances 
The following list of core substances (analysed for in all countries that participated in the roadside 
survey) as well as analytical cut-off values for analyses of both blood and saliva were decided upon 
based on discussions between all partners. These were carried out by means of email and personal 
communication and the final decision was made at the WP2 meeting in January 2007. 
Table 3: Core substances analysed in WP2 
Substance Whole blood analytical cut-off 
(ng/ml) 
Saliva analytical cut-off (ng/ml) 
Ethanol* 0.1 g/L 0.1 g/L 
6-acetylmorphine 10 5 
Alprazolam 10 1 
Amphetamine 20 25 
Benzoylecgonine 50 10 
Clonazepam 10 1 
Cocaine 10 10 
Codeine 10 20 
Diazepam 20 5 
Flunitrazepam 2 1 
Lorazepam 10 1 
MDA 20 25 
MDEA 20 25 
MDMA 20 25 
Methadone 10 20 
Methamphetamine 20 25 
Morphine 10 20 
Nordiazepam 20 1 
Oxazepam 50 5 
THC 1 1 
THCCOOH 5 NR 
Zolpidem 20 10 
Zopiclone 10 10 
* Quantitative breath analyser results valid as well; NR: Not recorded 
 
 
2. Extra substances  
Besides the core list, each country added a minimum of 3 extra substances for analysis, based on 
knowledge on distribution in the various countries and impairing effect on driving performance (e.g. 
based on pharmacological profile or previous studies). 
Analytical cut-off values for analyses of both blood and saliva were decided upon based on 
discussions between partners who analysed the same extra substances. These were carried out by 
means of email and personal communication. The final list was made in February 2010. 
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Table 4: Extra substances analysed in WP2 Extra substances by country (based on final databases) and their cut-offs  
 FIN LT DK PL BE CZ ES PT NO NL IT HU S  
Cut-off 
(ng/mL) 
  THL TMI 
DTU/ 
UKBH 
ITS/ 
IES UGent CDV/UGent 
DGT/ 
UVa 
CPS-
NILM FHI SWOV/NFI 
TFA-
UNPD USZ 
VTI/ 
RMV Total OF 
Whole 
blood 
Carisoprodol 1        1    1 3 50 500 
Ketamine           1 1  2 20 20 
Buprenorphine 1  1  1      1   4 1 1 
Tramadol 1 1 1 1 1 1 1 1   1 1 1 11 50 50 
7-a-clonazepam  1  1 1 1 1 1 1 1 1 1 1 11 1 10 
Carbamazepine 1    1                     2 10 NA 
Olanzapine           1   1 5 10 
Bromazepam   1  1 1     1   4 5 20 
Meprobamate         1    1 2 1200 2000 
Chlordiazepoxide   1           1 10 20 
7-a-flunitrazepam  1 1 1 1 1 1 1 1 1 1  1 11 1 2 
Midazolam 1         1  1  3 2 10 
Nitrazepam 1  1      1 1  1 1 6 2 10 
7-a-nitrazepam     1            1  1     1 4 1 10 
Temazepam 1         1  1  3 10 20 
Amitryptiline 1    1  1    1   4 10 10 
(Es)Citalopram 1    1 1        3 5 5 
Fluoxetine 1          1   2 5 10 
Mirtazapine 1    1 1        3 5 5 
Trazodone     1 1        2 5 10 
Venlafaxine                     1     1 5 10 
Diphenhydramine             1             1 10 NA 
Levomepromazine 1           1             2 10 NA 
Norbuprenorphine 1          1   2 5 2 
11 OH-THC                   1       1 NA 1 
Number of extra 
substances 13 3 8 3 9 7 6 3 6 7 11 6 7    
NA: Not applicable 
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BAC quantification  
 
Alcohol concentrations were based on either breath, saliva or blood. 
Table 5: Methods used for BAC quantification in the different countries involved in WP2 
Country Breath Saliva Blood 
Belgium  X X (3) 
Denmark X (1) X  
Finland X   
Hungary X   
Italy  X X 
Lithuania X   
Norway  X  
Poland X   
Portugal X   
Spain X   
Sweden (2)    
The Netherlands X   
 
(1) Due to missing information of the police, no breath test was carried out in 194 cases. In these 
cases concentrations are based on oral fluid.  
(2) Ethanol was not included in the analysis since drivers positive for alcohol in the breath test 
were excluded from the study 
(3) For the drivers who did not provide an oral fluid sample (4 cases), concentrations are based 
on whole blood 
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Proficiency tests 
 
Two institutes conducted proficiency testing (PrT). 
For blood PrT: Arvecon GmbH, Germany 
For Oral Fluid PrT: Center for forensic sciences, RTI International, North Carolina, USA 
Both qualitative and quantitative results were measured 
Qualitative results were evaluated using sensitivity (and specificity), Quantitative results were 
evaluated using the standard deviation according to Horwitz (SDHOR). Z-scores were calculated using 
SDHOR.  
)log5,01(2 CVC −=  
    VC = variation coefficient (%) 
    C = analyte concentration (kg/L) 
 
 
 
1. Oral fluid proficiency testing  
A proficiency testing scheme was set up for the DRUID research project, in which oral fluid is analysed 
by eleven laboratories. A common collection and analysis methodology was used: Statsure Saliva 
Sampler was used for collection and LC-MS/MS or GC-MS confirmation analysis of 22 substances 
containing both licit and illicit drugs is performed on all samples. 
Four rounds of proficiency testing were organized between March 2008 and September 2009. 
Oral fluid PrT samples were prepared in a synthetic oral fluid matrix developed at RTI International. 
Each sample was formulated to contain 3 to 5 analytes. 1.5 mL of neat oral fluid was dispensed into a 
4 mL silanized amber vial (Supelco St. Louis, Missouri, USA), capped with a Teflon-lined cap 
(Supelco) and frozen until shipment. Samples for each survey year were prepared in a single 
production. 
Laboratories were instructed to add 1 mL of the neat oral fluid sample to a StatSure collection device.  
The 1 mL of neat PrT oral fluid was added directly to the buffer in the collection tube. 
Analytes were screened, identified and quantified using a mass spectroscopy-based technique. 
Reported analyte concentrations were corrected for dilutions to provide the concentration for the neat 
oral fluid shipped to the laboratory. Samples were expected to be tested and electronically reported to 
RTI. Results were reported back to each participating lab anonymously, but with identification to the 
DRUID coordinator to allow the latter to make corrective actions. 
Qualitative results were evaluated using sensitivity and specificity. Sensitivity is defined as the number 
of analytes correctly reported positive divided by the total number of analytes spiked in the samples. 
Specificity is defined as the number of analytes correctly reported negative divided by the total number 
of core list analytes not spiked in the samples, high specificity means a low number of false negatives. 
Quantitative results were evaluated using z-scores and the standard deviation of Horwitz. 
 
Eight laboratories reported results in the first round, three laboratories did not report because method 
development and validation were still being performed. In the second to fourth round, all eleven 
laboratories reported results. Not all laboratories reported results for ethanol, since in some countries 
ethanol concentration for each volunteer was already known based on breathalyzer results from 
standard police procedure and hence analysis was not mandatory. 
Specificity was above 99% in each round, sensitivity increased during the program, also reaching 99% 
in the last round. The percentage of satisfactory z-scores (absolute value lower than 2) increased from 
79.4% to 89.2%. This trend was seen for all drug classes, except zopiclone. False negatives were 
mostly attributable to Z-drugs, benzodiazepines and THC.  
Different results were obtained for benzoylecgonine per testing round. In the first round, five 
laboratories reported the presence of benzoylecgonine in samples in which cocaine but no 
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benzoylecgonine was spiked. After consultation with participating laboratories this problem could be 
explained by hydrolysis of cocaine during extraction and low extraction yields for benzoylecgonine. 
Laboratories adapted their procedures accordingly and in the second round, there were no longer 
false positives for benzoylecgonine. In the third and fourth round, again all the laboratories reported 
false positives, this phenomena could be explained by pre-analytical hydrolysis, either in sample 
preparation or shipment. Therefore these were not scored as false positives. 
In the first round of proficiency testing, most laboratories were still in the process of development and 
validation or had only recently completed this, explaining the lower scores in the first rounds.  
 
 
2. Whole blood proficiency testing  
A proficiency testing scheme was set up for the DRUID research project in which whole blood was 
analyzed by twelve laboratories. A common collection and analysis methodology was used: vacuum 
tubes containing sodium fluoride and potassium oxalate were used for collections and LC-MS/MS or 
GC-MS confirmation analysis of 25 substances (26 in second round) containing both licit and illicit 
drugs is performed on all samples. 
Four rounds of proficiency testing were organized between March 2008 and December 2009. Results 
of the fourth round are still to be sent.  
Whole blood samples were spiked with analytes and lyophilized at Arvecon. 
Laboratories were instructed to first store the vials at room temperature for 30 min. After reconstitution 
with exactly 5.0 ml bidistilled (demineralised) water, the specimen had to be swirled gently and stored 
for 15 minutes at room temperature. Before sampling, the vial had to be inverted gently to ensure 
homogeneity. It was strongly recommended to prepare the sample material for the analysis of cocaine 
and zopiclone on the day of reconstitution. 
Analytes were screened, identified and quantified using a mass spectroscopy-based technique. 
Samples were expected to be tested and electronically reported to Arvecon. Results were reported 
back to each participating lab anonymously, but with identification to the DRUID coordinator to allow 
the latter to make corrective actions. 
Qualitative results were evaluated using sensitivity. Sensitivity is defined as the number of analytes 
correctly reported positive divided by the total number of analytes spiked in the samples. 
Quantification was evaluated using the standard deviation according to Horwitz (SDHOR). Z-scores 
were calculated using SDHOR: When |z|<2, one point was given, |z|<3 got a score of 0.5. These points 
were added up and divided by the total number of analytes spiked in the samples. 
Ten laboratories reported results in the first and third round. In the second round, all twelve 
laboratories reported results. Two laboratories did not report in the first round because method 
development and validation were still being performed. 
Sensitivity increased during the program from 92.6 to 96% the third round. The percentage of z-scores 
increased from 81% to 91.6%. False negatives were mostly attributable to Z-drugs and 
benzodiazepines. 
In the second round sample A was spiked with 10 micrograms THC/L. However only 7 participants 
detected this substance, including 4 labs with values less than 1 microgram/L. Therefore these values 
were only reported for informative purpose (only 24 compounds were taken into account instead of 25 
for the results of the proficiency test). A spiking error was excluded, so the deviation was to be 
reducible to the difficult whole blood matrix. 
In the first round of proficiency testing, most laboratories were still in the process of development and 
validation or had only recently completed this, explaining the lower scores in the first rounds.  
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 Annex 3 Excluded samples 
 
Country Total number of 
samples original 
database 
Excluded records: 
no sample 
available 
Excluded records: 
missing substance 
group 
Excluded records: 
underage drivers 
Number of 
samples for 
analysis 
BE 2957 -- 4 4 2949 
CZ 2039 -- -- 2 2037 
DK 3030 27 -- 1 3002 
ES 3174 -- -- -- 3174 
FI 4091 15 235 -- 3841 
HU 2743 -- -- 5 2738 
IT 1310 -- -- -- 1310 
LT 1309 45 -- -- 1264 
N 9261 19 -- 6 9236 
NL 4822 -- -- -- 4822 
PL 4276 251 19 1 4005 
PT 4002 35 -- 2 3965 
SE 6372 168 -- 5 6199 
Total 49386 560 258 26 48542 
Table 1. Number of samples included for analysis by country 
Table 1 presents the number of cases that were removed from the database. The Spanish, Italian and 
Dutch databases were complete and no records needed to be excluded. 
The Belgian database missed THC and THCCOOH analysis in 2644 blood samples. For 2640 of 
these records a saliva sample was available which were used for the analysis. The 4 records with 
missing values for THC and THCCOOH for which no saliva sample was available where removed from 
the database. An additional 4 records were removed since they contained underage drivers. 
The database from Czech Republic contained 2 underage drivers that were removed from the 
database.  
The Danish database contained 1 underage driver and 27 records with no samples. In total 28 records 
were removed.  
The Finnish database contained 250 records in which one or more substance groups were missing. 
These records were deleted. Around the same number of records miss part of a substance group (e.g. 
1 of the 7 benzodiazepines was missing). These records have been kept in though.  
From the Hungarian database 5 underage drivers were removed. None of the 2738 included records 
contained a value for flunitrazepam or 7-a-flunitrazepam. 
For Lithuania 45 records with no toxicological analysis have been removed. 
The Norwegian database contained 19 records with no toxicological results and 6 underage drivers. 
The have been removed. Furthermore, samples were not analysed for tramadol since this medicinal 
drug is not available in Norway. 
251 records with no sample and 1 record from an underage driver were removed from the Polish 
database.  
From the Portuguese database 35 records without sample were removed as well as 2 underage 
drivers. 
From the Swedish database 168 records with no sample were removed as well as 5 records with 
underage drivers. Furthermore, due to legislation, it was not allowed to collect data on alcohol use 
from all drivers. Therefore, the prevalence results from the Swedish roadside survey will not contain 
information on alcohol. 
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Annex 4 The distribution of traffic over time periods. 
 
Background 
In the European DRUID-project population based case-control studies are conducted to assess the 
relative risk of driving under the influence of psychoactive substances. In a population based case-
control study controls are selected in a way that they are representative for the study base from which 
the cases were selected. This means that if cases are injured drivers that were included from a 
specific hospital, the controls should be selected from this hospital's catchment area and moreover, 
the controls should represent the traffic. According to this, the controls should be distributed over time 
according to the distribution of traffic over time. If this is not the case, weight factors would be needed 
to correct for an unevenly distributed control group.  
If the distribution of traffic over time is not available from (national) travel surveys or traffic counts, 
estimates could be used to approximate the distribution of traffic over time in the DRUID-study. 
The following paragraph will give an overview of the distribution of national and regional traffic volume 
over the DRUID time periods. These data is provided by OECD-members who were requested to 
provide these data if available. We are very thankful that several OECD-partners took the effort to 
provide us the data or to let us know that this data is not available for their country.  
Next, the data will be averaged to form an estimate that could be used by partners in the DRUID 
project. This process is described in paragraph 3. 
Finally, conclusions and recommendations for the use of the calculated distribution estimates of traffic 
volume will be given in paragraph 4. 
 
Data 
On February 4th a request by e-mail was sent SWOV to all OECD-members for data on the distribution 
of vehicle kilometers in person cars by hour and day of the week. The goal of this e-mail was to collect 
as many data as possible on the distribution of traffic volume over time, in order to provide good 
estimates of traffic distribution for those DRUID partners that were not able to collect this data.  
A table with vehicle kilometer data from the Netherlands was attached to the e-mail as an example. 
Furthermore, a link was attached to the homepage of the DRUID-project to provide more background 
information on the project that the data was used for. 
It was stated that other time or vehicle categories were accepted as well, if better data was not 
available. 
 
Four OECD-members replied to have data available. Data for a 5th country was made available by 
other resources than the OECD-members.  Peter Silverans, who is also involved in the DRUID-
project, prepared an estimate of the DRUID-distribution based on traffic counts that were available in 
an other time-distribution (6 a.m-22 p.m. and 22 p.m- 6 a.m). Two other countries delivered data that 
was only available for other time periods than the 6-hour DRUID periods. Seven OECD-members 
replied that no such data was available in their country.  
 
Table 1 presents the distribution of traffic volume in those countries that were able to provide data 
aggregated for the DRUID time periods.  
 
Table 1. Distribution of traffic volume in DRUID-time periods. 
  NL NO BE SE GB New Zealand 
Weekdays 04-10 22,0% 22,9% 18,7% 23,5% 18,9% 19,9% 
10-16 23,6% 27,7% 25,2% 25,4% 26,3% 27,9% 
16-22 26,9% 19,9% 25,2% 24,3% 25,4% 24,1% 
22-04 3,0% 4,1% 5,8% 1,7% 2,4% 1,9% 
Weekenddays 04-10 2,7% 2,2% 6,3% 4,2% 3,5% 4,0% 
10-16 11,1% 8,0% 8,2% 12,2% 12,2% 12,9% 
16-22 8,0% 12,9% 8,2% 7,3% 8,8% 8,2% 
22-04 2,7% 2,8% 2,5% 1,5% 2,5% 1,0% 
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The Norwegian data is based on traffic counts on a highway near Oslo. The Belgian data converted 
from an other time-distribution than the DRUID distribution. This conversion is based on a evenly 
distribution of traffic volume within the hours of a time-period. The data from the Netherlands, Sweden, 
Great-Britain and New Zealand are all based on large scale national travel surveys. 
 
The distribution over the different time periods is quite similar for the six countries in table 1. Table 2 
presents the mean of the share of traffic in each time period and its standard deviation. 
 
Table 2. Mean and standard deviation of the share of traffic in each DRUID time period 
Time period Mean Standard deviation 
Weekdays 04-10 21,0% 2,1% 
10-16 26,0% 1,6% 
16-22 24,3% 2,4% 
22-04 3,2% 1,6% 
Weekenddays 04-10 3,8% 1,4% 
10-16 10,8% 2,1% 
16-22 8,9% 2,0% 
22-04 2,2% 0,7% 
 
Table 3 provides an overview of the spread of the data per time period as compared to the mean 
share of traffic per time period. Green percentages lie within a distance of 1 standard deviation and 
yellow percentages lie between 1 and 2 standard deviations from the mean.  
 
Table 3. distance from the mean green is 1 SD, yellow is between 1 and 2 standard deviation) 
 
 
Table 3 shows that the traffic distribution data from Norway and Belgium have a bigger deviation from 
the mean than data from other countries. This can be caused by real life differences in traffic 
distribution. 
Another possible explanation is that the sample of the highway in Norway is not representative for the 
total traffic in Norway and that the rough estimate for the Belgian distribution is a bit too rough. 
 
Estimate of traffic distribution for DRUID time periods 
An estimation of the distribution of traffic can be calculated in various ways. One could use the mean 
of the six studies and get the estimate that were presented in table 2. A second option is that only the 
data from the four national studies are used. This means that the data from Norway and Belgium will 
be dropped. A third option is a middle-of –the –road option where the distribution data from the four 
national studies will be taken into account double under the assumption that the data from the other 
two studies will have a lower validity. 
A fourth option would be the same as the third but then with an exclusion of the Belgian data since this 
distribution is based on assumptions that are to general and therefore incorrect.  
The results of these three options are presented below in table 4. 
  NL NO BE SE GB New Zealand 
week 04-10 22,0% 22,9% 18,7% 23,5% 18,9% 19,9% 
 10-16 23,6% 27,7% 25,2% 25,4% 26,3% 27,9% 
 16-22 26,9% 19,9% 25,2% 24,3% 25,4% 24,1% 
 22-04 3,0% 4,1% 5,8% 1,7% 2,4% 1,9% 
weekend 04-10 2,7% 2,2% 6,3% 4,2% 3,5% 4,0% 
 10-16 11,1% 8,0% 8,2% 12,2% 12,2% 12,9% 
 16-22 8,0% 12,9% 8,2% 7,3% 8,8% 8,2% 
 22-04 2,7% 2,8% 2,5% 1,5% 2,5% 1,0% 
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Table 4. Average distribution per method 
  6 countries 5 countries 4 countries 6 weighted 5 weighted 
  Mean SD Mean SD Mean SD Mean SD Mean SD 
week 04-10 21,0% 2,1% 21,2% 1,9% 21,1% 2,1% 21,0% 2,0% 21,3% 1,9% 
 10-16 26,0% 1,6% 26,5% 1,7% 25,8% 1,8% 25,9% 1,6% 26,0% 1,7% 
 16-22 24,3% 2,4% 24,1% 2,3% 25,2% 1,3% 24,7% 2,0% 24,6% 2,1% 
 22-04 3,2% 1,6% 2,5% 0,9% 2,3% 0,6% 2,8% 1,3% 2,5% 0,8% 
weekend 04-10 3,8% 1,4% 3,4% 0,8% 3,6% 0,7% 3,7% 1,1% 3,4% 0,7% 
 10-16 10,8% 2,1% 11,6% 1,9% 12,1% 0,7% 11,3% 1,8% 11,6% 1,5% 
 16-22 8,9% 2,0% 8,9% 2,0% 8,1% 0,6% 8,6% 1,6% 8,6% 1,7% 
 22-04 2,2% 0,7% 1,9% 0,8% 1,9% 0,8% 2,1% 0,7% 2,0% 0,8% 
 
Table 4 shows that the differences in the outcomes of the four different methods are quite small. 
Weighting for the validity of the data has a small effect on the outcomes of the study and on the 
standard deviations. The standard deviation did decrease for some of the eight time periods.  
Exclusion of the country distributions from those two sources that were regarded as of less quality had 
a very big effect on the standard deviation of the traffic distribution of five out of eight time periods. 
Again the differences in means are quite small. 
Finally, the exclusion of the Belgian data alone had a small effect on both the mean and the standard 
deviation. The same effect was seen for the weighted data excluding Belgium, but the standard 
deviation did decrease more drastically than in the case of the unweighted data. 
 
Conclusion and recommendation 
The amount of data on national traffic data is small and even smaller when the data needs to be 
distributed per time period. Traffic data on the DRUID 6-hour time periods was available for 6 
countries, although Norway had data that was regional and Belgium had data that was based on 
estimates of aggregated data. We assume in this document that the Norwegian and Belgian data are 
of less quality than the national data from the other four countries. Furthermore, the Belgian estimates 
are based on the assumption that the traffic in a 16 hour period is evenly spread. This is certainly not 
the case as can be seen in the data from the other five countries.  
If we exclude the estimates from Belgium, three possible estimates of the distribution of traffic are left: 
the 5 countries method, the 4 countries method and the weighted 5 countries method. The data from 
Norway differs in some time periods extremely from the other countries and it can be questioned 
whether this is because of the real life situation for the whole of Norway or because the traffic counts 
just reflect the situation in a selective area of Norway, namely a highway near Oslo.  
Based on this information the weighted 5 countries method and the 4 countries method are assumed 
to be the best estimates for the distribution of traffic over the DRUID 6-hour time periods. 
 
Figure 1 presents the situation where the standard deviations from both estimates are used to create 
an upper and a lower boundary around the mean.  
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Figure 1. upper and lower limits of the 4 countries estimates and the weighted 5 countries estimates 
 
The upper and lower limits of the distribution mean of the 4 countries estimates are almost all on or 
within the upper and lower limits of the weighted 5 countries estimates. Therefore, the mean that is 
based on the four countries is recommended as the best usable distribution of traffic in the DRUID-
project. 
 
Table 5. Average distribution for the 4 countries (The Netherlands, Sweden, Great Britain, New Zealand) 
Mean SD 
21,1% 2,1% 
25,8% 1,8% 
25,2% 1,3% 
2,3% 0,6% 
3,6% 0,7% 
12,1% 0,7% 
8,1% 0,6% 
1,9% 0,8% 
 
Partners in the DRUID-project could be advised to use this distribution in case they do not have an 
alternative one. They could adjust this distribution as well if they have reliable sources that indicate a 
different distribution. The given standard deviations can then be used to get a feeling of the size of the 
new estimates.  
If, for example, a country has relative much traffic on weekend days because the Saturday is a normal 
working day, the distribution shifts somewhat to the weekend days providing higher estimates on 
weekend days and slightly lower estimates during the rest of the week. 
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 Annex 5 Logistic regression models 
Tove Hels, Kira Janstrup and Inger Marie Bernhoft, DTU Transport 
 
This annex gives an overview of the statistical method applied in chapter 5 to investigate the 
underlying factors that are of influence on the prevalence of the various substances. The logistic 
regression method was used to reveal (significant) relations between given explanatory variables 
(quantitative and qualitative) and a binary response variable. Here, the response variable consisted of 
a collection of samples that were either positive or negative for alcohol/psychoactive substances.  
Data of as many countries in the models as possible and including country, time period, age and 
gender as explanatory variables. These statistical models have been constructed to reveal significant 
differences in prevalence among countries, genders and age groups when corrected for the other 
variables. 
Applied statistical method 
Differences in prevalence of alcohol and drugs were calculated on the basis on various designs of 
blood and/or saliva sampling in the driving populations in the partner states. In case of two samples – 
both blood and saliva, the value of blood was leading. This leads to the following evaluation scheme: 
 
Blood sample Saliva sample Observation 
Positive No sample Positive 
Positive Negative Positive 
Positive Positive Positive 
Negative No sample Negative 
Negative Negative Negative 
Negative Positive Negative 
No sample Negative Negative 
No sample Positive Positive 
No sample No sample NA 
 
 
 
The drugs were grouped in nine different substance groups: alcohol, amphetamine, cocaine, THC, 
THC-COOH, illicit opiates, benzodiazepines, Z-drugs and medicinal opioids, see table 2.3 in the 
method section of the general report. Concentrations above the equivalent cut-offs, as indicated in 
table 2.2 in the method section of the general report, were interpreted as positive concentrations. For 
alcohol, two groups were tested: over or equal to 0.1 g/L and over 0.5 g/L. Moreover, there was a 
multiple drugs group for drivers tested positive for more than one drug. Finally, there was an alcohol-
drug group for drivers tested positive for an alcohol level above or equal to 0.1 g/L and simultaneously 
for one or more drugs. The substance groups were defined as mutually exclusive so that a driver 
tested positive for alcohol and for a drug did not count as positive in the substance group alcohol or in 
the concerned drug category but only as positive in the alcohol-drugs substance group. 
 
Most substance groups contained more than one substance. In the case of missing analysis of one or 
more (but not all) substances in a group, presence/absence of that substance group was evaluated on 
the basis of presence/absence of the non-missing substances. If all non-missing substances in the 
group were absent, that group was evaluated as absent. If on the contrary, one or more of the non-
missing substances were present, that group was considered present. In the case of missing analysis 
of all substances in one substance group, that group was considered not analysed. 
 
The alcohol-drug and the drug-drug categories were evaluated differently: In the case of missing 
analysis of one or more substances in a substance group, alcohol-drug and drug-drug were both 
considered not analysed. 
 
Sampling designs met certain common criteria, but they differed somewhat among countries.  
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Logistic regression 
Logistic regression relates a number of independent variables to the probability of an event, in this 
case the probability of a driver in the driving population being positive for alcohol or a specified drug 
group. Or put in another way: the prevalence. 
 
The logistic function is given by 
 ,   (1) 
 
where P(y) denotes prevalence confined to values between zero and one. y (the logit) is a linear 
expression of x on the form:  
 
   (2) 
 
where  denote the four independent variables (gender, age group, time period, country) and 
the six interactions between them.  denotes the intercept and  are coefficients scaling the 
variables.  
 
Logistic regression allows adjustment of non-linear variables and interactions between variables. 
Furthermore, the method identifies the presence of significant and insignificant variables and 
standardization by both continuous and categorical variables. Hence, with a large data set as this one 
it produces dependable estimates (Roalfe et al. 2008).   
 
The estimates found with this procedure denote the probabilities that an event will occur. In this case 
the probabilities that a driver is positive for the concerned substance group given certain values of the 
(significant) variables, including interactions, i.e. prevalence. Prevalence differences of alcohol and 
drugs can thus be calculated for groups of road users, for instance road users in different countries, 
being of different age or gender and in different time periods.   
 
Weighted prevalence estimates represent the probability that a driver drawn randomly from the driving 
population is driving with alcohol or drug (or both) in the blood. To exploit data to the maximum, one 
overall model was constructed for each substance group that included as many countries as possible.  
 
Weighting 
Most of the participating countries had a sampling skewness in their data set due mainly to practical 
constraints. Thus, samples were not collected according to traffic volume, and the bias had to be 
accounted for in the calculations. This was done by weighting the logit (cf. above) in each ‘cell’ of an n-
dimensional matrix, where n denotes the number of significant variables and interaction terms in the 
logistic regression model. If, for instance, gender was the only significant variable in a model, the logit 
was weighted with traffic volume fractions for the two genders to account for the fact that in most 
countries, men drive far more kilometers than women. If, in a model, gender, age and time were 
significant variables, logits were weighted with traffic volume fractions in a three dimensional matrix. 
Within the n-dimensional matrix, traffic volume fractions were normalized to sum up to 1. Some 
participating countries did not collect samples in all eight DRUID time periods. For these countries, 
interpolations were made in the matrices in order to normalize the traffic volume fractions. 
 
After weighting the logit in an n-dimensional matrix, the prevalence was calculated by back 
transforming the logit as shown in equation (1) and as described by Roalfe et al. (2008), including the 
confidence intervals. In addition to this, the variable coefficients for the significant variables and 
interactions were calculated.  
 
The procedure 
The logistic regression was performed in SAS by proc logistic. In Figure 1, the prevalence calculation 
method is described in graphic terms. Prevalence calculations were carried out separately for each of 
the nine substance groups (alcohol, amphetamine, cocaine, cannabis, benzodiazepines, Z-drugs, 
medicinal opiates, alcohol-drug combinations, multiple drug combinations). Attempts were made to 
construct prevalence models for THC-COOH and illicit opiates, but this was not possible due to a low 
number of positive samples. 
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Interaction terms were removed from the model if not significant. Main effects were excluded from the 
model if not significant and not a part of any of the remaining interaction terms. Therefore, if a main 
effect was insignificant but a part of a significant interaction, the main effect was included in the model. 
Some of the models have been reduced (fewer independent variables and interactions) because of a 
low number of positive observations. 
 
To construct models for some of the substance groups it was necessary to merge some of the time 
periods or even some of the age groups (cf. Chapter 5 for a description of each of the models). In 
some of the models a merge was done to run the logistic procedure the first time. After removal of 
some of the interactions, the original time periods or age groups were reintroduced into the model 
under the assumption that the removed interactions were not significantly different in the time periods 
or age groups in question.  
 
 
Figure 1.   Overview of the various steps carried out for each substance group, one by one.  
 
For some substances (cf. Chapter 5 for a more detailed description) due to a low number of positive 
samples and/or shortage of samples in some time or age categories, an assumption was made that 
one of the interactions was not significant. By removing that interaction from the model, a model could 
be constructed for the substance in question. 
All countries with positive concentrations for the substance group included in the logistic 
regression model  
Independent variables: Country, time period, age, gender 
 
           
 
Countries not fitting into the model excluded  
Reason for not fitting into the model: No positive values 
in a cell for one or more of the independent variables  
Construction of the logistic regression model including 4 main effects and 6 interactions 
1 
2 
Reduction of model to contain significant variables and interactions  
Interactions reduced first, then main effects 
 
 
Attempt to include countries that not fitting into the model 
from the beginning 
Reduction of model to contain significant variables and 
interactions only 
 
Unweighted prevalence estimates calculated 
2 
1 
Weighted prevalence estimates calculated  
Variable coefficients and confidence intervals for the weighted prevalence estimates calculated 
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For three of the substance groups (cocaine, alcohol-drugs and multiple drugs) a model was 
constructed for one gender only (i.e. men) because of too few positive observations for females. 
 
After construction of a model, weighting of the estimates were calculated by weighting the logit before 
back transforming as described by Roalfe et al. (2008).  After weighting, mean and confidence 
intervals of the prevalence estimates were calculated in each of the categories of the significant 
variables in the model as described by Roalfe et al. (2008).   
 
Weighting factors 
 
As described above the prevalence estimates (more specifically: the logits) have been weighted in 
order to adjust for sample skewness. The final prevalence estimate must reflect the driving population 
as a whole, and therefore weighting of the prevalence estimates have been done according to traffic 
volume. This means for instance that in an overall estimate of prevalence, more weight has been 
given to prevalence estimates in time periods with high traffic density, and at the other end of the 
spectrum: little weight has been given to prevalence estimates in time periods with low traffic volume.  
 
The following tables show weighting factors as reported from each participating country. The weight 
factors for the time periods for Hungary, Italy, Lithuania, Poland and Portugal are international 
estimates based on IRTAD-data (www.irtad.net). The figures represent the three weighting factors: 
Fraction of traffic volume in the period or for the gender or age group in question. 
 
 
Table 1  Fraction of traffic volume by DRUID time periods 
BE 0.1870 0.2515 0.2515 0.0580 0.0630 0.0818 0.0818 0,0254 1.000
CZ 0.2000 0.2900 0.1600 0.0200 0.0800 0.1100 0.1300 0.0100 1.000
DK 0.2230 0.3050 0.1710 0.0240 0.0310 0.1130 0.1080 0.0250 1.000
ES 0.1700 0.2700 0.2200 0.0400 0.0300 0.0800 0.1400 0.0500 1.000
FIN 0.1860 0.2890 0.1970 0.0330 0.0570 0.0880 0.1300 0.0200 1.000
HU* 0.2100 0.2600 0.2400 0.0300 0.0400 0.1100 0.0900 0.0200 1.000
IT* 0.2100 0.2600 0.2400 0.0300 0.0400 0.1100 0.0900 0.0200 1.000
LT* 0.2100 0.2600 0.2400 0.0300 0.0400 0.1100 0.0900 0.0200 1.000
N 0.1500 0.2700 0.2300 0.0600 0.0100 0.0800 0.1500 0.0500 1.000
NL 0.2200 0.2360 0.2690 0.0350 0.0270 0.1110 0.0800 0.0220 1.000
PL* 0.2100 0.2600 0.2400 0.0300 0.0400 0.1100 0.0900 0.0200 1.000
PT* 0.2100 0.2600 0.2400 0.0300 0.0400 0.1100 0.0900 0.0200 1.000
S 0.2100 0.2600 0.2500 0.0200 0.0400 0.1200 0.0800 0.0200 1.000
In total
Time 
period
Weekday 
morning
Weekday 
daytime
Weekday 
afternoon
Weekday 
evening/night
Weekend 
morning
Weekend 
daytime
Weekend 
afternoon
Weekend 
evening/night
* International estimates 
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Table 2 Fraction of traffic volume by gender 
Gender Men Women In total
BE 0.670 0.330 1.000
CZ 0.610 0.390 1.000
DK 0.640 0.360 1.000
ES* 0.590 0.410 1.000
FIN 0.703 0.297 1.000
HU 0.750 0.250 1.000
IT 0.570 0.430 1.000
LT 0.890 0.110 1.000
N 0.656 0.344 1.000
NL 0.698 0.302 1.000
PL 0.830 0.170 1.000
PT* 0.628 0.372 1.000
S 0.700 0.300 1.000  
* Fraction of driving licence holders 
 
Table 3 Fraction of traffic volume by age groups 
Age group 18-24 25-34 35-49 50+ In total
BE 0.100 0.230 0.320 0.350 1.000
CZ 0.062 0.331 0.387 0.220 1.000
DK 0.057 0.167 0.396 0.380 1.000
ES* 0.090 0.240 0.360 0.310 1.000
FIN 0.098 0.177 0.361 0.364 1.000
HU 0.101 0.323 0.338 0.238 1.000
IT 0.100 0.230 0.350 0.320 1.000
LT 0.160 0.250 0.340 0.250 1.000
N 0.079 0.194 0.356 0.371 1.000
NL 0.105 0.211 0.358 0.326 1.000
PL 0.184 0.331 0.297 0.188 1.000
PT* 0.099 0.238 0.312 0.351 1.000
S 0.070 0.150 0.330 0.450 1.000  
* Fraction of driving licence holders 
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